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ABSTRACT
High performance liquid chromatographic methods are 
described for the determination of various drugs in
biological fluids, using direct injection and a column 
switching valve. The methods are based on the enrichment of 
the drug on a reversed-phase concentration column followed 
by chromatographic analysis using various mobile phases. 
Members of three major drug groups were examined, Tricyclic 
Antidepressants, Antihistamines and Benzodiazepines.
One of the fundamental requirements of a bioassay is the 
capability to isolate and detect mixtures of polar and
non-polar substances simultaneously, as is often the case 
with a drug and its metabolites. In the determination of 
amitriptyline and its metabolites, nortriptyline, 
10-hydroxynortriptyline and 10-hydroxyamitriptyline, a 
direct injection/column switching procedure is described
which determines all four analytes simultaneously with 
excellent recovery. A conventional liquid-liquid extraction 
procedure is also described which failed to isolate the 
non-polar metabolites. Both methods are fully validated, 
compared and applied to samples from patients undergoing 
treatment with amitriptyline.
For the determination of tripelennamine (an antihistamine), 
in bovine plasma and milk an on-line solid phase extraction 
technique is described. Bovine plasma proved to be
chromatographically cleaner than human plasma but 
operationally more difficult to handle due to its viscous
(ii)
nature. The extension of the method for clean-up of milk 
samples was also investigated. With centrifugation prior to 
injection this proved possible. The method was fully 
validated. Setistine, a novel antihistamine was also 
determined using a solid-phase extraction technique.
In the final section a direct injection/column switching 
procedure for protein bound drugs is described. It is 
applied to the determination of diazepam and its metabolites 
desmethyl diazepam, temazepam and oxazepam, in plasma. The 
method is fully validated and compared to a classical 
liquid-liquid extraction scheme.
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CHROMATOGRAPHY - THEORY AND PRACTICE
CHAPTER I
1.1. INTRODUCTION AND HISTORY OF CHROMATOGRAPHY
The discovery of chromatography is generally credited to 
Tswett [1,2] who in 1903 described his work on using a chalk 
column to separate the pigments in green leaves. An English 
translation of his work is also available [3]. At around 
the same time D.T. Day was also using chromatography to 
separate petroleum fractions [4-6] but Tswett was the first 
to correctly interpret the chromatographic process. He not 
only separated and isolated the pigments of a green leaf but 
did this without any chemical change occuring so that they 
could be used for characterisation purposes. He described 
the procedure and emphasised its importance in analytical 
chemistry. The nomenclature used today derives from Tswetts 
original suggestions. The tube filled with adsorbent is the 
chromatographic column. The liquid is the chromatographic 
solvent, wash liquid or developer. The series of zones in 
the column are called the chromatograph and the washing of 
the mixture to form the chromatogram is the development.
The resolution of the mixture using the chromatographic
column is chromatographic adsorption analysis or 
chromatography.
Despite the work carried out by Tswett, a lull followed for
many years and it was not until the early forties that
chromatography started to evolve. The foundation for thin 
layer chromatography (TLC) was laid in 1938 by Izmailov and 
Scraiber [7] and later refined by Stahl [8,9] in 1958. The 
remarkable work of Martin and Synge in 1941 [10] not only
revolutionised liquid chromatography (LC) but in general set
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the stage for the development of gas chromatography (GC) 
[11]. Between 1952 and the 1960's gas chromatography 
evolved into a sophisticaLed analytical technique with much 
work accredited to Martin and James [12-15], who in 1952 
separated fatty acids and later on amines on a stationary 
phase of silicon oil containing 10% stearic acid. 
Manufacture of the first commercial gas chromatograph was in 
1955.
At first liquid chromatography was performed in large 
diameter glass columns with long analysis time. In the late 
1960's more and more emphasis was placed upon developing 
liquid chromatography as a complementary technique to gas 
chromatography. High performance liquid chromatography 
(HPLC) has evolved from this effort with advances in both 
instrumentation and column packings occuring rapidly. It is 
now among the most powerful and versatile separatory 
techniques ever devised and in the following section I will 
examine the various modes available today.
The feature distinguishing chromatography from most other 
physical and chemical methods of separation is that two 
mutally immiscible phases are brought into contact wherein 
one phase is stationary and the other mobile. The sample 
mixture, introduced into the mobile phase, undergoes a 
series of interactions (partitions) many times between the 
stationary and mobile phases as it is being carried through 
the system by the mobile phase. Interactions exploit 
differences in the physical or chemical properties of the 
components in the sample. These differences govern the rate
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of migration of the individual components under the 
influence of a mobile phase moving through a column 
containing the stationary phase.
Separated components emerge in the order of increasing 
interaction with the stationary phase. The least retarded 
component elutes first, the most strongly retained material 
elutes last. Separation is obtained when one component is 
retarded sufficiently to prevent overlap with the zone of an 
adjacent solute as sample components elute from the column.
The column is at the heart of chromatography and provides 
versatility in the types of analyses that can be performed 
with a single instrument. This versatility, due to the wide 
choice of materials for the stationary and mobile phases, 
makes it possible to separate molecules that differ only 
slightly in their physical and chemical properties but can 
also be a problem when it comes to select an appropriate 
chromatographic method.
1.2. CLASSIFICATION OF CHROMATOGRAPHIC METHODS
Chromatographic methods can be divided into two groups 
according to the mobile phase used. The mobile phase can be 
a gas (GC) or a liquid (LC).
Chromatographic methods can be classified further according 
to the nature of the stationary phase. Thus, under the gas 
chromatography category are GLC and GSC - gas liquid 
chromatography and gas solid chromatography. Liquid
chromatography is divided into two main types: column
chromatography and the planar chromatograpic methods - thin 
layer chromatography (TLC) and paper chromatography (PC) . 
Column chromatography is subdivided further into five major 
column types which constitute HPLC. These include LSC 
(liquid solid chromatography), BPC (bonded phas£ 
chromatography), IEC (ion exchange chromatography), and EC 
(exclusion chromatography).
Chromatography
Gas Liquid L
GSC GLC Column
1 1 1 1
LSC LLC RPC IEC EC
Planar
GPC GFC
Fig. I - Classification of chromatographic methods.
1.3. THEORY OF CHROMATOGRAPHY
Differential migration of components of a mixture is the 
basis of separation in chromatography. An understanding of 
this migration mechanism is therefore essential. This will 
now be discussed.
When a solute zone migrates through the column, it does so 
with a fraction R of the velocity of the mobile phase V^ . At 
the molecular level, at any given time some of the solute 
molecules are sorbed while some remain in the mobile phase 
getting carried along by it. The solute zone therefore 
constantly moves forward despite the fact that only a 
fraction of the zone's molecules are mobile at any given 
time. Due to the stop-go nature of the movement of each 
molecule in the column, molecules spread randomly in the 
solute zone. This explanation of zone spreading by random 
migration is usually referred to as the "random walk model".
One approach to the understanding of zone migration is the
kinetic model[16]. It is proposed that when a molecule is
in the sorbed state, it remains stationary for an interval
of time before it is desorbed again. This time interval
(t^) is called the desorption time. In the next stage the
same molecule then desorbs for a period of time (t ) knowna
as the adsorption time. It is during this time that the
can be stated therefore, that a molecule spends only a 
fraction of its time in the mobile phase, this fraction 
being the period of time during which the molecule is
molecule is carried forward with a mean flow It
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moving, divided by the sum of the adsorption and desorption 
times. Since the molecule is part of the solute-zone, the 
theory can also be applied to the zone.
R, = f1’
+ V
This equation expresses the fraction velocity, R, in terms 
of the time interval of a single sorption - desorption event 
indicating the kinetic nature of solute migration through 
the stationary phase in a column.
The second approach is based on an equilibrium system. In
this case, it is considered that an equilibrium is reached
in the distribution of the solute between the stationary and
mobile phase. It can be considered that in a small region
of the column the amount of solute in the mobile phase will
equal the local concentration of the solute (C ) times the
volume of mobile phase (V ) in that region. The amount ofm
solute in the stationary phase will equal the local
concentration of the solute (C ) times the volume of' s '
stationary phase (V ). Therefore
C V (2)Rf =  m m '
C V + C V m m  s s
which may also be written as
= Vn, < 3 >
Vm + < V Cm>VS
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But since K (distribution constant) = (C /C ) v ' ' s m
Then R-- = Vm______
For a given value of Vm and V , the value of depends only 
on the distribution constant. Factors that influence K will 
also affect the migration of the solute. Temperature has a 
marked effect on solute migration especially in gas 
chromatography. The temperature dependance of the 
distribution constant, is given in equation 6.
K = Constant. e"^H /RT (6)
where H° = Enthalpy, R = Gas Constant and T = Absolute
Temperature.
An increase in absolute temperature will lead to a decrease 
in K, since the change in enthalpy is negative for
exothermic sorption. This results in an increase in R^
which therefore means a shorter retention time. The 
temperature dependence of retention can be utilised to
improve resolution in chromatography. Another factor 
affecting Rf is pressure, which has a comparatively smaller 
influence than temperature. However at very high pressures 
K can be varied significantly. This has been observed in 
adsorption and gel permeation chromatography.
The chemical nature of the mobile and stationary phases also 
influences the value of K. In general polar solutes tend to 
be sorbed in polar phases and non-polar solutes in non-polar
(5)
(4)
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phases. Thus the migration of solutes can be controlled by 
changing the polarity of one or both phases.
1.3.1. Zone Spreading
There are three main contributions to zone spreading. These 
are
(i) multiple paths of a solute through the column packing
(ii) molecular diffusion
(iii) non-equilibrium mass transfer.
1.3.1.1. Multiple paths
Depending upon the bed structure of the column, the velocity 
of different molecules of the solute moving across the 
column bed may vary significantly. Some molecules will 
travel more quickly by going along the more open or low 
resistance paths near the top of the column. This is called 
channelling. Others diffuse into spaces between the 
particles and these get left behind. This is called eddy 
diffusion. (Fig. 2) Ideally the solvent molecules should 
proceed through the packed bed by a tortuous path avoiding 
either one of the above effects. It is the average velocity 
of the solute that determines its retention time.
Fig. 2 Schematic diagram showing multiple paths for 
different molecules moving across a column.
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1.3.1.2. Solute Diffusion
Diffusion causes the solute molecules, initially in a narrow 
band to spread out into the surrounding solvent and broaden 
the band profile. In principle, longitudinal diffusion may 
occur in both mobile and stationary phases, but because the 
rate is minimal in the stationary phase it is usually 
ignored. This phenomenon is much more important when the 
mobile phase is a gas. Band broadening by molecular
diffusion is rarely a factor important in lowering 
efficiency in an L C column.
Fig. 3 Illustration of Mass Transfer Effect.
Flow-------->
1.3.1.3. Mass Transfer
When the molecule is in the stationary phase, it is retained 
and falls behind the band centre as the band centre 
continues to migrate down the column. When the molecule is 
in the mobile phase it moves with the mobile phase. Its 
velocity is faster than the band centre since the flow 
velocity is always greater than the band velocity. This 
random transfer back and forth between the mobile and 
stationary phases causes dispersion in the chromatographic 
peak as some molecules will by chance migrate ahead of the 
average and others will migrate more slowly than the 
average (Fig 3). If there were no flow, the band would
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have an equilibrium concentration, as shown by the dotted 
line above the interface and the solid line below the 
interface. However since there is a flow in the mobile 
phase, the actual concentration of solute in the mobile 
phase is always in non-equilibrium with that in the 
immediately adjacent stationary phase. The dispersion or 
dilution of the chromatographic peak is minimized by 
choosing conditions such that the non-equilibrium is reduced 
and the rate of exchange is maximised.
The undesirable effects of the non-equilibrium processes can 
be decreased by reducing the flow rate to allow a longer 
time for the equilibrium to be reached. Another factor is 
the tightness of the packing. If the channels through which 
the mobile phase flows are narrow, a greater equilibrium is 
established since the solute molecules have less distance to 
diffuse before reaching the stationary phase. This will 
result in less zone spreading. For the same reason a 
thinner layer of stationary phase will minimise zone 
spreading.
1.3.2. Mechanism of Zone Migration
The simplest approach to the mechanism of zone migration is 
through considering chromatography as a "random walk" 
process[17]. This model enables us to have a better 
understanding of the processes occurring during the 
chromatographic separation.
1.3.2.1. The "Random Walk" model and the van Deemter 
equation
All of the factors affecting zone spreading occur in a
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random fashion. Ordinary diffusion occurs at the molecular 
level in a random fashion. Eddy diffusion results from the 
flow of molecules through randomly spaced particles that 
make up the stationary phase. Non-equilibrium mass transfer 
is governed by the rate of the kinetic processes that 
transfer the solute between the stationary and mobile phase. 
All such kinetic processes are random at the molecular 
level.
A simplified example of random walk is a drunken man not 
knowing his way. Each step he takes is independent of the 
previous one. Each step is the same length but the 
direction is chosen randomly. If many people were to take 
a "random walk" from the same point, some would end up on 
one side of the starting point and some on the other. If a 
plot of their number at various points against distance was 
to be drawn, one would obtain a bell-shaped Gaussian curve. 
Statistically, the extent of their spreading would be the 
standard deviation, < f . The value of &  obtained from 
the random walk theory is given by the following equation.
where 1, is the length of each step and n, the number of 
steps taken. If several random processes are involved, the 
net result is given by equation 8.
In the case of chromatography, three independent factors 
contribute to the overall result, each of which can be
(7)
(8 )
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calculated separately.
1 . 3 . 2 . 2 .  Calculation of the ordinary diffusion effect 
The CT'i value for ordinary diffusion can be related to the 
coefficient of diffusion, D, in the mobile phase, by the 
following equation.
x
= 2Dt (9)
where (t) is the time spent in the mobile phase since the 
beginning of the random process (it is assumed that only a 
negligible amount of diffusion occurs in the stationary 
phase).
The equation for distance on the other hand is given by:
L = \ f  t (10)
where (L) is the distance the zone migrates and the 
velocity of the mobile phase. Substitution of L/^ for (t) 
in equation (9) will give the final equation £ o v ( f o .
^  = 2DL/>/ (11)
This equation represents the total contribution of ordinary 
diffusion in the overall solute zone spreading.
1.3.2.3. Calculation of the eddy diffusion effect
Eddy diffusion is also a random process due to the solute 
molecules being carried through an uneven pathway by the
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mobile phase. The solute molecules alternate between "fast"
and "slow" channels. This is similar to a step forward and
a step backward. A channel between two particles will have
an approximate length of one diameter, d . Depending onP
whether it is a "fast" or "slow" channel, each step will be
in the order of +d or -d with respect to the centre of the
solute zone. Thus the equivalent step on the average is
approximately, d . The number of steps, n, is therefore theP
number of channels with the length, d^, present in the 
displacement distance of the zone, L.
L = nd or n = L/d (12)P P v '
However, it has to be noted that not all the channels can be
classified as "fast" or "slow". All the channels are not
equal to dp , but the assumption taken is approximately
correct. In the random walk equation (7) by replacing (1)
with d and n with L/d the final equation representing the P P
eddy diffusion contribution to the solute zone spreading is 
obtained.
1.3.2.4. Calculation of the non-equilibrium effect
In this case a similar analysis can be applied. The rate of 
equilibrium between the mobile and stationary phase can be 
controlled either by diffusion from one phase to the other 
or by an adsorption-desorption process. As previously 
defined, the average time required for desorption of an 
attached molecule is t^, and the time taken for adsorption
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to take place is t . This adsorption-desorption processcl
resembles a random walk process again. A desorbed solute 
molecule moves faster than the centre of the zone of 
velocity R V  (R<1). In the adsorbed state, it can be 
considered to be moving backward with respect to the centre 
of the zone. A resemblance with the random walk can be seen 
closely here, each step being a phase transfer process 
depending on a random energetic collision. In order to 
relate the random walk concept to those processes involved, 
one has to define the number of steps and the length of each 
step.
The number of steps, n, is the total number of adsorption 
and desorption steps (total number of cycles). Since each 
phase transfer terminates a desorption or adsorption step 
(or a "lifetime"), n is also equal to the number of phase 
transfers. Thus, n, is twice the number of adsorption (or 
desorption) steps. The time needed for a solute zone to 
move a distance, L, at a velocity R V" is simply L/RV .  The 
fraction, R, represents the time a molecule spends in the 
mobile phase while (1-R) represents the time it spends in 
the stationary phase. The average time spent in the 
stationary phase would therefore be: (1-R)L/V"R- To find
the number of desorption steps this value is divided by the 
average time required for a single desorption step, t^,
(1-R)L/RVt^. And from this,
2(1-R)L (14)
RVtd
The length of step, 1, is the length of the step the solute
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molecule moves back with respect to the centre of the zone. 
In fact, it is not the molecule that is moving back, but 
rather the centre of the zone that is moving forward, when 
the molecule is immobilised during the sorption process. 
This time is t^, and the distance moved is Rl/t^ .
Substitution of RVt^ for 1, and [2(1-R)L]/[RVtd] for n, in 
the equation (7) results in the following equation:
<fc = R t J  [2(l-R)L]/RVt . (15)
or
CTC = \/2R(l-R)yLtd (16)
showing the contribution of non-equilibrium mass transfer to 
the solute zone spreading. Now it can be seen from the 
above equation that: (a) an increase in mobile phase
velocity will increase the zone spreading, (b) the rapid 
exchange of solute molecules from stationary phase to mobile 
phase will decrease the spreading (a smaller t^) , and (c) 
the spreading due to non-equilibrium mass transfer in
directly proportional to \/L.
The total zone spreading is therefore equal to the sum of 
the three values ofCT, written as:
(7 2 = L (2/DV*+ d + 2R(l-R)Vt,. (17)P Q )
A better known quantity representing the solute zone 
spreading in chromatography is given in "Plate theory". In 
this theory a chromatographic column is envisaged as being 
composed of a series of discrete, but contiguous, narrow,
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and horizontal layers called theoretical plates, between 
which the equilibration of solute molecules, between mobile 
and stationary phases takes place. Movement of the solute 
and solvent is then viewed as a series of stepwise transfers 
from one plate to the next.
Based on this theory, it is considered that as the number of 
plates increases so does the efficiency of a chromatographic 
column.
The definitions of efficiency are taken from this theory, 
with efficiency values being expressed as the number of 
theoretical plates (N) or the height equivalent to a 
theoretical plate (HETP). From this,
N L (18)
HETP
or
N L (19)
H
where L is equal to the length of the column.
Also H = C T/L (2 0)
or
—- 2- 
HL = C T (21)
By substituting HL for ( f in equation, 17 the final form of 
the equation is obtained.
H = (2D/y f ) + dp + 2R (22)
This equation is the van Deemter equation [18] and serves as 
a first approximation to plate height.
The important characteristic of H in this equation is that it 
is independent of the distance migrated by the solute 
molecule, in any uniform column. By plotting H, versusV 
the following graph is obtained.
Fig. 4
V
van Deemter Plot
A graphical description of the van Deemter plot is shown in 
fig 4. The plot shows the dependence of H on linear 
velocity for each of the three spreading sources, and the 
overall dependence as the sum of the three. At low flow 
rates, diffusion dominates spreading. At high flow rates, 
non-equilibrium dominates. There is an optimum velocity at 
which H is'a minimum. In LC the diffusion rates are so low 
that the minimum is seldom seen.
1.3.3. Optimisation of conditions in Chromatography
Temperature and the nature of the mobile phase are among 
other variables which affect the value of H. The effect of 
these variables can be explained by the fact that the 
efficiency of the separation depends on,
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(a) the separation of the zone centres
(b) the compactness of the bands.
In order to achieve a good separation both these factors 
must be optimised. Temperature affects both these factors. 
The velocity of the mobile phase only affects the 
compactness of the zones.
1.3.4. Resolution
The resolution R is defined by the distance between thes
band centres divided by the average band widths in the same 
units.
Rs — 2 R2 ^R1 in time units.
W1 + W2
It is an expression of the separation between components, 
depending on the narrowness of the peaks and the separation 
between the peak maxima.
Response
V2 = F x t2
F = Flow rate (ral/min)
t = Retention time of 
° non-retained component 
t.= Retention time for 
component 1 
t„= Retention time for 
component 2
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Purnell[19] has transformed the resolution equation to give 
Rs = 1/4 (L/H)[K'/(1+K')] ( o i - 1 )  (23)
where the separation factor is given by 
c< = (V2-V0 )/(V1-V0) = K 2/K x
Resolution may also be expressed as
R s  = ( W / [ 2 ( / 2  + f l ) ]  ( 2 4 )
where [  ^  and £ ^ are standard deviations in units of
time. The resolution should be greater than or equal to one 
for a satisfactory separation of any two compounds. The 
simultaneous optimisation of variables in the separation 
process is impossible in practice because of the numerous 
factors involved. The optimum conditions are best 
established by relating the individual factors in the 
resolution equation, (24), to temperature. Therefore t and 
I  should be expressed in terms of T.
Retention time t, can be expressed as [L]/[r /”] with L and\/" 
being independent of T. R^ can be related to T by the 
equilibrium equation.
R, = Vm <25>f
V +KV m s
and the equation
K = Constant .e ^ H/RT (26)
The standard deviation in units of time, /* , can be defined 
as the time required to sweep the zone along a distance
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equal to d Therefore:
cr
i
(27)
Rf
Of all three contributing factors to ( f .  only two are
influenced by changes in temperatures. Ordinary diffusion
depends on temperature through the diffusion coefficient, D.
The non-equilibrium term varies with changes in temperature
because of its relation with R and T ,. The value of t,d d
itself is related to rate constant through the Arrhenius
equation 6. In this fashion step by step and term by term
the temperature dependance of resolution is determined.
Then a plot of R against T, can be drawn from which the
maximum Rg can be obtained. Theoretically the derivative of
R with respect to T, f dR ]/[dT]=0 should lead to the R s s s
maximum. An inverse relationship exists between R and Ts
with a decrease in temperature improving the resolution.
The more straightforward variables like the column length 
can easily be related to R , since the retention time t, is 
equal to [Ll/tRV^], and is therefore proportional to /l. 
thus Rg is proportional to \J L. This means a longer column 
will give a better resolution. The major limitation in this 
case would be maintaining the pressure through a longer 
column, or in paper chromatography, the evaporation of 
solvent from the paper strip.
Other variables such as particle size, flow velocity, 
thickness of the stationary phase layer, and the mobile 
phase properties can be accounted for in the same fashion.
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In the same way, one can establish and calculate the mimimum 
time required for the separation of a multicomponent 
mixture, keeping in mind that Rg should not be less than 
one.
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1.4. CHROMATOGRAPHIC MECHANISMS
During a chromatographic separation solute molecules are 
continually moving back and forth between the stationary and 
mobile phases. While they are in the mobile phase, they are 
carried forward with it but remain virtually stationary 
during the time they spend in the stationary phase. The 
rate of migration of each solute is therefore determined by 
the proportion of time it spends in the mobile phase, or in 
other words by its distribution ratio.
The process whereby a solute is transferred from a mobile to 
a stationary phase is called sorption. Chromatographic 
techniques are based on four different sorption mechanisms, 
namely surface adsorption, partition, ion-exchange and 
exclusion. The orignal method employed by Tswett involved 
surface adsorption where the relative polarities of solute 
and solid stationary phase determine the rate of movement of 
that solute through a column or across a surface. If a 
liquid is coated onto the surface of an inert solid support, 
the sorption process is one of partition, and movement of 
the solute is determined solely by its relative solubility 
in the two phases or by its volatility if the mobile phase 
is gas. Both adsorption and partition may occur 
simultaneously, and the contribution of each is determined 
by the system parameters, i.e. the nature of the mobile and 
stationary phases, solid support and solute. For example, a 
stationary phase of aluminium oxide is highly polar and 
normally exhibits strong adsorptive properties. However, 
these may be modified by the presence of adsorbed
water which introduces a degree of partition into the 
overall sorption process by acting as a liquid stationary 
phase. Conversely, paper (cellulose) is relatively 
non-polar and retains a large amount of water which 
functions as a partition medium. Nevertheless, residual 
polar groups in the structure of the paper can lead to 
adsorptive effects.
The third sorption phenomenon is that of ion-exchange. 
Here, the stationary phase is a permeable polymeric solid 
containing fixed charged groups and mobile counter-ions 
which can exchange with the ions of a solute as the mobile 
phase carries it through the structure.
The fourth type of mechanism is exclusion although perhaps 
'inclusion' would be a better description. Strictly it is 
not a true sorption process as the separating solutes remain 
in the mobile phase throughout. Separations occur because 
of variations in the extent to which the solute molecules 
can diffuse through an inert but porous stationary phase. 
This is normally a gel structure which has a small pore size 
and into which small molecules up to a certain critical size 
can diffuse. Molecules larger than the critical size are 
excluded from the gel and move unhindered through the column 
or layer while smaller ones are retarded to an extent 
dependent on molecular size.
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In each chromatographic technique one of the four mechanisms 
pre-dominates, but it should be emphasised that two or more 
may be involved simultaneously. Partition and adsorption 
frequently occur together and in paper chromatography, for 
example, ion-exchange and exclusion play minor roles also.
These different modes will now be described in more detail.
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1.4.1. Liquid Solid Chromatography (LSC)
Adsorption HPLC, because of its versatility, is often the 
answer to a separation problem. If the sample is soluble in 
non-polar or moderately polar solvents such as hexane, 
methylene chloride, chloroform, or diethyl ether, then 
adsorption chromatography is a likely choice.
This technique depends on specific interactions of the 
solute with the surface of a finely divided adsorbent 
(silica gel, alumina or charcoal).
1.4.1.1. Snyder Model
According to the Snyder model [20], the mobile phase and the
solute are in competition for the active sites on the
adsorbent. This competition can be represented by,
X + nS . ---- - X , + nSm ads  ^ ads m
where n represents the number of mobile phase molecules that 
must be displaced to accommodate the solute molecule (Fig. 
6).
Equilibrium expression ^ a d s ^ ^ m ^
K = (X )(S , )n v m 'v ads'
This expression shows that the most important interaction 
governing the separation by LSC is the adsorbent-solute 
interaction. As the relative adsorption of the mobile phase 
increases the adsorption of the solute must decrease leading
26
Active Sites
Fig. 6 Schematic diagram of the adsorption process
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to shorter retention times. The value for K can be obtained 
from adsorbtion isotherm data or it is more common to obtain 
relative K values from TLC data.
1.4.1.2. Packings for L.S.C.
In liquid-solid adsorption chromatography, the mobile phase 
is a liquid while the stationary phase is either a totally 
porous particle or a porous layer bead - the pellicular 
packings, (Fig. 7).
40/jm
Shallow pores
5 m
Shallow pores
1- 2 pan
(a) (b)
Fig. 7 Stationary phases used in adsorption HPLC: (a) porous
layer beads; (b) porous microparticle.
1.4.1.2 .1. Porous Layer Beads or Pellicular packing
A pellicular or porous layer bead type of packing consists
of a solid, spherical glass bead with an average particle
diameter of 30-40 ;um, and a thin, porous outer shell. The
outer shell, typically 1-3 >im thick, may be a silica gel
layer, a network of small spherical particles' bonded to the
solid core, or a bonded monomeric or polymeric organic
phase. Surface areas of the porous layer beads range from 5 
2 -1to 15 m g . Columns are easy to pack with these materials 
because of the dense core but due to their small surface
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areas, porous layer beads suffer from limited sample 
capacity (approximately 0. lmg g ^) . Thus they are less
useful for preparative work or for use with the lower
sensitivity detectors. However, relative to a porous 
packing of equivalent diameter, stationary phase mass 
transfer is greatly improved in a thin porous layer bead and 
consequently, these packings exhibit good efficiency.
Longer columns are possible because the pressure drop is 
lower due to the larger particle size of porous layer 
supports.
1.4.1.2.2. Porous Particles (Microparticles)
The totally porous particle is generally a high surface area, 
active material such as silica gel or alumina. These are 
the most common phases in adsorption chromatography. Both 
silica gel and alumina have a high concentration of surface 
hydroxyl groups whose number and geometric arrangement 
determine the activity (retention) of the adsorbent. The
slightly acidic silanol groups (Si-OH) in silica gel exist
at the surface and extend into the internal channels of the 
pore structure. These hydroxyl groups interact with polar 
or unsaturated moieties by hydrogen bonding. During 
dehydration (activation) a certain proportion of these 
silanol groups will form siloxane linkages (Si-O-Si) between 
neighbouring silicon atoms. Siloxane groups are very weak
in their adsorptive properties. For silicas, surface areas
2 - 1  2 - 1  range from a low of 100m g to a high of 860m g with
2 -1the average being 400m g
Aluminas comprise about 20% of the solid adsorbents in use. 
Aluminas have low surface areas, larger average pore 
diameters, and higher packing densities than silicas. 
Aluminas do have some selectivity advantages, particularly 
for unsaturated hydrocarbons and halogen-containing 
compounds and are useful for very basic compounds which may 
adsorb too strongly on the acidic silicas. In addition, 
alumina possesses greater stability at high pHs where silica 
tends to dissolve.
In LSC the order of elution is the order of polarity and 
this has allowed the development of a generalised polarity 
scale for various classes of compounds. In the case of 
polyfunctional compounds, the most polar groups will 
dominate the adsorption characteristics, although all 
constituent groups contribute to the retention.
Both silica and alumina have surface OH-groups and Lewis 
acid type interactions. The number and topographical 
arrangement of these groups determines the activity.
1.4.1.3. Solvent Selection in LSC
The active sites appear to have varying degrees of strength. 
Very strong adsorption can lead to long rentention times and 
tailing peaks. To reduce the effect of strong interactions, 
the adsorbent activity is usually controlled or modified 
with a fixed water or alcohol content.
For non-polar mobile phases, having the proper water or 
alcohol content is very important, but as the polarity of
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the mobile phase increases the importance of the water 
content diminishes.
The mobile phase is in competition with the solute for the 
active sites. This equilibrium is controlled by the mass 
action law. It is very important to maintain a constant 
water or modified layer on the adsorber. Only when complete 
thermodynamic equilibrium exists between the mobile phase 
and the deactivated adsorbent will retention times be 
reproducible.
There is a difficulty in saturating non-polar solvents such 
as hexane with water. Another option is to add a small 
amount (0.1 to 0.5%) of an alcohol such as isopropanol or 
methanol. These alcohols serve to modify the adsorbent in 
much the same way as water and are more soluble in non-polar 
solvents.
1.4.1.4. Solvent Strength_in_ LSC
The solute and the solvent are in competition for the active 
sites on the adsorbent, it is easy to deduce that the more 
strongly the mobile phase interacts with the adsorbent the 
quicker the solute will elute from the columns. Thus the 
major factor determining retention in LSC is the relative 
polarity of the mobile phase and the solute. The solvent
is a quantitative representation of
solvent strength or solvent polarity (Table I).
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TABLE I Solvent strength Parameter, e° and Physical Properties of 
Selected solvents.
Solvent e° (Si02) e°(Al203) Viscosity(£0°C) 
mN sec m
Refractive 
Index (20°C)
Pentane 0. 00 0. 00 0.23 1. 358
Hexane 0.00 0.313 1.375
Cyclohexane -0.05 0.04 0.980 1.426
Carbon disulfide 0.14 0. 15 0. 363 1.628
Carbon tetrachloride 0. 14 0. 18 0. 965 1.460
1-Chlorobutane 0. 26 0.47 1.402
Disopropyl ether 0. 28 0.379 1.368
2-Chloropropane 0. 29 0.335 1.378
Benzene 0.25 0. 32 0. 65 1.501
Diethyl ether 0.38 0. 38 0.23 1.353
Chloroform 0. 26 0. A0 0.57 1.443
Methylene dichloride 0. 42 0.44 1.425
Methyl isobutyl ketone 0.43 1.394
Tetrahydrofuran 0.45 0.55 1.407
Acetone 0.47 0. 56 0. 32 1.359
1,4-Dioxane 0.49 0.56 1.54 1.422
Ethyl acetate 0.38 0.58 0.45 1.370
1-Pentanol 0.61 4. 1 1.410
Acetonitrile 0.50 0. 65 0. 375 1.344
1-Propanol 0. 82 2.00 (25°) 1.38
Methanol 0.95 0.60 1.329
Water Large 1. 00 1.333
Solvent strength parameter, e° is defined as the adsorption energy per 
unit area of standard adsorbent.
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1.4.2. Partition Chromatography
Two different types of partition chromatography may be 
distinguished, classical liquid - liquid chromatography 
(LLC) in which the stationary liquid phase is coated on a 
support material and bonded phase chromatography (BPC) where 
there is chemical bonding of groups to the support surface 
(fig. 8).
In classical liquid - liquid chromatography (LLC) the 
stationary phase should be a good solvent for the sample but 
a poor solvent for the mobile phase. Operationally there 
are many problems. The coated phase may be stripped by 
strong solvents or gradually removed due to lack of mobile 
phase presaturation. Under high pressures shearing forces 
tend to remove the stationary liquid. Another limitation is 
that column temperatures must be carefully controlled within 
0.5°C. These factors, the inability to use classical LLC 
with gradients and above all the advent of efficient stable 
bonded phase packings has almost made the use of these 
coated phases obsolete.
Partition chromatography can be operated in two different 
modes (a) normal phase and (b) reverse phase, a division 
based on the relative polarities of the mobile and 
stationary phases. Normal phase chromatography uses a polar 
stationary phase (often hydrophilic) whereas reverse phase 
employs a non-polar stationary phase (usually hydrophobic) 
and a polar mobile phase. In the reverse phase mode the 
compounds that are non-polar selectively interact with the 
liquid phase and are retained more strongly then the ones
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which are polar. Reverse phase chromatography will most 
likely provide optimum retention and selectivity when
compounds have no hydrogen bonding groups or have a 
predominance of aliphatic or aromatic character. The 
reverse phase technique in its various forms - regular
partition, ion-pair partition and ion-suppression is the 
most widely used mode in HPLC now that bonded phase supports 
have provided a suitable stationary phase.
Partition chromatography is potentially more versatile than 
adsorption LC because of the wide variety of organic 
stationary phases which can be coated on the packing.
However the most popular bonded phase comprises a linear
hydrocarbon, most commonly an octadecyl Cg or alkyl
chain. In normal phase mode, one uses the packings that 
have polar groups bonded to them. Polar examples of such 
packings are those with alkylnitrile (CN column) and 
alkylamine (NH2 columns) groups bonded to them. The 
technique is called normal phase since usually the solvents 
used are those of LSC.
The most common chemical reactions that are employed to bond 
organic molecules to silica are shown below.
Esters (hydrolytically unstable)
silica - OH + HO-R => Silica - OR + H20
Silicones or Siloxanes
RSiCl3 OH
BONDED PACKING
c h 3c iV h p
Interaction on the surface of a bonded 
phase packing.
In reverse phase liquid chromatographic packings silanol 
groups on the surface of the silica are reacted with thionyl 
chloride followed by reaction with a Grignard reagent 
[16-19]. The R group of this reagent dictates the 
properties of the stationary phase.
SiOH + S0C12   ^ SiCl + S02 + HC1
SiCl + RMgBr  > SiR
As mentioned the most commonly used hydrocarbons attached to 
the stationary phase are octyl, octadecyl, and phenyl. 
Alkylamine may also be attached to the silica surface.
1.4.2.1. Theory
The exact mechanism of bonded phase chromatography is still 
the subject of much study [21-25]
Briefly when a solute is added to the system, and the system 
allowed to equilibrate the solute will distribute itself 
between the two phases according to the equation
where K is the distribution coefficient and C and C ares m
the concentrations of the solute in the stationary and 
mobile phases, respectively. The capacity factor k^ is 
related to the distribution coefficient by the following 
equation
gm - grams of solute in mobile phase = (Cm)(Vm) (3)
gs = grams of solute in stationery phase = (Cs)(Vs) (4)
1 V,m (5)
Vs
or upon rearrangement
k1 = K Vs (6)
V.m
The more soluble the solute is in the stationary phase, the 
longer it will be retained. In addition retention and
resolution can be increased by increasing the amount of
stationary phase.
The mechanism that causes separation in bonded phase 
partition LC is not well understood, however it is clear 
that columns packed with these materials exhibit separation 
properties that are similar to adsorption under certain
conditions and to liquid - liquid partition under other 
conditions. This is probably due to the fact that a high 
initial concentration of silica surface hydroxyls is needed 
in order to bond the organic phase and many of these 
hydroxyls remain free for adsorption after even the most
careful bonding procedures. In the determination serum 
theophylline evidence is presented which suggests that an 
octadecylsilane phase bonded to silica particles acts via 
mixed retention mechanisms probably due to the action of 
free silanol groups rather than pure reversed phase 
partition [26].
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Separation due to adsorption on the residual hydroxyls of a 
bonded-phase packing will be most important for small polar 
solutes and nonpolar mobile phases. The solute size is 
important because the highest concentration of residual 
hydroxyls is likely to be in sterically hindered places 
where bonding is incompete. The effect of this adsorption 
mechanism can be tested or eliminated by adding a small 
amount of polar modifier such as water or acetic acid to the 
hydrocarbon mobile phase to deactivate the remaining 
hydroxyls.
1.4.2.2. Normal Bonded Phase
Bonded phases using Si(CH2 )n Nf^ or Si(CH2 )n CN moieties can 
be used in normal bonded phase chromatography.
They are very similar to the packings used in LSC but have 
some advantages
(a) Irreversible retention is less likely due to absence of 
strong silanol groups
(b) Unnecessary to control the level of water
(c) Equilibration is rapid
(d) Compatable with a wide range of solvents
(e) Difficult to damage
(f) Different selectivities
(g) The alkylamine column can function as a weak anion 
exchange column.
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1.4.2.3. Reverse Phase
Liquid chromatography where the mobile phase is more polar 
than the stationary phase was termed "reversed phase" (RP) 
chromatography since early in its use [27, 28]. With the
advent of packings with covalently bonded functional 
moieties on pellicular and microparticulate particals RP 
became significant in the practice of HPLC. It is now 
estimated that 60-80% of all HPLC separations are 
accomplished using RP packings [29, 30], In a publication
by Horvath et al. it was considered that RP was primarily a 
tool for non-polar substances [29] whereas Karch et al. 
believed that the main advantage lies in the separation of 
polar samples that are not eluted from silica columns [31]. 
However it is now accepted that RP may be used over a broad 
polarity range and in diverse applications. In an 
investigation by Twitchett and Moffat it is claimed that 
drugs of any lipid solubility, molecular weight chemical 
structure and acidity/basicity can be chromatographed using 
RP if an appropriate eluent is chosen [32].
1.4.2.3.1. RP Retention Mechanisms
Although it is generally accepted that in RP systems the 
most polar solutes are the least retained however the 
precise mechanism of retention has yet to be agreed upon. 
Karch et al- have suggested that it is due to solute 
interaction with the nonpolar stationary phase by dispersion 
forces [31]. In contrast Locke considers the solute 
interactions with the nonpolar stationary phase to be weak 
and non selective [24]. Karger et al.have emphasised, the
39
importance of understanding water solubility [33]. Starting 
with water solubility theories which use the idea of cavity 
formation [34, 35] they discuss hydrophobic effects to 
explain the experimental observations that reverse phase 
systems exhibit a marked selectivity for the hydrocarbon 
structure of solutes. From the hydrophobic effect it can be 
predicted that an increase in molecular size of solutes in a 
series of chemical homologues will lead to a longer 
retention time. An increase in the carbon chain length of 
the stationary phase will obviously increase the available 
surface of the non-polar moiety of the stationary phase to 
that of the solute molecules leading to a higher k^ value 
(longer retention time). On the other hand the introduction 
of polar groups causes a decrease in the retention time.
Horvath et al. also point to the importance of the role of 
the mobile phase [29], They have adopted solvophobic theory 
[36,37] an<3 point out that the most pronounced solvophobic 
effect is the hydrophobic effect which results from the very 
high cohesive density of water. Mobile phase surface 
tension is shown to play a key role. They further point out 
that, whereas in stationary phases having ionic or hydrogen 
bonding moieties (normal phase systems) the driving force of 
retention is predominantly the attraction between the solute 
and stationary phase, in stationary phases having a 
hydrocarbon character (RP system) the driving force of 
retention is the concomitant decrease in the non-polar 
surface area exposed to the solvent. The hydrophobic "bond" 
between solute and stationary phase results primarily from 
the aqueous solvent forcing the molecules to associate 
rather than from any real attraction.
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Snyder has provided a clear description of this effect 
within a general discussion of polarity and the four 
bond-breaking or bond making steps involved in the transfer 
of a solute from mobile to stationary phase [38]. The 
energetically favourable transfer of non-polar solutes from 
the aqueous mobile phase to the hydrophobic stationary phase 
is related to the heat required to form a cavity within the 
water structure into which the solute is placed. The solute 
is repelled or "squeezed out" of the water because its 
interactions with water are weaker than the interactions of 
water with itself [39]. When the organic constituent of the 
mobile phase is increased, the surface tension is reduced, 
understandably this change shortens the retention time.
1.4.2.3 .2. Ion Suppression and Ion Pairing
A useful extension of the reversed phase technique is that 
of ion suppression or ion pairing. Consider a short chain 
carboxylic acid (<C&) which exists in aqueous solution as 
follows:-
RCOOH ^ RCOO~ + H+
Using a methanol water mobile phase the acid would be poorly 
retained and elute as a skewed peak. By adjusing the pH on 
the acid side, the equilibrium will move to the left, 
suppressing ionization and allowing the acid to be separated 
by reverse phase techniques. This technique is termed 
"ion-suppression" and is useful for weak acids and bases.
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However strong acids or bases cannot be handled by this 
technique since many are completely ionized in the pH 2-8 
range. However, by forming an ion pair with a counter ion, 
these strong acids and bases can be made into electrically 
neutral compounds and therefore be retained on a reverse 
phase column. The reverse phase ion-pair partition 
technique is favoured over the normal phase one since a 
bonded phase is used and the counterion and buffer are added 
directly to the aqueous mobile phase.
4 2
1.4.3. Ion-Exchange Chromatography
Ion-exchange chromatography should be considered when a 
compound is water soluble and ionic.
Commercial ion-exchange packings consist of porous organic 
or inorganic gel or resin networks to which various ionic 
functional groups have been attached. The two most commonly 
used starting materials are styrene divinyl benzene resin 
and silica gel. The nature of the ionic functional groups 
attached to these stationary phases is the most important 
factor governing retention and selectivity for a given ionic 
solute. Ion-exchange can be carried out in aqueous or 
non-aqueous solvents. The mobile phase normally contains a 
supply of counter ions opposite in charge to the surface 
ionic group.
Fig. 9.
Fig. 9: Schemetic diagram showing ion-
exchange .
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1.4.3.1. Packings for Ion Exchange Chromatography
Three main types of packing are used, pellicular, phases 
bonded to silica microparticles and classical crosslinked 
PS-DVB resins of small particle diameter. Pellicular 
packings are more widely used in ion exchange than in LSC or 
BPC. They provide unique selectivities, different to porous 
resins or ion-exchange silicas, and greater permeability. 
Due to their larger particle size they display lower 
pressure drop with the aqueous solutions employed, and show 
rigidity - neither swelling nor shrinking with changes in 
pH, temperature or ionic strength. In addition they are 
easily packed and allow the use of an extended pH range 
compared to silica but still not as wide as for resins.
1.4.3.2. Ion-exchange equilibria which occur on the column 
can be represented as fo1lows.
Strong Anion Exchange Packing:
Retention
& © 0  R + M + X R4 N gel & Q  0M + X  + R R 4 N -  gel
Elution
Strong Cation Exchange Packing:
Retention
<9 G  0R + X + M 0 3 S - gel 3 “ 9el
Elution
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Weak Anion Exchange Packing:
Retention
Elution
Weak Cation Exchange Packing:
Retention
C>2C - gel
Elution
The equilibrium expression for a strong anion exchange 
process may be given by:
The higher the value of K, the distribution coefficient, the 
more strongly the ionic solute interacts with the ion 
exchanger. The distribution coefficient will be determined 
by the nature of the solute and the stationary ionic group 
and a great number of other variables such as gel pore 
structure, pH, ionic strength and temperature. In
addition, separation characteristics can be influenced by 
specific interaction between the non-ionic part of the solute 
and the non-ionic part of the resin or gel. In this latter 
case, small amounts of polar organic solvents as modifiers 
to the aqueous mobile phase can have a dramatic effect upon 
the separation.
Vm
K= [R0 ] [-NR^ X ] k' Vs
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Ion-exchange chromatography is probably the most 
experimentally difficult mode of HPLC because there are more 
parameters that need to be controlled. The two most 
important variables that can be adjusted are pH and ionic 
strength.
The pH should be adjusted so that the solute and stationary 
ionic groups are in attractive, oppositely charged states. 
For example with a weak anion exchange packing, select a low 
enough (acidic) pH so that the amine group is protonated but 
not so low that the solute is protonated.
1.4.3.3. Solvent Selection
Because of the excellent solvent and ionising properties of 
water, most ion exchange chromatography is carried out in 
aqueous buffer salts. It is often useful to choose a 
buffering salt that has a functional group similar to the 
sample. For example choose an acetate anion as a buffer to 
elute organic acids. When developing the chromatographic 
conditions it is usual to start with a very low concentration 
of ions in order to maximise the change of retention. A 
counter-ion usually from a buffer, is one which has the same 
charge as the solute and occupies the stationary site when 
the solute is not there. A decrease in the counter-ion 
concentration forces the equilibrium towards stationary 
phase retention while an increase in counter-ion 
concentration forces the solute to elute from the column. 
In other words increasing the buffer strength in 
ion-exchange chromatography is analogous to increasing the 
solvent strength in LSC or LLC.
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1.4.4. Exclusion Chromatography
Other names include gel permeation, gel filtration, 
exclusion, or molecular sieving. It is applicable to a wide 
range of materials of both high and low molecular weight. 
It depends upon the physical restriction of the solute 
flowing into and out of the pores of the column packing. 
Ideally interactions such as adsorption, partition and 
ion-exchange should be absent from the ideal steric 
exclusion system.
The packing contains porous particles of various diameters 
and only solute molecules which have diameters small enough 
will diffuse into the pores (Fig. 10). Therefore the 
component with the largest effective diameter will elute 
first. As the effective diameter of the solute gets larger, 
the number of pores that it can fit into and its ability to 
diffuse into the pores decreases. Thus if it is of such a 
diameter that it cannot diffuse into any of the pores, it is 
defined as totally excluded and will be unretained that is, 
it will elute with the void volume of the column.
1.4.4.1. Types of packing
Semi-rigid gels 
Rigid packings 
Soft gels.
1.4.4.1.1. Semi-rigid gels
An example is Styragel made up of polystyrene divinylbenzene
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Directi on of Solvent Flow
Fig. 10: Schematic diagram
chromatography.
Large solutes cannot penetrate 
into the pores of the packing 
and thus move with the solvent. 
Small molecules diffuse into 
the pores and are retained.
showing exclusion
Exclusion Limit
Fig. 11: Typical calibration curve for exclusion 
chromatography.
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cross linked to give a semi-rigid structure. These can 
separate complex polymer samples such as rubbers and 
plastics. But the particle size in the region of 37 - 75 ^ im 
leads to slow mass transfer which leads to low flow ratio 
and long analysis times. Smaller particle sizes are now 
available however with smaller pore sizes and these give 
increased resolution and allow solutes of lower molecular 
weight to be separated. One should not change the solvent 
from that used to prepare the column, this may alter pore 
size and cause swelling of the packing
1.4.4.1.2. Rigid Packings
These packings are invariably made from glass or silica. 
They are available in a wide range of pore sizes and in large 
and small particle diameter. Advantages are that there are 
no limits on flow rates since higher pressures can be used, 
columns with high efficiencies are easy to prepare, aqueous 
and organic solvents may be used, however alkaline solvents 
with pH > 7.5 should be avoided since they dissolve silica 
or glass. The major disadvantage is adsorption effects 
(will alter the calibration curve and lead to tailing).
Adsorption effects can be minimised by treating the beads 
with Carbowax 400 or polyethyene glycol, or beads may be 
treated with various silylating reagents to deactivate the 
polar sites.
1.4.4.1.3. Soft Gels
These materials are typified by cross-linked dextrans, the
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most popular being Sephadex. The use of these materials is
called gel filtration. The packings swell in the solvents
used. They are useful for separating water-soluble
2 7substances in the M.W. range 10 to 2.5 x 10 , e .g. proteins 
and enzymes. They are not widely used in HPLC since they 
can only withstand pressures of 150 p.s.i.
1.4.4.2. Components of the volume of an exclusion column
1. Void volume - the volume occupied by the flowing mobile 
phase between the particles.
2. The volume occupied by the solid portion of the
packing.
3. The pore volume - (V ) - the volume occupied by the
stagnant mobile phase.
We can define the distribution coefficient K of a particular 
solute as the ratio of pore volume accessible to the solute 
(VA ) to the total pore volume V .
VA
K =  Vp
The retention volume is the given by the following equation.
VR = Vo + KVp
The ideal is a small void volume and a high pore volume to 
achieve maximum possible separation.
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Adsorption effects may be noted and these will increase 
retention time and also lead to tailing of peaks. Packings 
from porous glass often show adsorption effects probably due 
to the presence of SiOH groups.
1.4.4.3. Selection of column
This will depend on the size of the solute molecules to be 
analysed
Soft gels are not compatible with HPLC. The semi-rigid 
particles are available in high efficiencies and wide pore 
ranges. They are compatible with organic solvents but not 
water because it does not wet the surface. Changing of 
solvent can change the degree of swelling and therefore 
change elution behaviour.
Each steric-exclusion packing will have its own calibration 
curve. The distribution of the pores in the packing governs 
the slope of the calibration curve (fig. 11). If the pore 
distribution is wide the curve will have a steep slope. The 
molecular weight operating range will be large but will 
provide less resolution of species of close molecular sizes. 
If the pore distribution is narrow, the curve will be 
flatter, the molecular weight operating range will be 
smaller but resolution of molecules of closely related size 
will be increased.
A major disadvantage of rigid particles is adsorption.
Resolution is increased by using a packing with a large pore
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volume, a flat calibration curve or a high plate count or by 
use of longer columns.
1. 4.4. 4. Selection of_ mobile phase
In contrast to other modes of liquid chromatography, the 
solvent in exclusion chromatography is selected to minimise 
the solute interactions with the support surface. 
Interactions such as adsorption, ion-exchange and 
partitioning should be absent in the ideal steric-exclusion 
system. The solvent chosen must wet the surface of the 
packing. The solute can then permeate the pores by a 
totally diffusion type process.
Many of the solvents which are useful in exclusion 
chromatography are not compatible with U.V. detectors. 
Toluene, tetrahydrofuran (THF) and halogenated aromatic 
solvents are widely used because they have excellent solvent 
characteristics for the heavy molecular weight substances 
normally analysed by exclusion. Of these solvents, only THF 
is potentially usable with U.V. detection at 254 nm. It 
should be noted that exclusion chromatography requires only 
a single solvent in which to dissolve and run the sample.
1.4.4.5. General Uses of Exclusion Chromatography 
Exclusion chromatography may be used in polymer analysis and 
for sample clean up.
In most polymerisation processes the final product normally 
contains a range of molecular weights. (Molecular weight
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distribution). In routine use exclusion is used to "finger 
print" a polymer product and gross changes in the 
polymerisation process can be spotted easily. In sample 
clean-up, fractions of high molecular weight can be 
discarded.
Exclusion chromatography may also be used for small molecule 
separation. Advantages of this approach are:
1. Solvent requirements are minimal, it must dissolve the 
sample and be compatible with the detector.
2. Gradient elution is not necessary.
3. Retention times can be estimated easily and are short.
4. The technique is easily automated.
5. Because of the mode everything is eluted in a known 
solvent.
6. The column has high sample capacity.
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1.5. INSTRUMENTATION FOR HPLC
The main components of the HPLC system are as follows.
(a) The Solvent delivery system.
(b) The Injection device.
(c) The Column.
(d) The Detector.
1.5.1. Solvent Delivery System
Several features of the solvent delivery system must be 
considered: precise delivery of solvent over a relatively
broad flow range; maximum pressure attainable; compatibility 
with other components in the HPLC system; compatibility with 
a wide choice of solvents; and noise level in the detector 
resulting from any pulsations. There are two main 
classifications of pumping system: constant pressure and
constant displacement. Both types of pumps usually operate 
by displacing liquid from a chamber by a hydraulic piston.
1.5.1.1. Constant Pressure Pumps
Constant pressure pumps can be used with both large and 
small hydraulic chamber volumes. The constant pressure
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pump is inherently pulse free during its displacement
stroke and has additional advantages of being able to 
refill rapidly and pump liquids at high flow rates. In
this type of pump, pressure from an external source 
(air or N2 ) must be supplied to a gas piston of large
surface area which is attached to a hydraulic piston
of small surface area. Amplification is about 50:1,
i.e. a gas pressure of 100 psi will produce an inlet
pressure of 5000 psi. The gas pressure is released at 
the end of the pump stroke, and the pump refills
instantly by the action of gas pressure or a spring. A
check valve between the pump and column prevents flow 
reversal during the refill stroke.
The performance of constant pressure pumps depends on
the following:
1. Properly functioning seals and check valves.
2. Pressure of the gas supply.
3. Restrictions within the system due to septa 
particles, particulate matter and column 
resistance.
4. Solvent viscosity.
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1.5.1.2. Constant Displacement (volume) Pumps
Constant displacement pumps are divided into two main 
classes:
a) Single displacement screw drive or syringe pumps
b) Reciprocating (single and dual pistions).
Most of todays HPLC systems use reciprocating pumps
Fig. 12, Constant Pressure Pump.
1.5 .1.2 .1. Syringe Pumps
These pumps are pulse-free and relatively accurate. On the 
other hand, they are limited in flow rate range. Flow must 
be interrupted during refill, and they are not as convenient 
as other types for solvent changeover. Solvent delivery is 
accomplished using a variable speed motor to turn a screw 
that drives a hydraulic piston. Malfunction of the motor 
and drive mechanism or leaking seals and valves are the most 
frequent causes for inadequate solvent delivery. When it 
becomes necessary to refill the pump, the screw action must 
be reversed to withdraw the plunger.
T o W a s t s
Fig. 13, Screw Driven 
Syringe Pump
57
1.5.1.1.2. Constant Volume Reciprocating Pumps
b) Single - Reciprocating Piston Pump:
This pump consists of a small piston attached to a motor via 
gears and a cam which drives it back and forth in the 
hydraulic chamber. Pistons are typically fabricated from 
borosilicate glass, sapphire or Chrom-plated stainless steel 
with a mirror finish.
Advantages:
They deliver a truly continuous flow
Changing from one mobile phase to another is rapid with 
no waste of solvent (because of small piston volume)
Fig. 14, Single Reciprocating Piston Pump
COLUMN
Disadvantage :
Flow pulsations, thus noise
The pulsation is normally minimised by using pulse
dampers of various designs or the piston is designed
with electronic feedback to remove pulsation
I O ~ F R O M  *£SE AVOIR
## %
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Dual - Reciprocating Piston Pumps :
This pump features closed-loop flow control to eliminate 
both flow irregularities and pump pulsations regardless of 
system back pressure Using a differential pressure 
transducer that measures the flow-rate by measuring the 
pressure drop across a restrictor of fixed volume, any 
fluctuations in flow rate are detected and compensated for 
by feedback to a pump circuit that rapidly adjusts the pump 
motor speed. Because the response time of this system is in 
the order of tenth of seconds and is much faster than the 
pump noise created by reciprocating pistons, flow pulsations 
throughout the column and detector are virtually eliminated 
without the use of a pulse dampner.
The main considerations when choosing a pump are price, 
performance and convenience.
Fig. 15, Dual Reciprocating Piston Pump
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1.5.2. Inj ectors
Typical HPLC injectors include septum, stopped flow, loop valve 
(either variable or fixed), and autosamplers.
1.5.2.1. Stop-flow
The flow is stopped, the injection made at atmospheric 
pressure; the system closed and flow reinitiated. This 
technique can be used because diffusion in liquids is small 
and thus resolution is generally not affected.
1.5.2.2. Septum
These are on-stream injectors similar to the commonly used 
gas chromatographic injectors. These injectors are usable 
up to pressures of about 60-70 atmospheres. They are not 
compatible with all LC solvents. In addition, small 
particles tear from the septa and tend to cause plugging 
problems.
1.5.2.3. Loop-Valve
These are the most popular and most widely used injectors 
(fig. 16). In the fill position, the sample loop is filled 
at atmospheric pressure. When the valve is actuated, the 
sample in the loop is swept onto the column.
1.5.2.4. Auto-inj ectors
It is possible to automate a loop valve. Here the advantage 
of on-column injection is sacrificed for automation. The 
sample is contained in a small vial with a septum cap. The
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Load i ng Syr inge Load i ng Sy r i nge
Sample Loop
Samp Ie 
Dip Tube
From Pump
Load Pos i t i on In j ect i on Pos i t i on
Fig. 16 Loop Valve Injector
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injection sequence starts with the needle penetrating the 
top of the vial. A small pulse of air is added to the top 
of the vial, which forces the liquid in the vial up the 
dipper tube and into the sample loop of the loop valve. The 
amount of air is controlled in such a way that the valve 
loop is overfilled and flushed with excess sample. A signal 
to the actuator tells the valve to rotate, placing the 
sample in the eluent stream. From there it passes directly 
to the column. The majority of auto injectors for HPLC 
appear to rely on gas displacement of the sample through the 
loop valve for filling, but a few utilize suction to fill 
the loop. Filling by suction has the disadvantage of 
requiring the use of less volatile solvents for 
dilution of the sample. Otherwise, the amount of 
sample taken in may vary due to formation of bubbles in 
the transfer lines.
1.5.3. The Column
The column is at the heart of the chromatograph and provides 
the versatility in the types of analyses that can be 
achieved with a single instrument.
There are three categories of columns, each of which is used 
for different purposes.
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1.5.3.1. Analytical Columns
Analytical columns can be found in different shapes and 
sizes, they can be stainless steel or a cartridge system 
made of resistant plastic or glass. Their sizes can vary 
from 5cm in length up to 30cm with internal diameter of 3.5 
-4.6 mm. Although analytical columns are normally used for 
trace analysis, a column of say 4mm x 30cm can hold up to 
lOmg of sample. The packing materials are usually 3um for 
5cm length columns and 5 or 10^um for longer columns. These 
columns can provide up to 100,000 theoretical plates per 
meter.
1.5.3.2. Microbore Columns
Microbore columns are only used for trace analysis. They 
have internal diameters of 1 or 2mm and can vary in length 
between 5 to 25cm with 3um packing materials. To use 1mm 
I.D. columns small volume detector flow-cells are essential 
to produce satisfactory results. The advantages of 
microbore HPLC columns over analytical columns are a massive 
reduction in solvent usage (up to 95%) and increased sample 
sensitivity.
1.5.3.3. Semi-Preparative Columns
Semi-preparative columns are primarily used for the 
purification of components of a mixture for further 
characterization or study. A typical semi-preparative 
column 8mm x 50cm can hold up to around 500 mg of sample.
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To increase the sample capacity, larger columns, 5 x 50cm, 
may be used which can hold up to lOg of sample.
In the area of drug analysis, however by far the most 
popular choice is that of columns containing reverse phase 
packings. Technical aspects of column selection will be 
discussed in Chapter 2.
1.5.4. Detectors for Liquid Chromatography
The detector unit, as a component of the HPLC system is 
employed to continuously monitor the column eluent. 
Generally the detector signal is then amplified and passes 
to a potentiometric recorder to obtain a printed output in 
the form of a chromatogram. Two basic types of detector are 
encountered (a) a bulk property detector which measures some 
overall charge in the physical property of the mobile phase 
e.g. refractive index or (b) a solute property detector 
which responds to some physical property of the solute which 
is not exhibited by the mobile phase.
1.5.4.1. Detector Performance
When assessing the performance of a detector the following 
factors should be considered.
(a) Noise
(b) Response
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(c) Linearity of Response
(d) Detection limits
Detector noise may arise from several causes which may be 
electronic, flow, or pressure effects or due to temperature 
fluctuations.
(a) Short term noise is considered as the random or 
periodic signal fluctuations of the order of ten cycles per 
minute or higher and is usually seen as a fuzzy base line. 
Short term noise is generally used to define the detection 
limit.
(ii) Long term noise is of the order of low cycles or 
fractions of cycles per minute. At normal chart speeds this 
may be confused with solute peaks in the recorder trace.
(iii) Drift appears as a continuous increase or decrease in 
signal and its presence often makes the determination of the 
detection limit difficult.
Response: The response of the detector is defined by the
slope of the calibration plot for detector signal against 
solute concentration (or mass rate). For linear functions 
we have the following relationship where the response is a 
fixed value.
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(i) Concentration dependent response
R = k M-
R = detector signalc
k = a constantc
M^ = the sample mass rate
M2 = the mobile phase mass rate w.r.t. time
The units will depend on the physical parameter being
3 -1measured e.g. refractive index units (R.I.U.) cm mg 
optical density units (ODU) for a UV detector.
In HPLC M2 >> hence e.g. 1 becomes
R = k M1 (2)c c   v '
M2
(ii) Mass rate dependent response
R = k M. (3)m m 1 '
R = the detector signalm
k = a constantm
M  ^ = the sample mass rate w.r.t. time
or
The dimensions are usually quoted as coulomb g ^. At the 
present time none of the well known L.C. detectors function 
solely as a mass rate device.
The main difference between the two types of response is 
that the concentration detector response is flow-dependent 
where as that for the mass detector is not . The equations 
given above are valid for linear relativity between the 
detector signal and sample size. In the case of non-linear 
functions the response is a variable, dependent upon the 
rate of change of the slope of the calibration curve.
Linearity of Response.
The general response function relating detector signal and 
sample size can be represented by
R = kXn (4)
X = is a measure of the sample size (concentration or mass 
rate) and n is known as the response index. For a linear 
response it is required that n = 1. In practice, detectors 
are either non-linear or linear over a restricted range.
The linear range is defined as that region of response 
between the detection limit and the point where n deviates 
from unity by a given value i.e. 5%. Furthermore values of
0.99 < n < 1.01 provide a satisfactory linear calibration 
over a range of about 1000 which is acceptable for a wide 
range of quantification analyses. Equation 4 may be 
expressed in logaritmic form
Log R = n log X + log k (5)
For n = 1 the slope of the plot should be 45°.
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Detection Limit
The detection limit is defined as the minimum sample size 
which will produce a signal equal to twice the short term
_3noise level. The dimensions are g cm for a concentration
detector and gs  ^ for a non dependent device.
Other important factors are (1) mobile phase flow rate 
effects on noise, drift and response (ii) temperature 
effects on noise, drift and response (iii) pressure effects 
on noise, drift and response (iv) dead volume in the 
detector cell and interconnecting tubing (v) time constant 
and inertial problems of the detector system.
1. 5.4.2. The Ultra-Violet Absorption Detector
The ultra violet absorbtion detector is the most widely 
applied in HPLC, it is relatively insensitive to temperature 
and flow variations and in the case of some compounds 
detection at the nanogram level is possible. The detector 
responds only to substances that absorb U.V. light and a 
great number of compounds fulfill this requirment due to the 
presence of C = 0, C = S, N = 0 and N = N groups in their 
structure.
Both single and double beam instruments are commercially 
available as well as fixed and variable wavelength
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detectors. The fixed wavelength instruments are either 
single or dual beam arrangements usually containing the 
following sources: A Tungsten, or a Deuterium lamp .
The basic optical layout of a particular design of double 
beam UV detector is shown in Fig. 17. In this example the 
source, S, is arranged at the focal length of lens L which 
is the window of the cells (sample and reference) and . 
The element, W, is plane glass representing the other window 
of the cells. A calibration filter can also be incorporated 
in the sample side of the detector. A further filter, F, is 
employed as a block to all other wavelengths other than the 
one of interest. The resultant UV radiation is converted 
into electrical signals by the photoconductors D^ and ■ 
The two electrical outputs are generally fed into two log 
amplifiers, subtracted from each other, amplified and the 
resultant signal fed into a potentiometric recorder. Some 
commercial detectors do not employ log amplifiers but depend 
upon the photodetector response approximating to a log 
function. Extra care in calibration is essential with this 
type of device.
There are two cell geometries in common usage; the 
conventional Z-form and the novel H-form (Fig. 18.) The 
latter design is claimed to be more stable with respect to
69
drift caused by flow variations of the mobile phase (40jln 
both geometries the flow path has been indicated with 
arrows. The cells are usually less than 10 ^ 1 in volume. A 
recent innovation is the use of a tapered cell construction 
which allows better light transmission and offers greater 
stability and sensitivity.
FIG. 17. Diagram of a UV detector
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Fir. 18: Different Cell Designs for UV Detector.
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Principle of Operation.
The Beer Lambert Law states that the fraction of radiation 
absorbed by a compound is proportional to the number of 
absorbing molecules.
where Io = the intensity of the incident radiation, I is the 
intensity of the transmitted radiation, d is the radiation path 
length, c is the concentration of the absorbing sample and k is a 
constant known as the extinction coefficient, the value of which 
depends upon the nature of the absorbing molecule and the 
wavelength of the incident radiation. Equation 6 may be 
rearranged.
I Io exp (-kcd) (6)
In Io kcd (7)
I
By definition we have
optical density (OD) log 10 I o (8 )
I
from equations 7 and 8 we get
In Io
I
2.303 log = ^cd
I
(9)
72
Now in the detector we have
Io (sample) - sample cell - 1^
Io (reference) - reference cell - I.
The detector is arranged so that 
Io (sample) = Io (reference)
Hence
log in Io _ absorbance + absorbance
1^ of solvent of sample (11)
and Log ln Io absorbance
I2 of solvent (12)
From equations 11 and 12 we get
absorbance = Log 1-, - Log,» I„
of sample 1U 1 1U A (13)
i.e. Log I  ^ x sample concentration
X2
1.5.4.3. Fluorescence Detectors
Some substances have the property of absorbing light and then 
emitting it (essentially instantaneously) at a longer wavelength 
(lower energy). This is called fluorescence. The two main 
advantages of fluorescence detectors for HPLC are better
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detection limits for many compounds and frequently improved
selectively. Minimum detection limits for fluorescence
-12detectors can extend below the picogram level (10 g) for 
favourable samples.
A diagram for a sample fluorimeter is shown in figure 19. Light 
from a lamp passes through an optical system to form the beam and 
select the wavelength for excitation of the sample. The light 
beam is focused on the quartz sample cell. When a fluorescing 
molecule is present in the cell, light of a wavelength different 
from that used to excite the molecule is emitted in all 
directions. The emission optical system collects and filters the 
light which is then focused onto the detector. Within this 
general framework there are two different classes of fluorescence 
detectors for HPLC. The most expensive detectors use 
monochromators for selection of the excitation and/or emission 
wavelength. Filter fluorimeters replace the expensive 
monochromators with filters. Filters generally pass light in a 
wider band than do the monochromators. This frequently turns out 
to be an advantage since the detector does not need to be 
specifically tuned for each compound as it elutes. Generally the 
light sensitive element is a photomultiplier tube for best 
detection limits but solid state detectors are used in many less 
expensive models that are designed to take advantage of the 
specificity of fluorescence detectors rather than lower detection 
limits.
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LAMP
EXCITATION
FILTERS
Fig. 19 Optical Diagram of a simple filter 
fluorimeter for Liquid Chromatography.
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Requirements for Fluorescence Detection .
Organic molecules containing at least two c o n j u g a t e d  IT bonds will 
contain an absorption at A max > 200nm characterised by an
extinction coefficient £ 10 litre/mole. cm. These molecules
will be considered "absorbent" in the sense that LC - UV 
detection at concentration higher than 200 ppb is feasible. 
Absorbent organic molecules generally have fluorescence quantum 
yields between 0.0001 and 1.0.
Basic Rules for Predicting Fluorescence in a Sample
(1) Organic molecules which do not absorb strongly above 250 nm 
will not be fluorescent.
(2) Molecules in which the long-wavelength single absorbtion 
band (So - S^) is located at À > 250nm and is of a (TT, TT*” ) 
nature will be fluorescent.
(3) The higher the extinction coefficient, £ , for the 
long-wavelength band and the lower the band energy, the 
higher will be the fluorescent efficiency.
(4) Substituents which donate electrons to a "¡T system will 
enhance absorption of light and increase fluorescence. Key 
examples are OH > OR > NH2 >SH >SR > CH^ > CR^ e.g coumarin 
is non-fluorescent whereas 7-hydroxy coumarin is highly 
fluorescent.
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5. Functional groups or solvents that introduce a long 
wavelength (n;TT*) absorbtion band into a molecule will tend 
to significantly reduce fluorescence. The addition of 
electron donating functional groups can reverse the effect.
Most of the solvents used in UV detectors can be used in 
fluorescence detection, however halogenated solvents such as 
CH2 Cl2 or CHCl^ should be used with care as they tend to 
quench or diminish fluorescence.
1.5.4.4. Electrochemical Detectors
Electrochemical detectors are instruments which cause the sample 
to react (be oxidized or reduced) at an electrode surface under 
controlled potential conditions. The electron current at the 
electrode is monitored as a function of time to give the signal 
which is amplified and displayed on a recorder in the 
conventional manner.
The electrodes are encased in a very low dead volume cell (lul), 
which offers good chromatographic efficiency. Quantitative data 
can be obtained with injected samples in the picomole or nanogram 
range.
This detection mode is appealing because of its high sensitivity 
and specificity along with low cost. Unfortunately relatively 
few drugs are electrochemically active. The main application of 
the detector in clinical LC analysis is for catecholamines. 
Different electrochemical techniques include conductiometric 
(detects ions and has low background current) and polarographic 
(coulometric) methods.
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1.5.4.5. Diode Array Detector
The advent of the microprocessor has led to a new type of 
detector that offers many advantages to the user. It consists of 
a lamp that shines via a slit directly through the flow cell, the 
transmitted light goes through another slit and then to fixed 
grating, the resulting spectrum being refracted onto a small 
integrated circuit with a row of photodiodes on it. The diodes 
are scanned by the microprocessor giving a value corresponding to 
the intensity of the light over the wavelength range. This makes 
it possible to monitor all the wavelengths at once, (in practice 
every 10 ms) and generate either a spectrum at any time or a 
chromatogram at any wavelength. Combining these two features 
together can result in a three dimensioned output which may be 
displayed in real time using high resolution graphics on a data 
station.
Other detectors besides those discussed above are Evaporative or 
mass detector, radioactivity, Transport FID / ECD, Infra-red, 
Atomic absorbtion, photoconductivity, chemiluminescence and 
optical activity [41].
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1.5.5. DERIVATISATION IN LIQUID CHROMATOGRPAHY
In liquid chromatography derivatisation is used primarily to 
enhance detection and to a minor extent to reduce the polarity of 
very polar and ionizable compounds as an alternative to ion-pair 
chromatography.
The derivatisation step can be carried out either before the 
injection (pre-column) on-injection or after separation (post 
column) [42]
Reactions to Enhance Detection 
UV - vis Spectroscopy
(a) Precolumn reaction e.g. alcohols to 3,5 dinitrobenzoates.
(b ) Postcolumn reaction.
Amines by the Ninhydrin reaction.
Rulemann purple 570 nm 
or 440 nm
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Fluroescence Spectroscopy
(b) Pre- column.
Amines and dansyl reagents:
CH, CH 3
n /
N
RNH, +
CH, CH,\ / * 
N
RNH
Excitation 350-370 nm 
Emission 490-530 nm
Post Column
Amines and O-Phthaldehyde (OPT)
RNH,
HO SH 
I I 
ch3ch2
'CHO
Excitation 340 nm 
Emission 455 nm
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DRUG ANALYSIS IN BIOLOGICAL FLUIDS 
- METHODOLOGY AND CONSIDERATIONS
CHAPTER 2
2.1. WHY DRUG ANALYSIS ?
With few exceptions drugs are low molecular weight organic 
compounds of known structure and well defined 
physico-chemical properties readily available in pure form 
[1]. Their measurement may be required in areas such as
production control and in pharmaceutical preparations but of 
particular importance is their quantitation in biological 
samples. The analysis of drugs in biological materials 
poses a serious challenge to the analytical chemist due to 
difficulties imposed by the complexity of these media. Drug 
levels may be monitored for bioavailability studies, in 
testing the effect of new drug formulations, in cases of
drug abuse and overdose and as a guide to optimise
individual drug dose regimen (therapeutic drug level 
monitoring T.D.M.).
Bioavailability studies look at the plasma level time curve 
and at the pharmacokinetics of the deposition of the drug in 
man. Pharmacokinetics is the study of the absorption,
distribution, metabolism and excretion of the drugs and 
their corresponding pharmacological, therapeutic or toxic 
response in animals and man.
Therapeutic drug level monitoring may be required in the 
following circumstances, (a) where there is a question of 
patient compliance, (b) where there is a lack of therapeutic 
effect, (c) where the drug has a narrow therapeutic range,
(d) where there is danger of toxicity, (e) where there is a 
need for medico - legal variation of treatment. In many 
cases quantitation of metabolites in addition to the parent
drug will be required if these metabolites are 
pharmacologically active. T.D.M may involve quantitation in 
the microgram or ppm, nanogram or ppb or picogram or ppt 
concentration range [2].
2.2. METHODS AVAILABLE FOR DRUG ANALYSIS
Although the chemical structure of the drug will largely 
dictate the most suitable assay procedure for its 
determination [2], the magnitude and frequency of the doses 
administered and the pharmacokinetics of the compound govern 
the ultimate sensitivity and specificity required of the 
assay for its quantitation in biological fluids.
The major techniques used in clinical laboratories fall 
into three general categories
1. Chromatographic methods combined with a variety of 
detection modes.
2. Spectroscopic analysis (UV, fluorescence and 
colorimetry)
3. Competitive binding assays.
The requirement of any assay method are sensitivity, 
specificity, reproducibility and versatility.
87
2.2.1. Chromatographic Techniques
2.2.1.1. Gas Liquid Chromatography with a variety of 
detection modes i.e. flame ionization detection (FID), 
electrón-capture (ECD) and nitrogen-phosphorous (NPD), is a 
widely applied technique. Although analysis of the intact 
drug moiety (underivatized) is preferred to assure 
specificity, derivatization is often necessary. Simple 
derivatization reactions such as alkylation or silylation 
can be used when needed to yield very sensitive and specific 
methods. When making a derivative one must take account of 
the detection system to be used so that during sample 
preparation contaminants are not introduced into the 
extract which could be detrimental. NPD is susceptible to 
interferences by residues of silylating reagents and 
phosphate plasticizers contained in plastic syringes. The 
features, applications and limitations of the various GC 
detectors will be discussed more fully under the different 
drug groups.
2.2.1.2. Thin Layer Chromatography (TLC) Firstly TLC 
analysis allows rapid development of chromatographic 
parameters for use in HPLC analysis. Using a radiolobelled 
compound, the drug and its metabolites are separated and this 
allows qualitative identification by radiochromatographic 
scanning or autoradiography to isolate metabolites from 
either an in vitro 9000g microsomal incubation or from 
in vivo biotransformation studies [3]. The separated 
compounds can be eluted from the silica gel and analysed by
a variety of selective techniques e.g.
spectrophotometry/fluorimetry, polarography, GC, GC-MS (Mass
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Spectrometry) and NMR. These can be used not only for 
quantitation but also for structure elucidation purposes.
Quantitative analysis by in situ spectrophotometry/fluori- 
metry has been widely used, especially since the advent of 
HPTLC using a small sample aliquot (1^ul or less) applied to 
the chromatoplate followed by rapid development and 
densitometric analysis [4], This technique is especially 
useful in the fluorescence mode and has been applied to the 
analysis of flurazepam and its metabolite [5]. Some of the 
advantages of TLC analysis are the ability to analyse the 
entire sample by either one or two dimensional solvent 
ascending preparative scale chromogography, rapid 
development of the separation (HPTLC) and relatively low 
cost of the separation per se. However the
spectrodensitoineter required for quantitation is expensive.
2.2.1.3. HPLC
HPLC is an attractive approach for a number of reasons. 
Firstly, sample preparation is often minimal, a simple 
protein precipitation step followed by centrifugation and 
injection of the supernatant may be all that is required. 
Secondly, there is almost never a requirement for sample 
derivatization prior to the chromatography as there is in 
GC. Thirdly, it can be used for samples that are 
thermolabile and unsuitable for GC. Fourthly, most analyses 
can be performed successfully on reverse phase systems. 
These systems are ideally suited to therapeutic drug
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analysis. Most drugs possess sufficient hydrophobic 
structure to enswr'S'' retention by the stationary phase. 
However, many also contain hydrophobic groups which will 
limit this retention and allow the chromatographic process 
to occur in reasonable time. Mobile phase "strength" can be 
readily controlled by adjusting the organic solvent to 
buffer ratio. Variations in pH, ionic strength and the use 
of ion-pairing agents provide additional versatility.
Detectors for drug analysis using HPLC include ultraviolet 
and visible absorbance, fluoresence and electrochemical 
depending on the chemical properties of the drug to be 
analysed. To date, UV absorbance has found most 
application. Adequate detection depends upon the presence 
of the appropriate functional groups within the molecule and 
in turn the limits of detection will depend upon the value 
of the molar absorptivity coefficient at the existing 
wavelength. Many drugs possess conjugated chromophores and 
UV often allows detection at the low nanogram level for 
suitable analytes.
2.2.2. Spectroscopic Techniques
Spectrophotometric (UV-VIS) and luminescence emission 
(fluorescence and phosphorescence) methods have been the 
classical methods used extensively in drug analysis. They 
possess adequate sensitivity but lack high specificity since 
spectral characteristics cannot usually differentiate the 
parent drug from any metabolites present unless used in 
conjunction with either differential solvent extraction
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techniques using liguid-liquid or solid extraction 
separations. Most drugs exhibit moderate to strong 
absorption bands in the near ultraviolet region, exhibiting 
maxima in the 215-300 nm region. While UV methods are not 
as selective as chromatographic methods, they are simple and 
rapid, making them useful for screening purposes.
2.2.3. Immunoassay
All immunoassays are protein binding techniques. The 
binding of ligand (L) (drug) to a protein antibody (AB) a 
single specific binding site can be described by the 
following equation
L + Ab = LAb
According to the law of mass action
K = [LAb]
[L] [Ab]
Let [Ab], the bound ligand concentration = B; and [L] the 
free ligand concentration = F, then
F [Ab]
If total antibody = [AbT ] 
then [Ab] = [AbT ] - [B]
and
K = ± X -L-
F [AbT - BJ
or
J L  = K [AbT - B]
F
This equation shows that if the antibody concentration [ABT ]
is in excess of the total ligand [F+B] concentration then
[Ab,p] >> B and B/F will remain a constant with a value of
K[AbT]. As the concentration of the total ligand approaches
the total binding site (antibody) concentration ([Ab ]) then
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B becomes a significant fraction of KfAb^-B] and B/F will 
decrease. Finally at higher concentration of total ligand, 
B approaches [AbT ] and in turn B/F will approach zero. A 
graph of B/F vs total ligand yields a a sigmoid "standard" 
curve of protein binding assays (Fig. 1). It is evident 
that the useful portion of the curve begins when binding is 
about 50% (B/F = 1). Therefore in any assay the antibody 
should be diluted to the point where there is 50% binding of 
the lowest concentration of ligand to be measured.
Furthermore since B/F £ K [Ab^,],the maximal dilution of the 
antibody that yields this binding is actually determined by 
the value of K, the association constant (in fact at 50% 
binding B/F = 1 and [AbT ] = K ). In turn since that total 
ligand concentration is now of the same order of magnitude 
as [Ab^] then the minimum concentration of ligand that can 
be measured in an assay is also determined by K i.e. as K 
increases (K  ^ decreases) so does the sensitivity of the 
assay. A sensitive assay therefore requires a small amount 
of avid antibody.
2 . 2 . 3 . 1 .  Methods of Assessing_Binding
Binding can be assessed by having present a fixed amount of 
labelled ligand which competes equally with "unlabelled" 
ligand for the protein binding sites. This competitive 
binding arrangement is illustrated in fig. 2 i.e. when no 
unlabelled ligand is present binding of the labelled ligand 
is maximal (e.g 50%). However, as unlabelled ligand is 
added (as standard or sample) it competes with the labelled
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(Total Ligand)
Fig. 1 - Typical plot of bound (B) over free (F) ligand vs 
total ligand from a protein-binding assay.
fixed 
amount of 
labelled 
ligand
increasing amounts of unlabelled 
ligand (standard or sample)
Fig. 2 - The effect of adding increasing amounts of
unlabelled ligand to a protein-binding assay.
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ligand for a fixed number of binding sites and causes a 
reduction in the amount of bound label. In conventional 
radioimmunoassay the fixed ligand is labelled with a 
radioactive isotope and binding is assessed by measuring the 
radioactivity associated with the bound or free fraction. 
These fractions must of course be separated prior to the 
counting step. The so called homogeneous immunoassays do 
not require separation of bound and free ligand prior to 
assessment of the extent of binding because they use labels 
that are detectable only in one or other of the fractions. 
Three of these types of assays are particularly prevalent, 
enzyme multiplied immunoassay in which the label is an 
enzyme which is active only in the free fractions, 
fluorescence polarization assays in which the label is a 
fluorescent molecule and the binding is assessed by 
measuring the light - polarizing properties of the bound 
fluorophore - drug species and substrate labelled 
fluorsecent immunoassay in which the label is again a 
fluorophore but where binding is assessed by measuring the 
ability of the unbound fluorphore drug to compete to serve 
as an enzyme substrate. A good account of the various types 
of immunoassay is given in a review by de Silva [2].
2.2.3.2 Development of Drug Immunoassays
Drug immunoassays are simple to perform but complex to 
develop.
1. The drug has to be coupled as a hapten to a carrier
protein, usually bovine serum albumin in order to raise
94
antibodies against them since most drugs themselves are not 
immunogenic [6].
2. If the drug molecule does not have an appropriate group 
for direct conjugation reaction a chemical derivative 
may have to be prepared prior to the conjugation step.
3. After formation of the immunogenic species an animal 
(usually a rabbit or a goat) is immunized and the 
appropriate antibodies isolated.
4. The drug must be labelled with the appropriate label.
Finally when all the reagents are available the assay
procedure itself must be optimized in terms of variables 
such as antibody dilution pH, temperature and time of
incubation [7].
The advantages of immunoassay are that for determination of 
drug concentration in biological fluids they are (1) very
sensitive (ii) only a small volume of sample is needed (iii)
no purification (iv) chemically they are gentle (v) they can 
be applied to all classes of compound (vi) easy to perform 
and can be automated.
2.3 HPLC VS IMMUNOASSAY
Two techniques dominate the field of biopharmaceutical 
analysis (a) Chromatography especially HPLC and (b) 
Immunoassay.
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Chromatographic analysis requires that the drug be 
physically separated from the original matrix. The 
chromatographic process is actually part of the isolation 
procedure and is largely responsible for assay specificity. 
The subsequent quantification is outside the matrix. 
Immunoassay on the other hand, isolates the drug within the 
matrix and it is the quality of the antibody that determines 
specificity. Subsequent quantitation is often in the 
presence of the original matrix.
Currently immunoassays are used much more than LC for 
therapeutic drug monitoring because they are technically 
less demanding, avoid sample pre-treatment and have been 
able to offer a much higher throughput due to batching of 
samples and can be automated more quickly. Some further 
advances in this technique may arise from the potential 
application of monoclonal antibodies to drug analysis [8].
On the other hand LC because it is a powerful separation 
technique can be used to quantify closely related drugs and 
their metabolites such as tricyclic antidepressants. This 
capability is probably beyond the specificity available from 
antibodies. Related to this LC allows simultaneous 
determination of several drugs in a single run whereas 
separate immunoassays have been required for each drug and 
metabolite. LC is potentially more accurate because it is a 
more direct method. The potential for inaccuracy with 
immunoassays is illustrated by the tendency for antibodies
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recognising digoxin to cross react with digoxin metabolites 
[9]. The final advantage of LC is that one can set up new 
drug assays more quickly.
2.4. THE SIGNIFICANCE OF FREE DRUG MEASUREMENT
Drug molecules circulate in blood in two forms, those in 
association with blood components such as proteins, red 
cells or platelets and those which are unbound and are 
dissolved in plasma water [10, 11, 12]. The extent of drug
binding to plasma proteins varies widely among different 
types of drugs. The effects of changes in the extent of 
protein binding on free drug fraction and on drug metabolism 
are significant only for highly bound drug (greater than 80% 
bound) since even a relatively small change in the degree of 
binding has a dramatic effect on free fraction.
Albumin is quantitatively the most important drug binding 
protein for many drugs, particularly for the neutral and 
anionic (acidic) drugs such as warfarin, phenytoin and 
valproic acid [13]. In recent years, cationic (basic) drugs 
such as propranolol, quinidine, and the tricyclic 
antidepressants have been shown to bind not only to albumin 
but also to other blood proteins such as&^-acid glycoprotein 
(AAG) and lipoproteins [14-16],
A widely held view on the pharmacological effect of protein 
binding is that only the free form of the drug can cross the 
capilliary membrane and cell membranes. It is therefore 
assumed that the free fraction in vitro is equivalent to the
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pharmacologically active fraction in vivo and free drug 
levels will correlate better with drug effects and clinical 
conditions of the patients. It should be appreciated that 
the free drug hypothesis is unproven. The basic assumption 
that only unbound drugs can cross cell membranes has been 
questioned lately when it has been shown that globulin bound 
lidocaine and propranolol were transported into tissues such 
as the brain [17]. The equilibrium measurement of plasma 
free drug in vitro may underestimate the amount of 
exchangeable plasma drug in vivo that is available for 
transport into tissues.
2.4.1. Methods for Free Drug Measurement
In reality for routine therapeutic drug monitoring, the 
total concentration of the drug in serum is usually measured 
rather than the free fraction - a custom that probably 
reflects technical limitations rather than clinical utility. 
The two most common methods used to measure free drug are 
equilibrium dialysis and ultrafiltration.
2.4.1.1. Equilibrium dia1ysis
Equilibrium dialysis suffers from certain limitations, 
detailed reviews on the subject are available [18, 19, 20].
Briefly the technique is based on the principle that unbound 
drug will equilibrate across a semi-permeable membrane which 
is permeable to small drug molecules but not to drug binding 
proteins. The method is performed by placing serum or 
plasma in a chamber separated from buffer in another chamber 
by the membrane. At equilibrium the drug concentrated in 
the buffer compartment (dialysate) is considered to
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represent the unbound drug concentration which will be the 
same as the free drug concentration in the protein 
compartment (retentate). Experimental conditions such as 
temperature and buffer concentration can give irreproducable 
results. A number of papers which critically address the 
problems have appeared [19, 21-27]. Briefly the problems
are (a) that new equilibria are set up during dialysis so 
that the bound and unbound fractions at equilibrium are 
different from those of the original sample (b) significant 
Donnan effect (c) osmotic dilution (d) non specific 
adsorption of free drug and protein molecules to the surface 
of the dialysis apparatus (d) lack of attainment of 
equilibrium and (e) protein leakage into the dialysate.
2.4.1.2. Ultrafiltration
Ultrafiltration is the other commonly used technique. A 
pressure gradient generated by centrifugation is used to 
force plasma water and small molecules through a semi 
permeable membrane. Ultrafiltration is an attractive 
alternative to equilibrium dialysis because of the ease and 
speed with which it can be accomplished. Speed is an 
important consideration in studying the binding of drugs to 
albumin since binding of some drugs may be deceased by fatty 
acids [28, 29] which are released through hydrolysis of
plasma triglycerides when stored for long periods and in 
dialysis of long duration. Problems associated with 
ultrafiltration are :-
(a) disturbance of protein binding equilibria during 
filtration
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(b) non-ideal membranes which allow a higher filtration 
rate for water than for the drug resulting in dilution 
of the drug concentration.
(c) temperature and pH must be carefully controlled.
(d) adsorption loss to the membrane
(e) the Donnan effect.
In principle therefore, T.D.M. based on the measurement of 
free drug should be more meaningful than that of total drug 
because free drug reflects drug concentration at receptor 
sites. Unfortunately the technology to date for free drug 
measurement is complex compared to the routine assays for 
total drug, hence clinical correlation of drug effects with 
plasma levels has been based on total drug. As long as 
protein binding of drugs is normal and constant (within and 
between patients) free drug is a fairly constant fraction of 
the total drug. As such measurement of total drug is an 
adequate estimation of free drug making free drug 
measurement unnecessary.
This relationship between free and total drug does not hold 
however where protein binding is variable or abnormal which 
may be due to abnormal protein concentration, drug 
interaction or displacement and concentration dependent 
binding. For example with some commonly monitored drugs 
such as phenytoin the extent of binding varies greatly among 
individuals and the free fractions seem to correlate more 
closely with therapeutic efficacy and toxicity than does the 
total concentration [30, 31].
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2.5. CHOICE OF SAMPLE FOR DRUG ANALYSIS
In drug analysis the most commonly sampled body fluid is 
plasma or serum because a good correlation between drug 
concentration and therapeutic effect is usually found.
Whole blood can be broken down into its general components 
as follows: plasma which contains the serum and fibrinogen 
and the cellular elements which contain the erythrocytes, 
leucocytes and platelets. Plasma is the liquid portion of 
circulatory blood. The cells are separated from the blood 
by centrifugation of whole blood. If blood is allowed to 
clot, the fibrinogen is removed from the plasma leaving 
serum. The majority of clinical analyses are performed on 
whole blood, plasma or serum and most of these use serum.
Urine is useful when a drug or a rapidly formed metabolite 
is extensively excreted in it. Drugs can usually be 
detected in urine for some time after they have become 
undetectable in blood. Urine analysis for drugs is used in 
connection with urinary excretion and bioavailability 
studies. Saliva and cerebrospinal fluid (C.S.F.) are also 
analysed for drugs, but less frequently. Drug 
concentrations in saliva are sometimes assumed to represent 
free plasma levels, but this is found to be true only for a 
few drugs (e.g. carbamezepine and phenytoin). For others 
the correlations are less satisfactory or apparently non 
existant [32-34]. It is not practical to analyse C.S.F. 
samples routinely but occasionally C.S.F. levels may be 
required if damage to the blood brain barrier is suspected.
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2.6 COLLECTION AND STORAGE OF SAMPLES
Collection of an uncontaminated specimen at the correct time 
in relation to dose is vital in any projects involving drug 
analysis. If insufficient care is taken in the collection 
and handling of biological specimens the data generated will 
be invalidated. If plasma or serum is analysed, the 
expressions "blood samples" or "blood levels" should not be 
used in description of the analytical procedures unless 
whole blood samples are to be analysed for some reason (for 
example drugs with a high affinity for red cells such as 
chlorthalidone or cyclosporin). Specimen collection tubes 
containing anti-coagulants (for blood) or preservatives (for 
urine) are available. The choice of anticoagulant may affect 
assay results as may some plasticizers released from blood 
collection tubes. The selection of glass or plastic tubes 
for blood collection and subsequent separation of plasma or 
serum, and its effect on the drug in an in vivo sample with 
respect to adsorption losses, contamination by plasticizers, 
displacement of protein bound drug by plasticizers and their 
effects on the plasma to haematocrit ratio warrant 
investigation. Drug concentration data can be adversely 
biased by these phenomena, hence also pharmacokinetic 
implications. For example, significant decreases is plasma 
Tricyclic Antidepressant concentrations have been attributed 
to sample contact with the plasticizer tris - (2 - butoxy
ethyl) phosphate (TBEP) which may be present in the rubber 
stopper of collection tubes. TBEP free stoppers are now 
available [35]. Serum separator gel contained in serum 
separator blood collection tubes has also been demonstrated
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to decrease the resultant serum concentrations of lidocaine, 
phénobarbital and phenytoin [36].
On no account should a blood sample be frozen without 
treatment since this would result in haemolysis, preventing 
the subsequent separation of plasma or serum. After 
collection of blood (5-10 ml) a clot can be allowed to form 
and the supernatant liquid (serum) collected after 
centrifugation. Coagulation is complete in about 30 minutes 
at room temperature. Alternatively the blood can be 
collected in tubes containing an anticoagulant (e.g. 
heparin, E.D.T.A.) and the supernatant liquid (plasma) 
collected after centrifugation. Since the anticoagulant 
effect is temporary, collected specimens must be centrifuged 
quickly to prevent eventual clotting. Plasma is more 
frequently used than serum in drug analysis since although 
the results from both fluids are identical plasma is 
preferred since the anticoagulated blood can be centriguged 
immediately, whereas serum cannot be sampled until 
coagulation is complete. Secondly it is relatively easy to 
centriguge blood that has been treated with anticoagulant, 
since the plasma separates quickly and the maximal volume 
can be recovered if required.
Drug may be lost to the container or be degraded during 
storage. Thus the stability of a drug in a biological fluid 
at various storage temperatures should be studied. Fresh 
plasma or serum samples can usually be kept for 6 hours at 
room temperature, 1-2 days in a refrigerator at 4° or frozen 
at -20° for long term storage. The Council of the British 
Pharmaceutical Society has issued guidelines for a pharmacy
103
based pharmacokinetic service which includes instructions on 
sampling and storage of blood [37].
Urine drug analysis is done either on a single or 24 hr.
specimen. Both pH and volume are important factors in urine 
analysis. If urine is allowed to stand at room temperature
bacterial action causes the decomposition of urea into
ammonium carbonate and then to ammonia, with a resulting
change in pH. Urine may be preserved by freezing or by
addition of preservative (toluene, boric acid or
concentrated HC1). Frozen samples of plasma/serum or urine 
should be brought to room temperature and subjected to 
vortex mixing for 10 seconds to ensure homogeneity before 
analysis.
2.7. DIRECT INJECTION
In a few cases, direct injection of the biological fluid
into the chromatograph is possible. For example in the case 
of theophylline which is therapeutically present in 
relatively high concentration (mg/1) and possesses good UV 
absorption characteristics, a small volume of dilulted serum 
can be injected directly onto the chromatograph, thus 
minimizing the amount of non-eluting contaminants placed on 
the column with each injection. In this case the mobile 
phase and the column packing release the drug from protein 
binding sites as the sample enters the column. Direct 
injection has also been applied to analysis of salicylate 
and naproxin in serum [38].
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Urine can also be directly injected onto the chromatograph 
following centrifugation to remove particulate matter and 
suitable dilution preferably with the mobile phase. For
example, antibiotics [39] and other drugs [40] can be 
determined in urine by HPLC with on-column injection.
When using direct injection the analytical column should
always be protected by a guard column to prevent 
irreversible adsorption and blockage. Biological samples 
contain materials such as lipids and proteins which deposit 
on the chromatographic column and lower its performance. 
Direct injection is limited in its application.
Normally to improve both the sensitivity and selectivity of 
an assay some form of sample clean-up prior to injection 
will be necessary. These will now be considered.
2.8. SAMPLE PRETREATMENT
Some form of pretreatment of the biological sample prior to 
analysis is normally required. This is necessary for the 
following reasons (a) to release the drug from the protein 
binding sites, (b) to isolate the free drug, (c) to remove
interferents which may collect in the column and lower its
performance and (d) to concentrate the drug for more 
sensitive analysis. Various types of sample pretreatment 
will now be discussed.
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2.8.1. Protein Precipitation
In this method, one volume of plasma or serum is mixed with 
a certain volume of precipitant e.g. trichloroacetic acid, 
perchloric acid, methanol or acetonitri le. The volume of 
precipitant used will depend on how effective it is [41]. 
These solvents precipitate the proteins and release the drug 
from protein binding sites. After vortex mixing and 
centrifugation an aliquot of the clear supernatant is 
injected onto the HPLC column. Care must be taken that the 
solvent front does not interfere with the peaks of interest 
as some précipitants absorb in the UV. This method of 
sample preparation is simple, rapid and accurate. The 
protein precipitation technique protects the column from 
deposition of proteins. Up to 99% of protein may be removed 
by the addition of sufficient precipitating agent. The 
major drawback here is that dilution of the sample occurs 
which decreases sensitivity. This drawback may be 
counteracted by using a larger injection volume. Another 
drawback is that the procedure sometimes gives low 
recoveries of drugs that are strongly protein bound since 
they may co-precipitate or degrade during precipitation. 
When a new method is being developed, several precipitating 
agents in various proportions should be investigated to test 
their efficiency in removing protein and producing a 
relatively interference free supernatant with good recovery 
of drug. Although methanol is slightly less effective as a 
protein -precipitant than other organic solvents [41] it 
should be used whenever possible because of its relatively 
low cost and low toxicity.
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The protein precipitation method is particularly useful for 
highly polar (e.g. antibiotics) or amphoteric (e.g. 
sulphonamides) drugs which are difficult to extract from 
plasma with organic solvents. Analyses with good 
reproducibilities are often possible, without the use of 
internal standards [42].
It should be noted however that the drug peak may often be 
accompanied by other peaks, because the likelihood of 
interfering peaks is probably about the same as with direct 
injection because most if not all of the drugs and analogous 
physiological solutes will be included in the supernatant of 
these samples. Moreover late eluting peaks from previous 
samples may co-elute with the drug peak, thereby distorting 
peak measurements and adversely affecting precision. The 
potential for late eluting peaks to degrade assay precision 
in T.D.M. has been pointed out [43], Protein precipitation 
did not prove useful for any of the work described in the 
following chapters as it did not give adequate sensitivity 
or clean chromatograms.
2.8.2. Solvent Extraction
Liquid-liquid extraction is by far the most popular method 
used for the clean up of biological fluids mainly due to its 
versatility [44-47]. It provides chromatographically clean 
extracts and allows for concentration of the sample by 
evaporation thus enhancing sensitivity. The size of the 
sample chosen will depend on the sensitivity required of the 
assay. Generally however 1ml of plasma or serum is used and
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extracted into 5ml or more of organic solvent by vortex 
mixing followed by centrifugation. The addition of a large 
amount of extractant minimizes emulsion formation. 
Glassware used in extractions must be scrupulously clean and 
free from any residual detergents.
Polarity is usually the most important factor in the choice 
of extracting solvent and generally as this increases the 
range of components extracted also increases. The solvent 
should be selected with minimum polarity consistant with 
high recovery of the drug. Drugs of high polarity are 
difficult to extract and require strongly polar and hence 
non-selective solvents. Polar solvents that are miscible 
with water (e.g. n-propanol) can be forced to form a 
separate layer by saturating the aqueous phase with an 
inorganic salt, a technique useful for very polar drugs 
[48]. Salts can be important in other ways, as they help to 
form better phase boundaries (i.e. avoid emulsions) and can 
also reduce the water content of the organic phase. Further 
the addition of salts can be used to increase the 
selectivity of an extraction by aiding the transfer of a 
drug from the aqueous to the organic phase.
A solvent used for extraction should be of the highest 
purity, non-toxic, not highly flammable and have a suitable 
volatility. The most popular solvents are diethyl ether and 
chloroform. Although ether is flammable, it is reasonably 
selective, easy to evaporate and its low density favours 
phase transfer after extraction. Moreover ether emulsions 
are easy to break.
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Modification to the pH of the aqueous phase is also most 
important in the development of an extraction scheme. It is 
the unionised form of the drug that is extracted into the 
organic solvent. Thus acidic drugs are extracted under 
acidic conditions and basic drugs under basic conditions in 
order to suppress their ionisation. The optimum pH for 
extraction of acidic drugs usually lies 1-2 pH units below 
the pKa value and for basic drugs 1-2 pH units above the pKa 
value. Amphoteric drugs also show an optimium pH for 
extraction, the extraction of neutral drugs is independent 
of pH, they are extractable over a wide pH range. However 
consideration of pH is important even when assaying for 
neutral drugs, since a higher pH is often desirable to 
ensure cleaner extracts since many endogenous compounds are 
acidic and hence not extracted from alkali. Extraction can 
be problematic when the drug is water soluble at all pH 
values (water soluble amphoteric and neutral drugs, 
zwitterions) since pH adjustment will not help in this 
situation. In some cases a salting out procedure can shift 
the partition equilibrium in favour of extraction. Horning 
et al. [491 used this approach in the screening of plasma and 
urine for acidic, basic and neutral drugs and their 
metabolites. By using ammonium carbonate as the salt and 
ethyl acetate as the solvent they were able to extract the 
drugs with recoveries better than 80%.
Gas chromatographic analysis often requires a back 
extraction to prevent extraneous substances in the first 
extract from contaminating the detector especially NPD and 
ECD detectors. The drug present in the first extract
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is back extracted into an aqueous phase of appropriate pH 
and the pH of this aqueous phase is then readjusted to the 
pH of the first extraction and the drug re-extracted into 
organic solvent.
Metabolites of a drug are usually more polar than the drug 
itself and if they are to be quantified the solvent chosen 
for the extraction should be capable of extracting these. 
However, if desired,extraction with solvents of increasing 
polarity and/or at different pH values can achieve selective 
separation of a drug from its major metabolites. Another 
approach to extracting the more polar metabolites is to 
extract the drug, then add a high concentration of salt such 
as sodium chloride to the aqueous phase and re-extract. 
This forces the desired compounds into the organic phase. 
Absolute specificity by selective extraction alone is 
difficult to achieve and thus separation must usually 
include a chromatographic step. HPLC is usually the method 
of choice since the drug and its metabolites can usually be 
analysed without conversion into derivatives or use of 
extensive clean-up procedures.
2.8.3. Hydrolysis of Conjugates
Many drugs and metabolites are present in urine as 
conjugates such as glucuronides or sulphates which are very 
polar and not extractable into organic solvents. It is 
often necessary to hydrolyse these conjugates so as to 
release the parent molecules for extraction. This is done 
chemically with hydrochloric acid or sodium hydroxide or 
enzymatically with enzymes such as beta-glucuronidase. 
Chemical hydrolysis decreases the yield of drugs that are
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heat labile (e.g. certain benzodiazepines) and sensitive to 
aggressive reagents. Enzymatic methods on the other hand are 
slow but mild. After hydrolysis the products can be 
extracted following pH adjustment or back extracted if 
necessary. Generally a urine sample is divided into two 
sub-samples, one hydrolysed to give the total concentration 
of the drug and the other extracted to give the free 
concentraction of the drug. The concentration of the bound 
form is obtained by subtraction.
2.8.4. Ion Pair Extraction
A useful approach to dealing with a highly polar 
ionic drug is to convert it into a neutral ion-association 
complex by addition of an excess of suitable ions of 
opposite charge and extract it into an organic solvent such
as chloroform. The counter ions may be inorganic or polar
organic. Formation of the complex depends on factors such 
as pH of the aqueous phase, polarity of the extracting phase 
and the nature and concentration of the counter ion. The
ion-association complex technique can be used for all kinds
of ionizable drugs but it offers a particular advantage for 
compounds that are difficult to extract in uncharged form 
e.g. quaternary ammonium compounds [50].
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2.8.5. Liquid - Solid Extraction
Sample pretreatment by solid phase extraction involves 
applying the sample to a small column filled with adsorbent 
material, which binds the drug before elution. Among the 
adsorbent materials that have been used are Celite, alumina, 
silica, chemically bounded silica, Florisil and non-ionic 
and ion-exchange resins. Disposable columns of various 
sizes and covering the wide range of adsorbents are 
available commercially (e.g. from Waters Association or 
Analytichem International).
These materials fall into two broad categories. In the case 
of the first group, a hydrophilic packing material (e.g. 
inert particles of diatomaceous earth) is used to adsorb the 
whole sample so that an aqueous film is formed on the 
surface of each particle. A small volume of a 
water-immiscible organic solvent such as chloroform is then 
passed through the column and this effectively extracts the 
drug from the aqueous film of sample. Water and other polar 
endogenous materials are retained by the matrix. This type 
of extraction is essentially a liquid-liquid extraction so 
that drugs can be selectively eluted by approaches similar 
to those used in liquid-liquid extraction.
The second type of liquid-solid extraction works on 
chromatographic principles. Compounds of interest are 
retained on the absorbent surface when the sample is passed 
through. If undesirable compounds are adsorbed at this 
stage they may be removed by washing with a specific solvent 
or buffer. The drug of interest is then eluted with a
specific solvent and processed by HPLC. The key to 
obtaining high recoveries of the purified compound of 
interest is to identify the bonded silica phase that is most 
selective for that compound. The selectivity will be 
determined by the affinity the sorbent has for the isolate 
versus the interference in the matrix. To a great extent, 
one can predict the best type of sorbent by considering the 
following [51].
(1) The solubility of the isolate in non polar and polar 
solvents.
(2) Whether the isolate has the potential to become 
charged, thus becoming a candidate for ion-exchange.
(3) Whether the isolate has the ability to form a covalent 
bond (reversibly) with a sorbent such as phenylboronic 
acid bonded silica.
(4) To what extent the undesired compounds in the sample 
matrix have the potential to compete with the isolate 
for the sorbent binding sites [52].
The liquid-solid extraction technique is becoming a serious 
challenger to conventional solvent extraction (liquid-liquid 
partition). It is simple and time and labour saving (though 
prepacked disposable columns are by no means cheap). There 
are no losses due to emulsion formation and the extraction 
results in cleaner samples which extend the lifetime of 
columns. The efficiency and reproducibility are as good as 
or better than those of liquid - liquid extraction and they 
can be applied to a wide range of compounds.
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2.9. SOME TECHNICAL CONSIDERATIONS
2.9.1. Columns
For general clinical and biochemical L.C. analysis and
particularly for T.M.D., reversed phase columns are the ones 
of choice [53]. Advantages of these columns are (a) 
resistance to contamination and water based mobile phases,
(b) ease of equilibration and (c) broad applicability. The 
most popular reversed phase columns are C^g and Cg. The
differences in chromatographic properties between both these 
columns are subtle but at higher flow rates chromatographic 
efficiency decreases less with Cg than with C^g. More polar 
bonded phases such as cyano and phenyl can be also used in 
reverse phase mode by incorporating adequate water in the 
mobile phase.
Other important factors influencing separation efficiency 
are column length and particle size of the packing. The 
most widely used columns are those 15cm in length packed
with particles 5,um in diameter. Gaining in popularity is
"high speed liquid chromatography" which uses short columns 
3 to 8 cm long, internal diameter 4.6mm and packed with 3^ im 
particles. These are operated at a high flow rate (2 to 5 
ml/min), using a small volume flow cell (2.4^1) and a 
detector system with a fast response time. Analysis time is 
significantly shortened and there is less solvent 
consumption but since a higher than usual backpressure is 
used, wear and tear on equipment can be great. Another
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strategy is the use of short columns with 3;am packing in 
order to increase the internal diameter to 6.2mm and use a 
flow rate that is only moderately higher, perhaps twice the 
conventional [54]. In this case the chromatogram is about 
the same in overall appearance as that obtained with a 
conventional column but is obtained in a third of the time. 
A problem associated with the use of both these types of 
columns is that they can easily become clogged with 
particular matter from plasma because of the small particle 
size. Secondly clogging is more likely in the lower 
porosity filters and frits (0.5;nm vs 2. Oum conventional) 
used in these columns.
Most analytical columns have an internal diameter ranging 
from 3 to 6 mm. These dimensions provide a good balance 
among (a) ease of packing with minor contribution from wall 
effects [55, 56] (b) compatibility of the sample and peak
volumes on these columns with detectors in routine use, (c) 
limited elution volume of costly mobile phase, (d) limited 
amount of costly packing and (e) moderate pressure drop.
The stability of a column can be greatly improved by the use 
of a guard column before the analytical column which 
protects it from contamination and clogging. Modern columns 
can withstand more mechanical stress but more work is 
required to investigate the possibility of regenerating 
columns contaminated by impure substances, such as the 
usefulness of a strong solvent injection between samples 
[57]. A major factor affecting the stability of columns is 
the pH of the mobile phase. The pH range within
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which bonded-phase silica-based packings can be used is 
typically 2 to 7. At lower pH the bonded groups are 
hydrolyzed, and at higher pH, the silica matrix itself 
dissolves, leading to the release of bonded groups from the 
surface. The stability at higher pH may be extended by the 
use of a silica-packed pre-column between the pump and the 
sample valve, presaturating the mobile phase with silica 
before it enters the analytical column [58]. The use of 
amine vs alkali metal buffers also improves the column 
stability at higher pH values [59]. Mobile phases with a 
high pH can be used in normal phase L.C. with silica 
particles because the high organic content of the mobile 
phase minimizes the solubility of the silica. An example of 
this will be seen in Chapter 4, in the determination of the 
tricyclic antidepressants.
2.9.1.1. Column to Column Reproducibility
It is important that the same chromatographic conditions for 
a drug analysis give similar results with each new column. 
This is often not the case and modification to certain 
parameters is often required in order to achieve separation 
on a new column particularly for drugs that are susceptible 
to active sites on the column. It is important to develop 
mobile phase conditions not only to achieve separation but 
also to minimize column to column differences. Probably the 
most severe test of column to column reproducibility is the 
relative retention of acidic and basic substances analysed 
simultaneously. Although many drugs are netural, avoiding 
major problems in column to column reproducibility when
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analysed by LC, some of the potential interferences may be 
acidic or basic and so their retention may vary from column 
to column giving rise to interference in the chromatogram.
2.9.2. Mobile Phase
A major advantage of LC over GC is the opportunity to 
influence the separation of drugs by changing the 
composition of the mobile phase, giving extra flexibility 
and control.
Reverse phase chromatographic systems are the most popular 
for drug analysis. The two most commonly used organic 
solvents in the reverse phase mode are methanol and 
acetoni tri le, acetonitrile is the less polar of the two 
providing an equivalent solvent strength to methanol at a 
lower concentration. Acetonitrile also yields a mobile 
phase with water which is less viscous than with a 
water-methanol mixture, this makes the column more efficient 
and allows a lower pumping pressure. Selectivity 
differences between the two solvents arise because 
acetonitrile is a hydrogen bond acceptor while methanol is a 
hydrogen bond donor. Another solvent which may be 
considered is tetrahydrofuran because it offers further 
contrasting solubility properties (less polar, weaker dipole 
moment than acetonitrile, nonhydroxylic relative to 
methanol).
Another possibility is the use of a ternary solvent system
i.e. a combination of two organic solvents and water. Drug 
separation can be significantly affected by even a small 
proportion of a second organic solvent, especially if this 
solvent is a strong eluent relative to the mobile phase 
being modified [60]. This is because such a solvent tends
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to concentrate in and change the characteristics of the 
bonded phase. An example of this phenomenon is the 
observation that the separation of TCA's on an RP column is 
markedly improved by adding 5ml/l of methylene chloride to 
the mobile phase.
Temperature of the mobile phase can also affect 
chromatographic behaviour. The primary effect of increasing 
the temperature is to increase the solubility of drugs in 
the mobile phase solvent thus diminishing their 
chromatographic retention. A higher temperature also 
improves column efficiency, largely because the mobile phase 
is less viscous. A disadvantage of higher temperature is 
decreased column stability.
2.10. DEVELOPMENT AND VALIDATION OF A CHROMATOGRAPHIC ASSAY
The most logical approach in the development stage of an 
assay involves opposite chronology to the final protocol. 
Although isolation precedes measurement, it can be more 
convenient to develop the analytical technique first. This 
is followed by selection of an internal standard and 
development of the isolation procedure [61].
Samples of drug free material (serum, urine) spiked with 
known drug concentrations should always be employed for 
calibration. Alternative "external" approaches on assaying 
or even just injecting (in the case of chromatography) pure 
standard solutions are unacceptable because they ignore the 
specific peculiarities of the biological matrix. However, 
even drug supplemented samples are subject to criticism, as
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since externally added drug might indeed not be present in 
the same physico-chemical state as an in vivo delivered 
drug.
Most regulatory agencies, like the Food and Drug 
Administration, have mandated Good Laboratory Practice (GLP) 
regulations for clinical and non-clinical laboratory studies 
[62, 63]. Based on these regulations, the fundamental
criteria required for validation of chromatographic methods 
to check their reliability and overall performance are the 
evaluation of drug stability, specificity, limit of 
detection, accuracy, precision, linearity and recovery. 
Each of these individual criteria will now be discussed.
2.10.1. Drug Stability
Drugs stored under different conditions of heat, light, 
humidity and pH (stock solutions and spiked biological 
samples) should be examined for possible decomposition. The 
stability under prolonged storage conditions for possible 
adsorption onto glass or other materials, such as plastics, 
must be determined. In certain instances, plasticisers from 
plastic syringes and containers and certain polymers from 
Vacutainer stoppers have been known to interfere with drug 
measurement. The stability of the drug must also be checked 
under the conditions of analysis, since any losses or 
decomposition due to experimental manipulations can 
significantly affect the overall recovery, reproducibility 
and precision of the assay. The method chosen should be 
sufficiently sensitive to detect low levels of decomposition 
products and sufficiently precise to observe small changes 
in the assay of the drug.
2.10.2. Specificity
The biological sample should be examined for the presence of 
endogenous components and/or other drugs which might 
interfere with the drug or its metabolites in the assay 
system. Should any peak interfere with the assay, a 
systematic search should be undertaken to find the origin of 
the interference. For example, an interfering peak eluting 
at the same retention time as phentermine was found during 
its GC analysis in plasma [64]. This was subsequently found 
to be due to the use of plastic pipette tips. However, 
selective extraction procedures, use of specific detectors 
or a change in chromatographic parameters should normally 
eliminate interferences of this kind.
2.10.3. Limit of Detection
The limit of detection (LOD) is defined as the lowest 
concentration of an analyte that the analytical process can 
reliably detect. In mathematical terms, the most popular 
quantitative approach seems to be that which defines LOD as 
3S (S = standard deviation of the peak to peak noise) above 
the gross blank signal, taking into consideration that for 
the case of a linear dependence of R upon Cx x
S Cx SRx
C Rx X
Where Rx is the response corresponding to concentration 
and S is the response variability corresponding to
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concentraction variability s • It should be noted that theC X
limit of detection need not be a constant, because of e.g. 
day-to-day variation in detector response. The detection 
limit must be statistically defined, below which no data 
should be reported.
2.10.4. Accuracy and Precision
The term accuracy denotes the nearness of a measurement to 
its accepted value [65] and is expressed in terms of error. 
The absolute error is the difference between the observed 
and accepted value. The relative error is expressed as a 
percentage of the accepted value and is often used to 
express the accuracy of a chromatographic assay.
In real terms, accuracy should be tested by comparison of 
results to another reliable method. Correlation of the two 
methods against each other by regression analysis (r > .98) 
is the most acceptable form of validation.
The term precision is used to describe the reproducibility 
of the method [65]. The precision of a measurement is given 
by the percentage coefficient of variation of replicate 
experiments performed under identical conditions.
In chromatographic methods of drug analysis, the precision 
and reproducibility of the method should be described both 
in terms of intra-assay (within-day) and inter-assay 
(between-day) results. In performing intra and inter-assays 
at least four replicate analyses over the entire
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concentration range of calibration should be performed. For 
intra-assay, the mean values of the peak height or peak area 
ratios should be obtained and a linear regression analysis 
performed by plotting the mean values of ratios versus the 
accepted value (the accepted value is based on the amount of 
test drug added to the drug-free biological fluid). Then 
the concentration based on each individual value, expressed 
either as a peak height or peak area ratio is calculated 
from the generated linear regression curve and precision 
defined based on these results. For inter-assay, a linear 
regression analysis is performed for each day of calibration 
and then four or more of these calibration curves are used 
for statistical calculations and for expressing 
reproducibility. Many of these calculations will be shown 
in following chapters.
2.10.5. Linearity
The linearity of the assay should be defined by the linear 
regression analysis of replicates of spiked biological 
standards in the expected concentration range of the 
"unknown". In practice the linear regression curve obtained 
in intra-assay may be used to demonstrate the measure of 
linearity of the curve.
2.10.6. Recovery
The overall recovery of a given drug from spiked biological 
standards is calculated from the limit of detection to the 
upper end of the linear calibration curve by two different 
methods [64]. The first method compares the peak 
heights/area of a series of spiked biological samples which
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have been taken through the entire analytical procedure with 
the peak heights/area of a series of authentic standards. 
The second method compares the slope (determined by linear 
regression analysis) of a processed standard curve to that 
of the reference standards.
2.10.7. Quality Control
The performance and reliability of routine drug assays 
should be checked with each batch of samples. Quality 
control standards are prepared by accurately spiking 
drug-free biological fluids with known amounts of the test 
drug by a person other than the analyst. At least 10% of 
these standards should be subjected to quality control and 
the results of these should be within —10% of their 
accepted value, or the batch repeated [63],
If a method is modified it should be statistically 
revalidated even if one assumes that it had been correctly 
validated in the first place. A method might have to be 
modified in the following cases.
If the initial method had been developed on a used column 
and then is repeated on a "new" column, the two columns may 
behave differently for any of the following reasons
1. The lack of readily available identical columns, e.g. 
not all C^g columns behave similarly.
2. If the chromatographer decides to use a column which 
may perform differently, he or she may be forced to 
change other chromatographic conditions.
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3. Thé chromatographer may have different requirements 
from the method in terms of sensitivity, for example 
and may be forced to change the extraction technique 
say.
All the above points necessitate revalidation.
The above strategy for the development and validation of 
chromatographic methods of analysis of drugs in biological 
fluids forms the foundation for all the analytical work in 
the following sections. These studies demonstrate how the 
strategy has been applied in its entirity to the 
determination of levels of (1) Tricyclic antidepressant 
drugs, (2) antihistamines and (3) benzodiazepines.
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INTRODUCTION TO COLUMN SWITCHING
CHAPTER 3
3.1. INTRODUCTION TO COLUMN SWITCHING
As has been mentioned in the previous section, HPLC has 
become a widely applied analytical technique, particularly 
in the determination of pharmaceutically active compounds. 
Coupled with this growth there has been a rapid development 
in the quality of chromatographic supports and equipment 
available. However, particularly in the case of biological 
samples, extensive sample clean-up is often required prior 
to analysis and this has been a limiting factor in the past. 
HPLC coupled with column-switching offers the analyst a 
powerful tool, allowing him to combine the separative powers 
of HPLC with simple sample clean-up procedures.
Sample clean-up of biological samples is critical for the 
following reasons (1).
(a) Complicated sample clean-up is time consuming and 
expensive.
(b) There is a risk of loss of interesting compounds.
(c) Sensitive compounds may decompose during the sample 
treatment.
The goal of all sample preparation system therefore must be 
to cope with these problems. The following points have to 
be considered if the method is to be used for routine 
determinations.
(1) The total analysis time should be short.
(2) To facilitate the operation, the sample preparation 
should be on-line to the HPLC separation system.
(3) The sample preparation should be suitable for 
automation. noo
(4) The reproducibility should be good enough to use 
external standardisation, which eliminates complicated 
searches for adequate internal standards and the 
problem of interferences with the internal standard.
(5) The sample preparation should be mild so that sensitive 
compounds can be handled.
(6) To minimize the problem of interferences no loss of the 
separation power of the chromatographic systems is 
acceptable, on the contary an improvement in 
selectivity is desirable.
(7) To reduce the time for the development and optimisation 
of a given analytical problem the sample preparation 
should be generally applied in such a way that the 
experimental parameters can be changed on a rational 
basis with high flexibility.
In the following section, valve switching and in particular 
column-switching will be presented as on on-line method for 
sample preparation which allows the analyst to attain the 
goals set out above. The section includes a thorough review 
of important research in this area to date and highlights 
the versatility, efficiency and never-ending possibility of 
employing this technique, in particular for sample clean-up 
and trace analysis in biological fluids.
3.2. VALVE SWITCHING
In general, valve switching is a method of rerouting 
chromatographic eluents by means of valves. When combined 
with the automatic switching of pumps, samplers, detectors
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and other apparatus, valve switching allows automation of 
those areas of chromatography that can be time consuming and 
require large numbers of man hours [2].
The type of valve commonly used in valve switching is the 
Rheodyne 6-port, 2 way valve (model 7000) which operates at 
high pressure (fig. 1). This valve has two internal
pathways connecting ports 1 and 2, 3 and 4 and 5 and 6 in
the nonswitched or RESET position and in the SWITCHED
position parts 2 and 3, 4 and 5 and 6 and 1 are connected.
Depending on the valve position, different external
connections to the valve are selected.
NONSWITCHED POSITION SWITCHED POSITION
Fig. 1: Rheodyne 6-port switching valve.
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Valve switching finds application in the following areas.
1, Sample clean-up
2, Trace enrichment
3 . Method development
4. Sample identification
5. Boxcar chromatography
6. Multi-column chromatography
7. Incremental gradient elution
Of these, sample clean-up and trace enrichment are major 
areas of interest.
Valve switching may be used to carry out any of the 
following:-
1. Column switching
2. Column selection
3 . Solvent switching
4. Solvent selection
5. Zone cutting
6. Auxiliary pump on/off
7. Trap solute in detector
8. Recycle
9. Fraction collection
10. Sample injection
11. Detector selection
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3.3. COLUMN SWITCHING
Here an eluent can be re-routed from one column to another, 
by using valves.
The procedure is very important and is used to
(a) carry out zone transfer and zone cutting
(b) optimize analysis time
(c) change the selectivity of the system
(d) increase column length.
Zone transfer is illustrated in Fig. 2 and represents the 
basic principles of column switching where a zone is allowed 
to elute from one column to another. To minimize extra 
column band broadening, the tubing connecting the column to 
the valve should be made from the finest bore capillary
tubing.
Zone cutting is an extension of this principle and probably 
the most useful and versatile of all the column switching 
techniques[3].
Figure 2 shows how a front cut can be taken from column C^ 
and transferred to column . Once the cut has been made, 
can be isolated from the system. If further zones are 
required, can be used to store the remainder of the
chromatogram until elution from C2 is complete.
Further zone cuts can be made in the same way as the first.
This cutting technique overcomes the problem of the
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I„ „ . . , „ „ zone A transferred fromzones A & B eluted from Coiumn C1_Q2
Column G1
Fig. 2: Description of zone cutting by column switching.
138
concentration of interferences on the pre-column.
In front-cut ting only the first part of the chromatogram, 
including the interesting peaks are analysed by . After 
the elution of the last peak of interest from the column 
is bypassed by switching valve 1 and can be cleaned by the 
flow of a good eluting solvent using back-flush or forward 
flush mode. Using this front-cut the analysis time can be 
significantly reduced because late-eluting background peaks 
are not analysed on the second column [1].
Very often the first part of the chormatogram contains a 
large amount of polar substances. The tailing of peaks due 
to these substances often interfere with the compounds of 
interest. To eliminate these polar interferences, an 
end-cut technique is used, bypassing the column C^ during 
the elution of the first part of the chromatogram. By 
combining front cut and end-cut only the relevant part of 
the chromatogram (heart-cut) is analysed by the second 
column. This minimises the interference of fast-eluting and 
late eluting peaks and also reduces the ballast load on the 
main separation column which could change the separation 
characteristics. The valve system shown in figure 2 is a 
simple but versatile one, however much more sophisticated 
systems are is use (Fig. 3), by other workers [2],
139
Fig. 3: Kontron MCS 670 Tracer configuration suitable for
sample cleanup using zone cutting methods and 
automatic solvent change for regeneration of 
pre-columns.
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3.4. APPLICATION OF COLUMN SWITCHING
3.4.1. Sample Clean-up
One of the most important applications of column switching 
is in sample clean-up. The fundamental concept of column 
switching which relates to sample clean-up is "zone-cutting" 
which has been described above. is the pre-column where
clean-up takes place and once the zone cut has been made, C^ 
is then cleaned and re-equilibrated. The system has been 
applied to the determination of organic acids in urine, 
vitamin C in blackcurrant syrup and vitamin C in rose hip 
syrup [3]. The chromatograms with and without sample 
clean-up are show in Fig. 4. The pre-column used for the 
analysis was the Brownlee S5 ODS pre-column. However a wide 
variety of column types may be used such as size-exclusion, 
ion-pair, ion-exchange, adsorption and reversed-phase.
The valve switching system described above has also been 
applied to the determination of estriol in gelatin capsules, 
where the complex fatty matrix in which the estriol is 
dissolved is cleaned up by valve switching. By using a back 
flushing mode the difficulty of washing the fatty matrix 
through the column is overcome [4].
3.4.2. Trace Enrichment
Trace enrichment allows on-line concentration of samples and 
can be of particular use when dealing with samples from
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dehydro - Ascorbic acid
Fig 4. Chromatogram showing the separation of blackcurrant syrup 
without (a) and with (b) sample cleanup.
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environmental media such as sea water or mineral water. A 
large volume of the sample is passed through a concentration 
column (10-100 ml) under chromatographic conditions where 
the sample does not elute and is adsorbed onto the column. 
A reversed-phase column and water are typically used. After 
concentration, the precolumn is switched in line with a 
different solvent, so that it is rapidly eluted onto another 
column where separation can take place. Unfortunately trace 
enrichment also concentrates other material in the sample 
and this may cause interference and lack of sensitivity. 
One way to overcome this problem is to combine trace 
enrichment with automatic sample clean-up.
3.5. SAMPLE CLEAN-UP IN BIOLOGICAL FLUIDS
The use of column switching has been applied to the 
determination of drugs in biological matrices with much 
success. A pre-column is used for direct purification and 
enrichment of sample, thus circumventing "classical" 
purification via extraction. A drug and its metabolites are 
often separable by reversed-phase HPLC however, proteins 
(e.g. from plasma) and inorganic compounds have to be 
removed by time consuming work up procedures which are the 
most inaccurate steps owing to the often unknown partition 
coefficients for all tested compounds. If these by-products 
are not removed, the lifetime of the column will be 
dramatically reduced and contamination of the analytical
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column will result in a loss in efficiency. In biological 
samples interesting compounds are often present at low 
concentrations and may be accompanied by excessive amounts 
of high-molecular weight material (e.g. proteins) or salts.
Of growing importance therefore in clinical applications is 
the principle of adsorption of the aqueous plasma matrix on 
a special pre-column followed by:
1. Water wash to remove proteins
2. Solvent change and backflush of drugs onto the 
analytical column
3. Isolation of the precolumn for clean-up and 
re-equilibration. The need here is to remove strongly 
adsorbed species such as lipids and fats [6].
One of the first designs of major importance in the use of 
valve switching and pre-columns for the clean up of 
biological fluids was that described by Roth et al. T 71. It 
allows direct injection of plasma followed by "alternating 
pre-column sample enrichment". It uses an on-line 
enrichment technique on a small pre-column followed by 
pre-column backflushing. Many of the succeeding studies 
were based on this work with some modification. It will 
therefore be described briefly here (fig. 5).
Samples of the body fluid are pipetted into the sample 
holders of an automatic sampling device. Volumes of between 
10 and 200Qul of plasma, urine or saliva, preferentially 
between 10 and 15Qul can be automatically injected.
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[IPLC - switching tcchniquc wiLh alternating pre-columns
Fig- 5 : System for alternating pre column sample
enrichmen t .
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It should be checked that the samples contain no solid 
particles which might block the injection needle. 
Pre-column 1 (PCI) onto which the first sample is injected, 
has been conditioned with the purge phase (water or buffer 
solution delivered by pump A (Fig. 5). After the injection 
to PCI (typical dimensions 23mm x 4.6mm ID) the pre-column 
is washed for a further 5 minutes with water or buffer.
The adsorption material for the pre-column is reversed - 
phase or ion-exchange material with a particle size of about 
20-50um. Here the substances to be detected are selectively 
adsorbed on C^g Corasil (37-50jam) and thus enriched. At the 
same time all accompanying water-soluble co-products are 
eliminated with the purge phase (pump A). A second 
pre-column (PC2) has been added to save time. While PCI is 
reconditioned, PC2 is eluted in the backflush mode onto the 
analytical column and vice versa (= alternating pre-column 
sample enrichment). Simultaneously to the application/ 
injection step, the autosampler (WISP) activates an 
electronic controller (time relay) which controls the purge 
phase period, after which it switches the pneumatic valves 
and starts the printer/plotter integrator. This switching 
process causes two subsequent steps; pre-column 1 (PCI) 
where the injected drug has been adsorbed is switched to the 
solvent stream of pump B which delivers the eluent coctail 
necessary for separation and chromatography in the backflush 
mode form PCI to the analytical column. Parallel to this 
process PC2 is switched to the eluent steam of pump A (purge 
phase) which removes the rest of the organic solvent from 
the pre-column. The whole working cycle thus
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consists of an equilibration phase, an adsorption phase and 
a purge phase on the pre-column and a chromatographic phase 
on the analytical column.
The characteristic features of the device are that there is 
no sample pretreatment, only one pipetting step per sample 
and no further standard compound is required. Peak width is 
independent of the injected volume, fully automated 
chromatography with high precision is achieved with 
overnight runs and low cost.
3.6. CONSIDERATIONS IN SETTING UP A SYSTEM FOR 
BIOPHARMACEUTICAL ANALYSIS
The above basically describes how the system works, but in 
order to optimise the recovery and selectivity of an assay 
major consideration must be given to the various parameters 
listed below.
(a) Size and design of the pre-column
(b) Pre-column packing material
(c) Eluent for the wash phase
(d) Frits and tubing
(e) Backflush vs forward flush mode
(f) Sample pretreatment
(g) Lifetime of the pre-column
(h) Protein binding
(i) Memory effects
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To help in a discussion of these various conditions a table 
has been drawn up which reviews many of the studies which 
have been carried out in biological fluids. (Table I.) 
Reference to this table will prove useful during the 
discussion.
3.6.1. Size and Design of the Pre-column
Of major importance is the construction and geometry of the 
pre-column into which the adsorbent will be loaded. The 
design of the pre-column can be quite diverse ranging in 
length from 2mm to 3cm and an inner diameter anywhere from 
1mm to 4.6mm (for details see table I). It is best to use 
as short a pre-column as possible to save on expensive 
adsorbent, enable easy and manual packing and to reduce 
backpressure [8].
In a study by Werkhoven-Goewie et al. [9], different size 
pre-columns were examined for their effects on band 
broadening ranging from (1.45mm x 4.6mm) to (41mm x 1.1mm) 
to (30mm x 4. 6mm). Under the conditions of the study the 
on-line coupling of the pre-column to the analytical column 
has a negligible effect on band broadening and the system 
performance is hardly dependent on the pre-column design 
used. For more polar compounds the design of the pre-column 
may be more critical with shorter columns being preferred. 
Other workers [10] when comparing a pre-column of dimensions 
40 x 4.6mm with cartridges 5, 10 and 20mm long obtained full 
recovery of the analyte with all four types but found the 
number and amount of interfering peaks was reduced
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considerably with shorter columns, the 5mm cartridge giving 
the best result.
For the determination of Clobazam and its active metabolite 
desmethyl clobazam a micro pre-column was designed [11]. A 
hole 4.5 x 1mm I.D is drilled within the axis of a valve and 
filled with suitable packing material. This when used in 
conjunction with a narrow bore column allowed a limit of 
detection of 2.5ng/ml for each drug in plasma after direct 
injection of the biological fluid, with little contribution 
to band broadening.
So in general best results are obtained with a small
pre-column leading to fewer contributions to band
broadening. The pre-column serves as a preconcentration 
and clean-up column and as a guard column to prevent
contamination of the analytical column.
3.6.2. Pre-column Packinq Material
The pre-column packing chosen should display a high affinity 
for the analyte during the sampling step, a low affinity 
during the desorption stage and have high loadability. The 
most widely used packings are commercially available alkyl 
modified silica (C1Q, CQ and ), pyromodified carbon black, 
ion-exchange resins, XAD-2 and styrene divinyl benzene
co-polymer based materials (PRP). The PRP based packings 
have a higher affinity for chloro and nitro-substituted 
aromatics than does in fact PRP displays 10-20 times
greater affinity towards aromatics than does C^g packing 
[1 2 ] .
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In a study by Roth et al [12], the results for various 
packings reveal that different RP materials possess 
different affinities for the injected compounds. The 
packing in the pre-column should be chosen in such a way 
that the retention on them is lower than on the analytical 
column and ideally zero. This can be achieved by the 
selection of a packing material with different surface 
characteristics or using pellicular packings. For the 
analysis of Clovoxamine and Fluvoxamine in plasma an RP-8 
analytical column with methanol -0.01M phosphate buffer pH7 
(62:38 v/v) as a mobile phase was used [13]. However the 
use of RP-8 as a packing material in the pre-column was 
found to cause intolerable band broadening because of a too 
long retention time. With the use of RP-2 as the packing, 
the retention time of clovoxamine and Fluvoxamine are much 
less and consequently there is less band broadening caused 
by the pre-column. Plate numbers for the analytical and the 
pre-column were typically 4000 and 200 respectively and 
using the equation for variance below.
( !) 2 total =^tR2j + |tR2j
one can calculate that for the RP-8 pre-column c f -total = 1.9 
d^anal and for the 32um RP-2 pre-column ( f  total = 1.1
anal. The behavior of a much more expensive lQum RP-2 is 
similar to that of a 32^ im RP-2. Also the observed total 
standard deviation is often higher than the theoretical one 
because connections between the valve and the columns can
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contribute to band broadening [14-16]. A possible 
disadvantage of RP-2 with respect to the more apolar RP-8 is 
the smaller recovery of the pre-concentrated step. However 
in the determination of clovoxamine and fluvoxamine this was 
not found to be a problem. Zech et al. [17] have also found 
that RP-2 is to be preferred to RP-18 as a packing in the 
pre-concentration column as it allows faster transfer of 
compounds from the column due to weaker retention. They 
found that the combination of C^ and C^g material 
(pre-column and analytical column) results in a more 
complete removal of interfering matrix from the pre-column 
after injection of serum and a faster transfer of the 
compounds under investigation to the analytical column.
Particle size exerts a profound effect on pre-column 
performance. Although it is known that larger size 
particles cause greater band dispersion [18] most workers 
favour particles with size 25-50 ^ xm as pre-column packing in 
order to prevent clogging of the pre-column with particles 
from plasma. From an inspection of table 1 it can be seen 
that all of the studies which employ a direct injection of 
plasma use particles in the range 25-50 ^ um with Corasil C^g 
(37-50jjm) and Lichroprep RP C^g (25-40um) being the ones of 
choice. In studies where a smaller particle size packing is 
used in the pre-column some form of sample pre-treatment of 
plasma prior to injection is required.
Although these pellicular type packings give adequate 
recovery for medium polarity compounds, porous particles may 
be needed for more polar drugs [19]. In a study by Juergens
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et al. it was found that Nucleosil 30 C^g (30>am) gave better 
recovery and longer lifetimes than pellicular packings [20].
A packing which shows great potential is XAD-2 which was 
used in the determination of Metaqualine [21]. It has 
several properties which render it ideal for sample 
preparation and clean-up. It has strong adsorbent 
properties [22, 23] and is inert at all pH's. Most plasma
proteins have their isoelectric point below 7 [24] and thus 
have a large negative charge at pH 9.3 which contributes to 
higher water solubility. Similarly at pH 9.3 many small 
molecules in plasma are negatively charged and therefore 
should be unretained on XAD-2. However despite these 
advantages, the use of XAD-2 is likely to be limited due to 
its influence on band broadening.
A more recent approach is the use of pre-columns packed with 
immunosorbents. When a plasma sample containing phenytoin 
[25] was injected onto a pre-column containing a 
immunosorbant specific for the drug, a dissociation and 
partition of phenytoin from plasma proteins to a complete 
association with on-column insolubilized antibodies results. 
Desorption onto the analytical column then follows.
Whatever the choice of packing it should be such that the 
drug is completely retained while interfering substances in 
plasma are completely removed during the wash step.
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3.6.3. Choice of Eluent
The eluent must be chosen in such a way that the drug and 
its metabolites are retained while the bulk of unwanted 
constituents from plasma are flushed through. Almost all 
workers employ a purely aqueous wash solvent i.e. either 
distilled water or an aqueous buffer. We found in our 
laboratory that pure water as wash solvent gave the cleanest 
chromatograms as there is no possible interference from 
buffer salts when they come into contact with plasma 
constituents. Some workers may add a small amount of some 
organic modifier e.g. 4% acetonitrile to the wash phase but 
this may result in lower recovery for a drug [26].
Of the utmost importance however is that the mobile phase 
for flushing be pure otherwise impurities will be 
concentrated and later eluted onto the analytical column 
where they will cause interference.
Care must also be taken that breakthrough does not occur, 
this is a function of the sample capacity of the 
concentration column which depends on the composition of the 
sample and the eluting strength of the solvent.
3.6.4. Frits and Tubing
It is recommended [27] that the steel capillaries from the 
injector to the pre-column should be of wider bore than 
those from the pre-column to the analytical column. This is 
especially important for viscous plasma samples.
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Zech and Huber point to the importance of using sieves
(although with an adequate filter function) instead of frits 
in order to avoid column blocking [17]. Sieves of the 
pre-column should not be too fine, sieves of at least l ^ m  
pore size are recommended [27]. Also to guarantee a
homogenous distribution of the administered plasma to the 
top of the guard column, crossed grooves should be fitted 
onto the surface of the end fitting which crosses the top of 
the pre-column [27]. Other wokers have also found screens 
to be better than frits [19]. We found in our laboratory 
that if frits are used they need to be changed frequently.
3.6.5. Back flush/Forward flush
On inspection of table 1 outlining the various studies, it 
will be seen that the backflush mode for the desorbtion of 
the drugs from the pre-column to the analytical column is by 
far the favoured mode. Backflushing prevents contamination 
of the pre-column and minimizes band broadening. It can be 
shown by the use of a strong fluorescent substance that the 
analytes are concentrated in a small region at the top of 
the pre-column so that their removal by backflushing
minimizes their dispersion [7]. In the "elute through" mode
these drugs initially in a narrow band at the top of the 
pre-column must pass through say the full 2cm of packing
experiencing all the band dispersion effects of the column
[2 1 ] .
In the case of the few studies [28, 17, 29, 20] where
forward flushing is employed, it will be noted that the
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pre-columns are very small, less than 1cm in length so that 
the overall efficiency does not deteriorate as we might 
expect in straight flush mode. Forward flushing does 
prevent the build up of contaminants at the head of the 
analytical column.
However in general back flushing is to be favoured.
3.6.6. Sample Pre-treatment
In many cases the biological fluid is directly injected onto 
the pre-column with no sample preparation whatsoever [10, 
12, 20, 21, 25, 27, 28, 30 -40]. If this is the case care 
should be taken that there are no particles present which 
might clog up the column. This offers obvious advantages in 
terms of speed of analysis and sample throughput. Some 
workers favour centrifugation of plasma prior to injection 
[13, 17, 36, 41, 42], followed by injection of the
supernatant onto the pre-column.
In order to prevent clogging of the pre-column and reduce 
the viscosity of samples, plasma may be diluted with water 
[43] or aqueous buffer [44, 45] prior to injection. This
procedure will increase the limit of detection and may not 
be possible in the case of drugs which are present in the 
very low nanogram range. Plasma may be deproteinized prior 
to injection [29, 42, 46, 47] with an organic solvent such
as acetonitrile which causes precipitation of plasma 
proteins which are then separated by centrifugation and the 
supernatant injected. We have found in our laboratory that
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this procedure usually results in low recoveries for the 
drugs since acetonitrile acts as a strong eluent and the 
drugs do not become trapped on the pre-column [36, 37].
A problem which may arise and which will certainly result in 
low recovery for a drug during preconcentration is that of 
protein binding. Werkhoven-Goewie et al.[48, 49] have shown 
that incubation with the proteolytic enzyme subtilisin A 
releases strongly bound drugs from proteins and in addition 
prevents clogging of the pre-column. Proteinase K may also 
be used but since subtilisin A is milder towards labile 
drugs it is the one of choice. The use of proteinase K may 
however be favoured in the case of thermolabile drugs as its 
optimum incubation temperature is 25^C compared to 55^C for 
subtilisin A. The effect of the pre-column loading with (a) 
untreated and (b) hydrolysed serum and a backflush wash step 
with water on the pressure drop over the pre-column has been 
studied.
The pressure drop is expressed as the relative pressure drop
Prel., where
P P - Prel = o x 100%
P - P max o
P = pressure measured
Pq = the initial pressure drop over the pre-column
]?max = the pressure reached upon complete clogging of the
system.
A pre-column was almost completely clogged (prel = 90%) 
after injection of 7-10ml of 2 month old untreated serum,
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however for 1 month old hydrolysed serum Pre  ^ = 10% after 8 
subsequent 1ml injections. Upon introduction of backflush 
wash steps, the pressure could be kept consistently low 
(Prel = 0-10%) with all samples. It was also observed that 
dilution of the blood samples in an equal volume of enzyme 
solution had a favourable effect on the pressure profile due 
to the decreased viscosity of samples. A disadvantage of
using subtilisin A is that some of the peptides formed by
its action may interfere with the detection of the analytes 
of interest.
In general direct injection will provide best recovery, with 
faster analysis time and rapid sample throughput, the 
disadvantage is that the system will be more prone to
clogging and build up of back pressure.
3.6.7. Protein Binding
It is essential that the analyte of interest has a greater 
affinity for the sites on the surface of the packing than 
for the proteins in plasma. Otherwise recovery of the drug 
from the pre-columns will be low due to plasma protein
binding. In order to assess the extent of binding, the peak 
heights obtained for a series of recovered authentic 
standards are compared with the peak heights obtained for a 
series of recovered plasma standards from the pre-column. 
If there is evidence of binding, the drug must be released 
from the proteins prior to quantitation. As described above 
this may be achieved using an enzyme such as subtilisin A. 
In my work on the benzodiazepines I describe a simple
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novel procedure for the release of diazepam from plasma 
proteins. It involves the addition of a drug which 
preferentially binds to plasma proteins releasing the 
diazepam for measurement. This is an approach which may 
become useful.
3.6.8. Pre-column Lifetime
Although the lifetime of the pre-column will depend on a 
number of factors such as the particle size and type of the 
packing, the porosity of the frits, sample pretreatment and 
the age of the plasma in general each pre-column will be 
able to handle between 10-20mls of plasma with the average 
being 15mls. The lifetime of the column depends on the
total amount of plasma injected rather than the size of each 
injection. A pre-column therefore that can handle 400 x 50 
;ul injection will only handle 80 x 250 ^ ul injections. With 
larger injection volumes, the re-conditioning of the 
pre-column between injections is particularly important. 
Eventually the surface of the adsorbent in the pre-column 
will become modified with matrix elements from plasma 
resulting in a loss of efficiency and a decrease in 
recovery.
3.6.9. Memory Effects
Memory effects from the pre-column ("substance bleeding") 
may be easily checked by injecting blank solutions between 
approximately every 10 injections. No memory effects should 
be observed.
The switching procedure employed for clean-up of biological 
fluids in our laboratory will be described in Section4.2.1.5.
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TAKT F. 1
1
Name of Biological 1 Sample
1
| Valve Size & Mobile
1
Analytical Backward/
1
1 L.O.D.
t
1 Purge
1 1 
1 Detection | Internal
T
1 Ref
Substance Medium 1 Pre-treatment | System Type of Phase Column Forward 1 Time I Mode 1 External
Pre-Column Flush t 1 
! 1
Tr iamcinol- Urine 1ml 1 Direct |Automated 2 pre-columns A variety of Shandon Backflush 15ng/ml
1 1 
1 1 
1 U.V. at 254;m| Ext.
one sample 1 injection | 3 valves both mobile 0GS - 1 1
1 1 low 40 x 4.6mm phases Hypersil 1 1
|pressure (a) PRP 1 I 1 32
|2 high I20-30um) I [
|pressure ( b ] CDS silica 1 1 
I 1
I I
Methotrexate Plasma |Deproteinizat- |2 valves 4.6 x 3mm A: Water Partisil Backflush 1 9 ppb 1 20ml
1 1 
|u.v. at 306nn |Ext.
[ ion filled SAX in 1 I
with B : Sodium (lOum) 1 plasma I 1
RP - 8 phosphate 250x4.6mm 1 1 1 46
Merck (1Oum ) containing 1 I
sodium 1 i
chloride 1 1
methanol 4.1 I 1 
-1--------------- 1----------
Clovoxamine
Fluvoxamine
Plasma Centrifugation 
of 2 0 0ul 
5-10 samples/ 
column
Z valves 5cm x 4.6mm 
RP - 2 
(32um )
A: Hater 
B : Methanol 
- buffer to 
pH 7 
62:38
Lichrosorb 
RP - 8  
(7 urn ) 
150x4.6mm
Backflush 3ng/ml
in
plasma
5 mins Derivatization
+
fluorescence 
Xex = 380 tun 
Xex = 470 nm
Ext.
13
I I _1_ JL
TASE 1 (Gontd. )
Name of
1
1 Biological Sample Valve
T"
1 Size &
1
1 Mobile
— I--  ' "I
1Analytical
i
Backward/ | L.O.D.
1
1 Purge Detection
i I 
1 Internal |Ref
Substance Medium Pre-treatment System 1 Type of 1 Phase 1 Column Forward | 1 Time Mode 1 External |
1 1 Pre-Column 1 1 Flush 1 I 1 Standard |
Pentoxifyll­ Plasma 1 Direct 1 2 valves 40 X 4.6mm A: SmM'l Nucleosil Backflush |50ng/ml |4.5min 1 U.V. at 273nm Ext. 1
ine 1 injection and cartridges Ha HPO2 Phenyl 1 1 1
+ jSOOul 1 automated 5, 1 0 » 20mm pH 7.1 <7um) 1 1 1
Hydroxy- 1 filled with B: 40 X 4.6mm 1 1 1 1 0
metabolite !
1
!
1
I
1i
lichroprep 
RP - 2 
+
RP - 18
Best: 5mm with 
RP - 2
acetonitrile 
Phosphate 
pH 6.7
23:77
1 I 
1 i 
1 1 
1 I 
1 1 
i I
I I
1
1
1
1
i
1
— !_
Metoprolol Plasma
i
¡Diluted + ¡ 2 valves 25cm X  4. 7mm A: Water Lichrosorb Backflush
1 i
1 1 0 ng-/ml| 1 Fluorescence Int.
i
1
+ 1 Centrifugation |air Lichroprep RP - 8 1 1 |Xex = 225nm 1
Hydroxy - 1(0.5 or 1 ml) 1 actuated RP - 2 B: ( Sum ) 1 I [Xend = 320nm 1
metabolite 1
1
1
1
1
25-40um
or
10cm X  4.7 mm 
ID nucleosil 
5CN (5 urn)
acetonitrile
/sodium
acetate
75:25
25cmx4.7mm 1 1 
1 1 
1 1 
1 ! 
1 1
1 *3 
1 
1 
1 
1
Lonazolac Serum I Direct 1 1 valve 130 X 4 mm 1A : Water Lichrosorb] Backflush | |4 min |U.V at 282 nm ¡Ext. !
+ 1 injection I 1Lichroprep Ib  : Gradient RP - 8 1 1 1 or 1
P-hydroxyl- 1 2 0 0 ul 1 |RP - 8 1Acetonitrile (5 urn} 1 110 ng/ml[ 1Fluorescence | 1 30
Metabolite
i
I
1Í
1
1
i
1 Í 30um )
1
i
1Water 
|PH 2.7
i
125 X  4mm [ [ |
1 I 1i r i
|Xex = 282 ] 
|Xem = 389 |
1 1
i
1
I
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Type of 
Pre-Column
1
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[ Phase
I
Ï
!
Analytical!
Column
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Forward
Flush
! i 
1 L.O.D. Purge
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Detection
Mode
1
1 Internal
1 External
1 Standard 
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|Ref.
t
1
I
I
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\
Corticoster­ Serum
1
]ZOOul direct - porous
1
|Dichlormeth- - 1 20 ppb U.V.at 240rnn
1
[ Ext.
oids |injection styrene- |ane Zorbax SIL| [
I divinyl I - methanol or [
1 benzene 197* 3 Jasco 1 1 33
I co-polymer 1 SS-05 ] 1
1 10-30mm x 1 I
i
j
0.5nun of PTFE 1
I tí
Sulmazole Plasma | Direct (Automated Corasil C
!
|A: Water Hypersil Backflush 1 8ng/ml 2-4min Fluorescence
I
|Ext.
+ Urine |injection |3 valves JO 1 COS | detection l
its two Bile |of 5-50ul |with (30-50um) |B: Phosphate (5um) Xex = 345nm !
metabolites 1 | alterna­ 4-0x4. 6mm | Buffer 125x4.6mm| Xem = 515nm 1 1 27
1 ting pre |Acetonitrile 1
1
I
|columns ¡2 : 1
t 1r
Cephalospo­ Plasma
1
|Deproteinizat- |Automated (a)lcm x 4mm
1
i A: 0.03M Toya Soda | Forward |50ng/ml 75 secs U.V at 295nm
I
|Ext.
rin Urine | ion + (2x3 port ID anion 1ammonium COS | 1 for 1
¡Dilution |valves exchange 1 dihydrogen 150x4.6um | 1300ul 1
I 1 1 x6 port (5um) |phosphate + (5um) 1injecti- 1 j 29
1 |valve (b)lcm x 4mm [phosphoric |on of 1
1 RP (5um) |acid 1 serum 1
1 |B: 0.5mNaCl |500ng/ml 1
i | + |for 1
1 |acetonitrile |50ul 1
1 + 1injecti- 1
j |sulphuric |on of I
i |acid 1urine !
1r t 1
|15:85 : 0.2 
I l l i l.
i
i 1
TABLE 1 (Contd.)
Name of
“I
1 Biological Sample
C
Valve
T 1 " ' 
| Size &
J
1 Mobile
- T-- I
¡Analytical
' I
Backward/ | L.O.D.
I
1 Purge Detection
1 1---
| Internal ]Ref
Substance 1 Medium Pre-treatment System | Type of 1 Phase I Column Forward | 1 Time Mode | External |
1 | Pre-Column 1 1 Flush j 1 | Standard |
Biogenic 
Amines 
dopamine, 
norepinephr­
ine,
epinephrine
and
serotonin
related
metabolites
Urine 1
1
1
1
1
1
1
1
1
1
1
¡Automated 
¡4 valves 
¡and 4 
¡columns 
| (Kontron 
| system)
Nucleosil
C (lOum) 18
KH PO 
2 4 |Na EDTA,
¡SDS + 12.SX
¡methanol
Nuclosil
C18(lOum )
4 columns
1
1
1
1
1
I
1
1
1
-I
Electrochemic­
al
+
Fluorescence 
Xex = 282nm 
Xem = 314nm
Int. 1
1
1
1 52 
1 
1 
1 
1 
1 
1
. J____
Doxorubicin Plasma
1
1 Direct ¡ 1 valve 23 x 3.9nun ¡A: Water R.P. Backflush 2. 3ng
1
¡0.5ml Electrochemic­ Int.
1
1
+ 1 injection u Bondapak on ¡of al 1
three ¡after high phenyl ¡B: Water column ¡water + 1
metabolites 1 speed (37-50um ) ¡Acetonitrile 1 is the Fluorescence I * 1
1 centrifugation ¡glacial 1 purge Xex = 480nm 1
1 ¡acetic acid ¡volume Xem = 560nm 1
I
1
|69i30i1 !
i
1
I
Antiepilept­ Serum
— r  ■
|ppt with | Automated 2 alternating |A : Water Spherisorb Backflush 2 0 0ng/
i
¡5 min U.V at 200nm Ext.
1
1
ic 1 0 -1 0 0 ul ¡acetonitrile | 2 valves pre-columns |B: 250x4.6mm ml (at 1
drugs ¡Direct |(Roth et (SO x 4.6mm ) ¡acetonitrile CCS in ] 2ml/min 1
ethosuximide 1injection |al} Lichrosorb |water (5um ) serum I 1
primidone, ¡after RP - 18 | ( 2 1 t80) 1 1
phénobarbit­ ¡centrifugation (lOum] |low-step 1 1 42
al |at 1 2 , 0 0 0  rpm ¡gradient 1 1
phenytoin |for 1 min. 1 1
carbamazepi- 1 1 1
ne 1
1 I 1 i I 1 1I I I 11
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Flush
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Detection
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Standard
Ref
Cephalospor­
in
Ro 14-1761
Plasma
Milk
Dilution
+
Precip itation 
with
acetonitrile
1 valve 
automated
4cm x 4mm 
RP - 18 
Lichrosorb
Acetonitrile 
TO AB
Backflush 0 .lug/ml 0 .8min U.V. at 274nm Ext.
Hypersil
C ( 5um ) 
8125mm x 
4mm
47
Tripelennam- Plasma -
-t----------------
|Direct 1 1 valve
“I--------------
11cm x 1,5mm
- 1 -------------
1A : Hater Techsphere| Backflush 1 2ng/ml
1 -------- 1---------------
(3 min (U.V. at 246nm [int.
-- 1----
1
ine |injection 1 manual Corasil C
1(37-50um)
1
1
1
1
1
I
1 3 CN ! 1 1
Milk |Centrifugation
| +
| Direct 
1 injection 
1
1
]
1B :
1Acetonitrile 
1Acetate 
1Buffer 
170:30
I
I
( 1 0 0 x
4.6mm )
15ng/ml 1 1 
1 1 
1 1 
1 1 
1 1
1 1I !
1
I 36
i
1
1
1t
Amitriptyli­ Plasma
I
|Direct 1 1 valve
1
11cm X 1,5mm
1
1A t Hater Techsphere| Backflush 15ng/ul
1 1
11.5min |U.V at 215nm | Int.
1
1
ne |injection 1 manual ICorasil C181(37-50um )
|B : 3CN 1 1 1 1
+ 1 1Acetonitrile 100x4.6mm | I 1 1
its 1 ! 1Acetate 1 1 1
Metabolites
_
1
1
1
l
l
«
!
1
1
1
1
1
¡Buffer
1 6 0 :40
1
1
1
1 1 1
t 1
1 1
1 1
1 1
1 1 « « _L
1
1 37
1
I
11
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TASE 1 (Contd.)
1
Name of Biological
1
1 Sample
1
| Valve Size &
1
Mobile
1
Analytical Backward/
1
1 L.O.D. Purge
1
1 Detection Internal
1
¡Ref
Substance Medium 1 Pre-treatment | System Type of 
Pre-Column
Phase Column Forward
Flush
Time 1 Mode External
Standard
Antiepilept­ Serum |Defribrination (Automated 25 x 3.9 mm A : Phosphate Fast LC- 8 Backflush \ 1 0ug/ml 4 min (U.V.at 214 nm Ext.
ics |of |2x6 port dry packed buffer pH3.5 150x4.6mm
- Primidone* 1 plasma (valves with 30um RP B : Phosphate 5 um
- Phénobarb­ Lichrosorb buffer: particles I I ’
ital, Si 60 bonded methanol of porous
- Carbamaze- with 55i45 + silica
pine C in the lab 18 65 ul/1 triethyamine
bonded
dimethyl
octylchlor
osilane
Methaqualone Plasma ¡Direct 
1 injection 
¡500 ul
| 2 valves 2cm x 2mm 
Amberlite 
XAD - 2 
(37-44 um)
A:
Ammonium 
Chloride + 
Ammonia
Lichrosorb 
250x4.6mm 
(lOum)
Backflush 1 l-2ng/ml 5 min |U.V. at 254 nm 
or
265 nm
Ext.
I 21
pH 9.3 
B: Citrate 
buffer 
acetonitrile 
68:32
Clobazam Plasma
-- 1-----------
¡Direct
---- 1---------- 1--------------
(Automated¡Micro pre-
1 -----------
(A : Water
— t----------- 1----------
|Spherisorb| Forward
1 1 1 i 
|2.5ng/ml¡3000ul ¡U.V at 254 nm ¡Ext.
1
1
+ or | 1 0 0  ul ¡ 2 valves ¡column 1 1 2 0cm x 1mm( ] ¡900 sec) 1 1
Desmethylcl- Serum 1 | inserted I ¡0DS - 2 1 I I I  1 i
obazam 1
1
1
1
1
1I
¡within the 
|axis of a 6- 
|port valve 
|40 um C8¡4.5mm X 1mm
1 1
1 1
1
1
1
1
I
1
•
1 ( 3 um )
I 1
1 1
1 1
I 1
1 1 
1 I
I I I  1 
1 1 1  1 
I I I  1 
1 1 1  1 
I I I  1 
I I I  1I I I  1
1
1
1 11
I
1
1
1
16
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Flush
LQD
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Detection
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Standard
Ref
AR-L 115 
(Y)
Rapenton (X) 
Dipyridamole
Plasma
Urine
Saliva
lOul - ISOul
direct
injection
Automated 
3 valves
2 alternating
pre-columns
25mm x 4.6mm
C corasil 18(37 - 50um)
A: Water or 
buffer 
B: Methanol 
tris buffer
Lichrosorb 
RP-18 
(5um) (X) 
Hypersil 
OOS
(5um) ( Y Ì
Backflush 50ng/ml 5 min Fluorometric
Anti­
convulsants
Serum
— 1-------------
1 Direct 
1 injection
I
1
1
1
1
,1
---1---------- 1--------------
|Kontron |Brownlee RP18 
1"TRACER" | (20um )
|MCS 670 1 
|column |
|switching|
|unit with|
|5 valves | 
t 1
|A: Water
|B: Water
|Methanol 
|Acetonitrile
Spherisorb 
SS C
8125x4.6mm
------------ 1--------- 1-------
Backflush |
1 1 
1 1 
1 !
1 1 
1 1 
I [
I I
1 --------------- 1--------
|U.V. |lnt.
1 1
1 1
1 1
1 1
1 1
1 !
I I
— i—
1
1
1
1 35
1
1
!
i
Phenytoin Plasma
1
1 Direct
1 1 
| 1 valve |50 x 4 mm |A : 0 .1mol/l Lichrosorb
1 t 
Backflush ¡20umol/l¡4 min
1 1 
|u.v. a-fc 254run |Ext. 1
I injection |pneumatic|packed with 1 phosphate RP-18 1 1 1 1 1
1 |an immuno- |buffer ( 7um ) 1 1 1 1 1
1 |sorbent |B : (250 x 1 1 1 1 1
1 1 1 | phosphate 3.9mm ) 1 1 1 1 1
1 1 1 |buffer 1 1 1 1 1 25
1 1 1 |ethanol 1 1 I 1 1
1
-- !-------------
1 1 
--- 1---------- 1--------------
|( 60:40, v/vl 1 1 
------------ 1---------1------- 1 1 -i---------------1-------- 1---1----
Diazepam Plasma
— i---------------- r
|Addition of 1 11cm x 1.5mm
—1------------- 1-----------
|A: Water |Lichroso-
V  1 - T  ' 
Backflush |25ng/ml ¡2 min
1 ------------ T
lU.V.at 246 nm ]Ext.
r
I 34
+ |Salicylic acid | valve |Separalyte fB: Methanol |rb 1 1 1 1 I
Metabolites |+ direct | IC ( 40um ) 
8
i
|Phosphate |RP 
|Buffer 50:50|
I I
1 1 I 1 1
|injection
i i
1 1i 1 t 1 !1 1
I
1
TABLE 1 (Contri.)
1
Name of 
Substance
Biological
Medium
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j Pre-treatment
Valve
System
Size & 
Type of 
Pre-Column
1
| Mobile 
| Phase
T
Analytical
Column
Backward/
Forward
Flush
r
1 L.O.D.
1
Purge
Time
1
Detection | Internal 
Mode [ External 
{ Standard
t
I
1 Ref
Antiepilep­ Serum 1Direct Automated Cartridge |A: 0 .0 1 '/. Shandon Forward | ug/m1 300 sec
1
1
U.V. at 205nm| Ext.
tics 300-400 |injection 3 valves 5mm x 4.6mm | vol OOS 1 region 1
e.g. injections |50ul filled with 1 phosphoric Hypersil 1
phénobarbit­ column Nucleosil 30 |acid (5um ) 1 1 2 0
al. C18 (30um) |B: buffer/ 250mm x 1
phenytoin» ¡acetonitrile <+.6111111 1
etosuximide ]gradient 1
carbamazep- I
ine + 1
metabolites I
1-
Hydroxyphen- Urine |Acid hydrolysis Automated Lichrosorb |A: Hater Zorbax Backflush 1 50ug/ml 2 0 0see
1
U.V. at 205nm|Int.
ytoin 400-500 |of glucuronic 3 valves RP - 18 OOS 1
injections |acid conjugate I lOum) |B: Water/ (5um ) 1
¡Dilution 40mm x 4.6 mm |acetonitrile 250mm x 1 ! 50
|Centrifugation |gradient 4.6mm i
1
Etoposide Serum |Hydrolysis ¡Automated 2mm x 4.6mm A s Hater 1Lichrocart; Backflush 1 0 0 ng/ml1 1 2 0 sec ¡Fluorescence ¡Ext. 1
Teniposide Plasma |with |4 valves or 1 1 0 um 1 1 ¡Xex = 230nm 1 1
Urine |Sulstilisin A ¡ 1  low 1 0mm x 2mm B: Hater 1Lichrosorb| j |Xem = 328nm i 1 48
| 0 . 2  - 2 mis i pressure with Methanol 1 CIS 1 1 I 1 I
1 |3 high Nucleosil C18 1 ( 125nun x j 1 1 1 1
1 sample ¡pressure or 140mm ) 1 I 1 1 1
1 1 PRP 1 I 1 1 1 I
1 I (divinylbenz- I 1 1 1 ! 1
1 I ene styrene CD 1 I 1 1 1 !
1 1I 11
polymer) 1 1 
1 1
1 11 1 1
11 1•
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Pre-treatment
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Phase
Backward/
Forward
Flush
L.O.D. Purge
Time
Detection
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External
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Ref
Secoverine Plasma 
500 ul
Enzymatic
hydrolysis
with
Subtilisin - A
Kontron
system
2 types 
(a ) 30 x 4. 6mm 
Lichrosorb 
CN (10 urn) 
prepacked 
(b ) (1.5-4mm ) 
x4 . 6mm ID
A: Hater 
B: Dioxan: 
Buffer 
15:85
Polygosil
CN
(10 urn)
Backflush 20ng/ml Z ml 
of 
water
U.V. at 
274.5nm and 
Fluorescence 
after post 
column 
ion-pairing 
with DAS
49
Spiramycin 1 Plasma lml of plasma 
+
1.5ml of 4X 
acetonitrile
1 valve 
automated
50 x 7 mm 
Perisorb RP-18 
(30-40um)
1 ml of mixture 
in injected
A: 4/i
acetonitrile 
B: 26* 
acetonitrile 
in ZV.
perchloric
acid
Nucleosil 
C8 15um ) 
150x4.6mm
Backflush 50ng/ml 400sec U.V. at 230mm Int.
26
Aminopyrine
+
its
Metabolites
Serum 50 - 1000 ul 1 valve 50 x 4.6 mm 
Lichroprep 
RP - 8 
(25-40 um)
A: Hater 
Bi Gradient 
Acetonitrile 
Phosphate 
buffer
Lichrosorb 
RP - 18 
( 5 urn )
(250x4mm 
ID)
Backflush 2.2ug/ml lml
purge
volume
U.V. at 257nm Int
31
JL
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Flush
L.O.D. Purge
Time
Detection
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Ref
Catecholami­
nes
i.e.
noradrenali­
ne,
adrenaline,
dopamine
Plasma
Urine
Direct 
injection 
(6Oui )
Contron
Valve
switching
unit
1. 10x4.6nun 
phenylboronic 
acid gel for 
plasma
or
20x3.8mm 
dihydroxyboryl 
silica for 
urine
2. 20x4.6mm 
5um Supelcosil 
LC - 18
Ar Phosphate 
buffer with 
2mM decylsu- 
lphate + 
0.3mM EDTA 
B:
Phosphoric 
acid +
2mm decylsu­
lphate
C:
Phosphate 
buffer- 
citrate 
buffer- 
Methanol 
(37.5 37.5 
25) with 
decylsulpha- 
te
Supelcosil 
LC - 18 
( 8um )
75 x 4.6mm
Backflush 0.05
nmol/1
6 min Electrochemic­
al
+
rluorescence
after
dérivâtization
Ext.
38
Chloramphen­ Serum
---1-------------
¡Direct
— 1---------- 1-------------
|l valve |20 x 2.1mm
— i-------------
1A : Hater
-----------1-
Hypersil -
-- 1---------
|5ug-/ml
-------- 1--------------- 1--------
2 min |U.V. at 277 nm|Ext.
--1----
1
icol 1 injection 
1(25ul)
1
1
!
1
1
1
| automated|Hypersil 
1 loos 
| |(lOum )
1 1 
1 !
1 1 
I 1
I I
|B: 3m1/1 
[Triethylam- 
1 ine
+
1Acetonitrile 
j gradient
1
I
cos 1
100x2.1mm | 
(5um )
1
1
1
i
1
1
i
1
1
1
1
1
1 1
1 1
1 1
1 1
! I
1 1
1 1 
i i
1
1
1 39 
1 
1 
!
i
1
Procainamide Serum
I
|Direct
i i
|l valve |20 x 2.1mm
1
]A: Hater +
1
Hypersil [ - ! 4ug/ml
t i 
0.8min |U.V at 270 nm |Ext.
i
1
+ (injection |automated!ODS - 13m 1/1 OOS j 1 1 I 1
N. Acetyl 1 ¡Hypersil |Triethylami- 100x2.1mm ] 1 1 1 1
Procainamide
l
1
1
1
1
1
«
1 1
1 1
1 1
1 1
1 1 
i i
1 ne
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TABLE 1 (C ontri.)
1
Name of 
Substance
Biological
Medium
Sample
Pre-treatment
Valve
System
Size &
Type of 
Pre-Column
1
1 Mobile 
1 Phase
1
!
1
Analytical
Column
Backward/
Forward
Flush
1
1 L.O.D.
I
1 Purge 
1 Time
Detection
Mode
Internal
External
Standard
1
|Ref
Fluorpro- Animal feed 20ul injection 2 valves 50 x 4.6mm
1
1
|A: Water Lichrosorb Backflush |50 ppm 1 2 min. U.V. at 240mm Ext.
qualzone (mixture of after automated RP - 18 1 RP - 8
cereals. extraction into (10 um) 1 B : (5um )
potatoes, methanol. 1Acetonitrile Z5cmx4.6mm 1 51
Amino acids 1 Water
+ vitamins) |55:45
1
1
Pimobendene Rat Bile Direct 2 valves Variety of
1
1A : Water Hypersil Backflush 1 1 3 min. Fluorescence Ext.
+ injection fully packings |with 1 '/. COS detection
O-Oesmethy1- automated (30-50um Ì 1 ammonium ( 5um ) Xex = 332nm
ated - various 1 acetate 125x<+. 6mm Xem = 405nm 1 12
metabolite amounts |B: Methanol
+ 1 ammonium
Polar 1 acetate
Conjugate
l | .
1(2g/l) 
• 1 1 1 1 1 1
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TRICYCLIC ANTIDEPRESSANTS
CHAPTER 4
4.1. INTRODUCTION TO TRICYCLIC ANTIDEPRESSANTS
Tricyclic Antidepressants (TCA's) (Fig. 1) are widely used 
in the treatment of patients suffering from depression. The 
concentration of these drugs in plasma and their effect on 
depression symptoms is controversial [1] but it is very 
important that their therapeutic levels be monitored so that 
therapy can be made optimal. Several reports have shown 
that there are large individual variations in plasma 
concentrations among patients receiving the same dosage of 
these drugs [2-4].
Many methods have been described for the analysis of these 
drugs since 1960[5]. Earlier techniques had neither the 
sensitivity or selectivity demanded for the analyses. The 
problem of achieiving good selectivity is important since, 
because of their extensive metabolism[6], a large number of 
active metabolites of antidepressants are produced and in 
assessing relationships to clinical effects these must be 
quantified.
Methods employed for analysis include spectrofluorimetry [ 7 ] 
GC-FID[8-12], GC-ECD[3-17] , GC-NPD[18-27], radioimmunoassay 
[28-31], GC-MS[32], isotope derivatization dilution analysis 
and thin layer chromatography[33-34].
Spectrophotometric and fluorimetric techniques lack adequate 
sensitivity and or selectivity for routine application. 
Isotope dilution assays are tedious but no more so than the 
extraction required for GC. Radioimmunoassays provide a
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Fig 1
(a) Amitriptyline R1 CH3 * R2 = CH3
Nortriptyline R1 c h 3, r ? = h
Desmethylnortriptyline R1 - H, R2 = H
(b) Imipramine R3 = CH3 , R4 = H, R5 = H
Desipramine R3 = H, R4 = H, R5 = H
Clomipramine R3 - CH3, r 4 = H, R5 = Cl
Desmethylclomipramine R3 H, R4 = H, R5 = Cl
Trimipramine R3 = CHV R4 = CH3, R5 = H
(C) Doxepin R6 = CH3, X = 0
Desmethyldoxepin R6 - H, X = 0
Dothiepin R6 = CH3, x = s
Northiaden R6 = H, X = S
sensitive and rapid analysis from a small plasma volume. 
They are usually direct assays eliminating the need for 
plasma extraction but have the disadvantage that they are 
often not selective since the antisera raised against a 
secondary amine will cross react to varying degrees with 
tertiary amines[35].
Although all the above techniques can be applied to analyses 
in clinically relevant situations, by far the most commonly 
used methods for antidepressant analysis in plasma are those 
based on chromatographic methods i.e. GC and HPLC.
Gas chromatography is a highly selective technique, 
sensitivity depending on the type of detector used. 
However, an extensive clean up of plasma samples is required 
with a three step extraction procedure being commonly 
employed.
The flame ionization detector[8-12] is not highly sensitive 
hence large volumes of plasma must be extracted in order to 
give adequate sensitivity and detection limits. The limit 
of detection of most FID methods is around 10 - 20 ng/ml, so 
it is more suitable for routine monitoring and forensic 
applications than for pharmacokinetic studies.
Gas chromatography with electron capture detectionf13-17] 
offers a lower limit of detection and increased sensitivity 
but a limitation of its use is the need to convert drugs 
into a species which rapidly captures electrons. While 
secondary amines can be easily converted into a
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trifluroacetyl or heptafluorobutyryl derivative, this proves 
to be a more complex procedure for tertiary amines. These 
may either undergo quantitative oxidation to a species 
capable of electron capture or derivatization to form a 
halogenated compound, the nature of the product is not 
important once quantitative conversion occurs. ECD is well 
suited to all applications of antidepressant measurement 
even if it is somewhat difficult technically.
The nitrogen phosphorous detector is a modification of a 
conventional flame ionization detector with a high 
selectivity for organic compounds containing nitrogen or
phosphorous and a much lower detection limit than 
FID[18-27]. A three step extraction procedure is usually 
required for plasma but smaller volumes i.e. 1ml can be 
used.
The majority of recently published methods for TCA's are
based on NPD and this would appear to be the technique of 
choice for routine monitoring and pharmacokinetic studies.
The combination of the separative power of GC and the
selectivity of mass fragmentography has produced one of the 
most powerful analytical techniques available but it is not 
suitable for routine use since highly sophisticated 
equipment is required.
HPLC now rivals GC-NPD as the method of choice for the
analysis of the tricyclics. Separation of antidepressants 
by HPLC was first achieved in 1975[ 39-40] but is was not 
until 1976 that the practicality of measuring clinical
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samples by this technique was demonstrated!41]. Most of the 
existing methods are similar, they require solvent 
extraction from basic plasma followed by ion-pair partition 
[42-46], adsorption[47-55], bonded or RP chromatography 
[56-75] with a number of different types of stationary and 
mobile phases in each mode.
Of these, RP appears to be the most popular. HPLC methods 
provide good sensitivity and the chromatographic run is 
usually 10-20 minutes.
Quantitation is usually done using UV absorption at 254nm, 
however an enhancement in sensitivity can be achieved by 
monitoring at 215nm. Fluorimetric detection has also been 
used[50, 59, 67] and generally lower detection limits can be 
achieved using this detection mode.
Tricyclic antidepressants undergo extensive metabolism with 
major metabolic pathways being demethylation and 
hydroxylation[76]. More recently quantitation of the
hydroxylated metabolites has become important with the
demonstration that they are pharmacologically active[77]. 
For amitriptyline the metabolic pathway is shown in fig. 2. 
All of its metabolites have shown pharmacological 
activity[51, 70].
In any of the HPLC methods described to date for the
analysis of the tricyclics, direct injection of the plasma
or serum sample has not been possible. Consequently the
drugs must be extracted from the biological medium prior to 
their determination. The majority of antidepressants are
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AMITRIPTYLINE
HYDROXYLATION
DEMETHYLATION 
 »
NORTRIPTYLINE
/ N\
DESKETHYL
-NORTRIPTYLINE
GLUCURONIDE  >
DEMETHYLATION
CONJUGATION 
 > GLUCURONIDE
lO-HYDROXY-AMITRIPTYLlNE
S '  X
10-HYDR0XY-N0RTRIPTYLINE
Fig. 2: Metabolic Pathway for Amitriptyline.
secondary or tertiary amines, lipophilic strong bases so 
that at high pH the free base can be extracted into an 
organic solvent from aqueous solution. This behaviour 
allows for the separation of antidepressants from plasma 
constituents and provides a relatively pure sample for 
chromatographic analysis.
It is worth noting here that for the collection of plasma 
samples containing the tricyclics, it is important that 
standardization of blood collection techniques occurs. It 
has been shown[79] that significant decreases in tricyclic 
analytical concentrations have been attributed to sample 
contact with the plasticizer tris (2 butoxy-ethyl) phosphate 
which may be present in the rubber stoppers of collection 
tubes, these losses are more significant at lower 
concentrations[79].
For extraction of the collected samples, a three step 
procedure is usually employed but as little as one step may 
be sufficient for some applications. Various solvents have 
been applied, n-hexane or n-heptane being the most common. 
Others include diethyl ehter, ethyl acetate or acetonitrile. 
A small amount (1 - 5%) of isoamyl alcohol is sometimes used 
in the extracting solvent to increase the polarity of the 
medium and to inhibit emulsion formation. Overall recovery 
for a three step extraction of the order 60 - 80%, while for 
the individual steps it is around 90%.
Solid - phase extraction procedures are becoming 
increasingly popular for sample clean-up prior to drug
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analysis and these have advantages over the three step 
procedures in terms of analysis time.
The use of bonded-phase columns for sample clean-up has
been described[55, 71, 80, 81]. and equivalent results
obtained using these and the three step method have been 
demonstrated!80, 25].
In the following chapter, two analytical methods for the 
determination of amitriptyline and its metabolites in plasma 
are described, validated and compared. The first method 
allows direct injection of plasma using a column switching 
valve. The method is based on the enrichment of the drugs 
on a reverse phase concentration column packed with Corasil 
RP The enriched drugs are then separated, using back
flush mode on a bonded phase CN column using an isocratic 
acetonitrile - acetate buffer (60:40, v/v) mobile phase. In 
the second method, the drugs are extracted by conventional 
liquid-liquid extraction and separated using a silica column 
with methanolic mobile phase.
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4.2. A COLUMN SWITCHING DIRECT/INJECTION METHOD
4.2.1. EXPERIMENTAL
4 .2.1.1. Reagents
10-Hydroxynortriptyline, 10-hydroxyamitriptyline and
desmethyl-doxepin were obtained as a gift from the 
laboratory of Clinical Pharmacology and Toxicology, Groot 
Ziekengasthuis, The Netherlands.
Amitriptyline, nortriptyline, doxepin and protriptyline were 
obtained from Jervis Street hospital, Dublin and the other 
members of the tricyclics were obtained as gifts from I.C.P. 
Dublin. Hexane, methanol, acetonitrile and isopropanol (all 
HPLC grade) were purchased from Fisons, England. Ammonia 
solution, sodium hydroxide, sodium acetate and zinc sulphate 
were obtained from BDH Chemicals Ltd., Poole, England. 
Trichloroacetic acid was purchased from May and Baker, 
Dagenham, England and perchloric acid from Riedel-de-Haen, 
Germany.
For the preparation of the plasma samples, dried human 
plasma (from the Blood Transfusion Service Board, Ireland) 
was dissolved in deionised water (obtained by the Mili-Q 
water purification system). The control plasma obtained was 
examined for the presence of endogenous components which 
might interfere with the tricyclic drugs in the assay 
system. The reconstituted plasma was stored frozen and used 
within two weeks of preparation.
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4.2.1 - 2 . Instrumentation
The HPLC system consisted of two Waters Assoc. P-45 liquid 
chromatograph solvent delivery systems equipped with a 
Waters U6K manual injector and fitted to a Shimadzu SPD-6A 
variable wavelength U.V. detector. The chromatograms were 
recorded on a Philips PM 8251 single-pen recorder. A 
Rheodyne 7000, 6-port switching valve was used.
4.2.1.3. Chromatography
The instrumental arrangement for the chromatography is shown 
in Fig. 3. The chromatographic conditions for the 
separation were as follows. Mobile phase pump A: water;
concentration column (10x1.5mm) dry packed with Corasil RP 
C^g packing (37-50pm) in our laboratory; wash time, 1.5 
min. ; flow rate, 0.8 ml/min. Mobile phase PUMP B: 
acetonitrile - 0.05M acetate buffer (60 : 40, v/v) pH 7;
stationary phase, Techsphere 3CN (10cm x 4mm); flow rate, 
0.9ml/min; recorder chart speed, 0.5cm per min; detection 
wavelength, 215nm; injection volume 25Qul of plasma. Under 
the described chromatographic conditions the mean retention 
times, (fig. 4) were as follows, 10-hydroxynortriptyline 6.0 
mins; 10-hydroxyamitriptyline, 7.5 mins; nortriptyline, 10.0 
mins and amitriptyline 12.5 mins.
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Fig.4 Chromatograms of (a) a small pooled human drug-free plasma, (b) plasma spiked with lOng/ml of each 
of the drugs and (c) plasma spiked with 150 ng/ml of each of the drugs. Peaks: 1 =
10-hydroxynortriptyline; 2 = 10-hydroxyamitriptyline; 3 = desmethyldoxepin (internal standard); 4 =
nortriptyline; 5 = amitriptyline.
4.2.1.4. Preparation of Standards
Amitriptyline HC1 (11.32mg), Nortriptyline HC1 (11.39mg), 
10-hydroxyamitriptyline HC1 (11.25mg) and 10-hydroxynortript- 
line HC1 (11.31mg) were weighed and dissolved in 100ml of 
methanol to yield a stock solution of 100,ug/ml of 
amitriptyline, nortriptyline, 10-hydroxyamitriptyline and 
10-hydroxynortriptyline.
This stock solution was then diluted with water-methanol 
(1:1) to yield working standards ranging from 0.2 to 5jig/ml.
Desmethyl-doxepin (11.4mg) was weighed and dissolved in 
100ml of methanol to yield a solution of lOOug/ml. This was 
then diluted with a methanol-water mixture to yield a 
solution of 10 ¿ig/ml desmethyl-doxepin. Spiked plasma 
standards ranging for 10 to 300 ng/ml of the drugs in plasma 
were then prepared in each assay day by spiking 1ml of 
plasma with 50 ^ 1 of the working standards and 50 ^ 1 of the 
internal standard. Patient and blank plasma samples were 
spiked with 50^jal of a methanol-water mixture to compensate 
for any changes in the composition of plasma.
4.2.1.5. Column Switching Procedure
The spiked plasma sample is injected through the injector 
port and washed by the water in pump A onto the 
concentration column (position 1, Fig. 3). The drugs are 
held on the concentration column while the other components
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in plasma are eluted to the drain. Meanwhile the eluent 
from pump B is passing through the analytical column and out 
to waste. On switching the valve (position 2, Fig. 3), the 
eluent from pump B elutes the drugs in back flush mode, 
which have been held on the concentration column, onto the 
analytical column where they are separated. In using the 
column switching valve the following variations in sample 
handling were studied:
Sample pretreatment 
Concentration column packing 
Wash time and flow rate 
Analytical column 
Buffer in the mobile phase
4.2.1.5.1. Sample Pretreatment
Protein precipitation prior to injection was investigated 
using:
(i) Acid precipitation with perchloric acid or 
trichloroacetic acid
and
(ii) base precipitation of proteins with NaOH and ZnSO^.
The proteins were precipitated by addition of the reagent to 
plasma in tubes which were then centrifuged for 15 minutes 
and the supernatant injected for analysis according to the 
method described by Blanchard [81]. Direct injection with 
no sample pre-treatment was also tried. For all
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concentrations, acid precipitation gave the lowest recovery- 
due to ionization of the basic tricyclic drugs in the acid 
solution which were then eluted with water from pump A and 
not retained on the RP concentration column.
Base precipitation also gave poor recovery probably due to 
co-precipitation of the drugs with plasma. The strong acids 
and base also dissolved the packing in the concentration 
column. Over the range of packings tried therefore, best 
recovery, sensitivity and reproducibility were achieved 
using a 250 ^1 direct injection of plasma, (Fig. 5a). 
However, as has been outlined in other publications direct 
injection is not without its problems.
These problems include (a) deterioration in the performance 
of the concentration column due to precipitation of plasma 
proteins when they come into contact with the buffers and 
organic solvents from pump B, i.e. the mobile phase and, (b) 
build up of back pressure due to accumulation of particulate 
matter from plasma, however this can be minimized by using 
the backflush mode.
4.2.1.5.2. Concentration Column Packings
The following packings were tried in the concentration 
column.
(a) Lichrosorb RP C^g lO^ im
(b) Hypersil phenyl lO^ am
(c) Vydak cyano 3 0 ^
(d) Corasil RP C^g 37 - 50 ^ m
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The main factor is the size of the packing particles.
Packings with particle size lOum do not allow direct 
injection since the small size particles act as an efficient 
filter and after 1-2 injections become clogged with 
particulate matter from plasma (Fig. 5b and 5c). Using 
10p.m packings, acid or base precipitation must be used and 
as outlined above these give poor recovery. A 30nm Vydak 
cyano packing allowed direct injection, however, the column 
capacity was only 150ul of plasma. No enhancement in 
sensitivity was achieved by using larger injection volumes 
(Fig. 5d).
Corasil R.P. packing, particle size 37 - 5C)um proved to be 
the best among the packings tried in terms of recovery and 
cleanliness of chromatogram. Although greater injection 
volumes of plasma provided endhanced sensitivity, it limited 
the number of injections per concentration column. An 
injection volume of 250ul plasma allowed for at least fifty 
consecutive injections.
4.2.1.5.3. Wash Times
Wash times were varied from 1 minute up to 10 minutes, and 
flow rates from 0.5 to 1.5ml/min. Variation in these 
factors did not affect the chromatograms obtained to a large 
extent, but the sharpest peaks and cleanest chromatograms 
were obtained for a wash time of 90 seconds and a flow rate 
of 0.8ml/min. Shorter wash times result in very large 
plasma peaks while longer wash times give rise to band 
broadening.
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Fig. 5a Reverse phase concentration column:
Chromatograms obtained for lOOng/ml of amitriptyline in 
plasma using (a) acid precipitation (b) base 
precipitation and (c) direct injection of plasma.
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Fig. 5b Concentration column containing Lichrosorb Reverse Phase 
10 ^ m packing -
Chromatograms showing a 250 ^ il Direct Injection of 
Plasma containing lOOng/ml Amitriptyline (A).
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Fig. 5c Concentration column containing Hypersil Phenyl 10 pam 
packing - Chromatograms showing the
(A) The First and (B) The Third
250 ¿il direct injection of plasma containing lOOng/ml 
Amitriptyline (A).
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Fig.5d Chromatograms showing
(A) 100 ^ 1 injection
(B) 200 yjil injection
(C) A 400j i l  injection of lOOng/ml Amitriptyline in 
plasma using a Cyano concentration column.
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4.2.1.5.4. Other CN Columns
Separation of the drug and its metabolites may also be 
achieved using other CN columns.
A /lBondapak CN column (300 x 3.9mm) was tried but it was 
necessary to vary both the composition of the mobile phase 
from 60:40 to 70:30 acetonitrile-acetate buffer and also to 
vary the molarity of the buffer from 0.05M to 0.03M in order 
to obtain separation.
4.2.1.5.5. Phosphate Buffer
Phosphate buffers were also used to buffer the mobile phase 
to pH7 but the chromatograms obtained were not as clean as 
when acetate buffers was used Fig. 5e.
4.2.1.6. Calibration and Calculation
Evaluation of the assay was carried out using four-point 
calibration standards in the concentration range 10-300ng/ml 
of the drugs in plasma. The slope and intercept of the 
calibration curves were obtained by linear regression of the 
peak height ratios of drug/internal standard versus the 
concentration of the drug (internal standard method).
The internal standard (IS) used was desmethyl-doxepin which 
had a suitable retention time (t = 8.5min). These
calibration curves were then used to interpolate the 
concentration of drugs in patient plasma from the measured 
peak height ratios. The chromatograms obtained are shown in 
Fig. 4.
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Fig. 5e Chromatogram of blank plasma obtained using a mobile 
phase containing phosphate buffer.
197
4.2.2. RESULTS AND DISCUSSION
4.2.2.1. Limit of Detection
Using a 250ul direct injection of plasma, and under the 
procedural conditions outlined, the limit of detection for 
each of the four drugs was between 5 - lOng/ml. The
variation in detection limit was due to day to day changes 
in operational conditions and detection system. The 
detection limit was taken as the amount of compound giving a 
signal to noise ratio greater than 3:1.
4.2.2.2. Precision
The data presented in tables Ia-d demonstrate the 
within-batch (intra-assay) and tables IIa-d between batch 
(inter-assay) variation. Intra-assay variability was 
determined at four concentrations in quadruplicate at levels 
of 10, 50, 150 and 300 ng/ml of each drug in plasma.
Inter-assay variability was determined singly and at the 
same four concentrations in four replicate runs.
The precision of the method (mean coefficient of variation) 
for the values of the recovered determinate standards when 
calculated as "unknowns" against the linear regression lines 
for intra-assay and inter-assay respectively were 3.5% and 
4.2% for amitriptyline, 4.2% and 5.7% for nortriptyline, 
3.7% and 8.0% for 10-hydroxyamitriptyline and 3.0% and 1.7% 
for 10-hydroxy-nortriptyline. Tables I +11, a, b, c, d and 
Table III.
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Table 1(a) Intra - Assay Amitriptyline AT = Amitriptyline
Concentration
added
(ng/ml)
1
Peak Height 
(cm)
Peak
Rt
2
Peak Height 
(cm)
Peak
Rt
Peak
(cm)
3
Height
DD =
Peak
Rt
Desmethyl doxepin 
4
Peak Height 
(cm)
Peak
Rt
MEAN
RATIO
*AT DD “ AT
DD
J.
AT " DD AT
DD
JU
AT DD AT
DD
AT DD AT
DD
AT
DD
0
10 0.5 10.3 0.0485 0.5 9.8 0.0459 0.4 8.2 0.0488 0.4 8.3 0.0482 0.0479
50 2.5 9.8 0.2551 2.4 9.8 0.2449 2.0 9.5 0.2105 2.2 9.5 0.2316 0.2355
150 6.4 8.8 0.7273 6.2 8.5 0.7294 6.2 8.2 0.7561 5.9 8.0 0.7375 0.7376
300 6.3 4. 1 1.5366 6.3 4.0 1.5750 5.5 3.7 1.4865 5.7 3.6 1.5833 1.5454
Concent.
Slope
C.C.
= 5.18 
= 0.999
e-03 I = -.0186
Concentration Concentration found (ng/ml) Mean Concentration S.D. % %
added found (ng/ml) C.V. Difference
(ng/ml) 1 2  3 4
0 - - - - - - - -
10 12.96 12.46 13.02 12.90 12.85 0.25 1.95 28.5
50 52.85 50.84 44.25 48.32 49.08 3.72 7.58 1.84
150 144.05 144.46 149.61 146.02 146.04 2.53 1.73 2.64
300 300.34 307.76 290.67 309.36 302.04 8.53 2.82 0.68
Mean % C.V. = 3.5%
UU
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Table 1(b) Intra - Assay Nortriptyline NT = Nortriptyline
DD = Desmethyl doxepin
1 2  3 4
Concentration
added
(ng/ml)
Peak Height Peak 
(cm) Rt
Peak Height Peak 
(cm) Rt
Peak Height Peak 
(cm) Rt
Peak Height Peak 
(cm) Rt
MEAN
RATIO
NT " DD NT
DD
NT " DD NT
DD
NT * DD NT
DD
-1-
NT " DD NT
DD
NT
DD
0
10
50
150
•o 300 
D
1.0 10.3 0.0971 
4.5 9.8 0.4592 
12.3 8.8 1.3977 
12.2 4.1 2.9756
0.8 9.8 0.0816 
4.5 9.8 0.4592 
12.3 8.5 1.4471 
12.0 4.0 3.0000
0.8 8.2 0.0976 
3.9 9.5 0.4105 
11.9 8.2 1.4512 
10.7 3.7 2.8919
0.8 8.3 0.0964 
3.9 9.5 0.4105 
11.2 8.0 1.4000 
11.4 3.6 3.1667
0.0932
0.4349
1.4240
3.0086
Slope = .0101 
C.C. = 0.999
I = -.0491
C one ent r at ion 
added 
(ng/ml)
Cone ent r at ion 
1 2
found (ng/ml)
3 4
Mean Concentration 
found (ng/ml)
S.D. %
C.V.
%
Difference
0 - - - - - - - -
10 14.46 12.93 14.51 14.39 14.07 0.76 5.40 40.70
50 50.27 50.27 45.45 45.45 47.87 2.78 5.81 4.26
150 143.08 147.96 148.37 143.31 145.67 2.88 1.98 2.89
300 299.11 301.53 290.84 318.01 302.38 11.39
r r  \T —A IV
3.77 0.79
Mean % C.V. = 4.2%
2
0
1
Table 1(c) Intra - Assay OH - Amitriptyline OH AT = Hydroxy-amitriptyline
DD = Desmethyl doxepin
1 2  3 4
C one ent r at ion 
added 
(ng/ml)
Peak
c
Height
cm)
Peak
Rt
Peak
(cm)
Height Peak
Rt
Peak Height
(cm)
Peak
Rt
Peak Height 
(cm)
Peak
Rt
MEAN
RATIO
mi.
0H- DD " OH-AM I 0H- DD OH-AMI OH- DD OH-AMI OH- DD OH-AMI OH-AMI
AMI DD AMI DD AMI DD AMI DD DD
0
10 0.8 10.3 0.0777 0.8 9.8 0.0816 0.7 8.2 0.0854 0.7 8.3 0.0843 0.0823
50 4.6 9.8 0.4694 4.6 9.8 0.4694 3.9 9.5 0.4105 4.0 9.5 0.4211 0.4426
150 11.8 8.8 1.3409 11.9 8.5 1.4000 11.6 8.2 1.4146 11.5 8.0 1.4375 1.3983
300 12. 1 4.1 2.9512 11.2 4.0 2.8000 10.5 3.7 2.8378 10.4 3.6 2.8889 2.8695
Slope = 9.635 e-03 I = -.0303
C.C. = .9999
C one ent r at ion 
added 
(ng/ml)
Concentration found 
1 2
(ng/ml)
3 4
Mean Concentration 
found (ng/ml)
5.D. %
C.V.
%
Difference
0
10 11.21 11.61 12.01 11.89 11.69 0.36 3.08 16.90
50 51.86 51.86 45.75 46.85 49.08 3.24 6.60 1.84
150 142.31 148.44 149.96 152.34 148.27 4.28 2.89 1.15
300 309.44 293.75 297.67 302.98 300.96
Mean °
6.80 
i C.V. = 3.7%
2.26 0.32
2
0
2
Table 1(d) Intra - Assay OH - Nortriptyline 0H-N0R = Hydroxy-nortriptyline
DD = Desmethyl-doxepin
1 2  3 4
Concentration
added
(ng/ml)
Peak Height 
(cm)
Peak
Rt
Peak
c
Height
cm)
Peak
Rt
Peak Height 
(cm)
Peak
Rt
Peak
(cm)
Height Peak
Rt
MEAN
RATIO
o h -n t" DD OH-NOR
DD
o h -n o r" DD 0H-N0R
DD
o h -n o r “ DD 0H-N0R
DD
o h-n o r" DD OH-NOR
DD
OH-NOR
DD
0
10 0.8 10.3 0.0777 0.8 9.8 0.0816 0.6 8.2 0.0732 0.6 8.3 0.0723 0.0762
50 4.6 9.8 0.4694 4.9 9.8 0.5000 4.5 9.5 0.4737 4.6 9.5 0.4842 0.4818
150 14.4 8.8 1.6364 14.6 8.5 1.7176 14.1 8.2 1.7195 13.9 8.0 1.7375 1.7028
300 13.6 4.1 3.3171 13.3 4.0 3.3250 12. 7 3.7 3.4324 12.9 3.6 3.5833 3.4145
Slope = 0.0116 I = -.0606
C.C. = 0.999
Concentration Concentration found (ng/ml) Mean Concentration S.D. % %
added found (ng/ml) C.V. Difference
(ng/ml) 1 2  3 4
0 - - - - - - - -
10 11.92 12.25 11.53 11.45 11.79 0.37 3.14 17.90
50 45.67 48.31 46.05 46.95 46.74 1.17 2.50 6.52
150 146.25 153.25 153.41 154.97 151.97 3.89 2.56 1.31
300 291.10 291.78 301.04 314.04 299.50 10.71 3.58 0.18
Mean % C.V. = 3.0%
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Table 11(a) Inter - Assay Amitriptyline AT = Amitriptyline
DD = Desmethyl doxepin
Concentration
added
(ng/ml)
DAY I 
Peak Height 
AT DD 
(cm)
Peak Rt 
AT 
DD
DAY II 
Peak Height 
AT DD 
(cm)
Peak Rt 
AT 
DD
Peak
AT
(
DAY 3 
Height Peak Rt 
DD AT
cm) DD
Peak
AT
c
DAY 4 
Height 
DD
cm)
Peak Rt 
AT 
DD
0
10 0.5 6.7 0.0746 0.6 9.6 0.0573 0.5 7.7 0.0649 0.5 6.2 0.0806
50 2.0 6.6 0.3030 2.5 9.5 0.2632 2.4 7.8 0.3077 1.8 5.4 0.3333
150 6.3 6.6 0.9545 7.9 9.7 0.8144 7.1 7.9 0.8987 5.6 5.4 1.0370
300 5.9 3.2 1.8438 7.9 4.8 1.6458 6.9 3.9 1.7692 12.6 6.0 2.1000
Concentration Concentration found (ng/ml) Mean Concentration Standard Coefficient %
added found (ng/ml) Deviation of Difference
(ng/ml) DAY 1 DAY 2 DAY 3 DAY 4 Variation
0 - - - -
10 10.27 11.38 9.06 12. 12 10. 70 1.34 12.52 7.00
50 47.49 48.87 50.43 48.24 48.76 1.25 2.56 2.48
150 153.66 149.20 151.10 148.84 150.70 2.21 1.47 0.47
300 298.58 300.54 299.41 300.80 299.83 1.03 0.34 0.06
Mean % C.V. = 4.2%
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Table 11(b) Inter - Assay Nortriptyline
Concentration
added
(ng/ml)
Peak
NT
(
DAY I 
Height 
DD
cm)
Peak Rt 
NT 
DD
DAY II 
Peak Height 
NT DD 
(cm)
Peak Rt 
NT 
DD
Peak
NT
DAY 3 
Height 
DD
(cm)
Peak Rt 
NT 
DD
Peak
NT
DAY 4 
Height 
DD
(cm)
Peak Rt 
NT 
DD
0
10 0.8 6.7 0.1194 1.0 9.6 0.1042 0.7 7.7 0.0909 0.8 6.2 0.1290
50 3.7 6.6 0.5606 4.7 9.5 0.4947 4.0 7.8 0.5128 3.0 5.4 0.5556
150 11.2 6.6 1.6970 14.6 9.7 1.5052 12.5 7.9 1.5823 9.4 5.4 1.7407
300 10.2 3.2 3.1875 14.6 4.8 3.0417 12.3 3.9 3.1538 18.8 5.8 3.2414
Concentration Concentration found (ng/ml) Mean Concentration Standard Coefficient %
added found (ng/ml) Deviation of Difference
(ng/ml) DAY 1 DAY 2 DAY 3 DAY 4 Variation
0 - - - -
10 7.47 10.96 9.79 8.11
50 49.11 49.45 49.71 47.66
150 156.37 149.06 150.90 157.54
300 297.05 300.52 299.60 296.68
9.08 1.59 17.51 9.20
48.98 0.92 1.88 2.04
153.47 4.12 2.68 2.31
298.46 1.89 0.63 0.51
Mean % C.V. = 5.7%
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Table 11(c) Inter - Assay OH-Amitriptyline
Concentration
added
(ng/ml)
Peak
OH-AMI
DAY I
Height
DD
(cm)
Peak Rt 
OH-AMI 
DD
Peak
OH-AMI
DAY II 
Height 
DD
(cm)
Peak Rt 
OH-AMI 
DD
Peak
OH-AMI
DAY 3 
Height Peak Rt 
DD OH-AMI 
(cm) DD
Peak
OH-AMI
(cm)
DAY 4 
Height 
DD
Peak Rt 
OH-AMI 
DD
0
10 0.8 6.7 0.1194 0.9 9.6 0.0938 0.8 7.7 0.1038 0.8 6.2 0.1290
50 3.3 6.6 0.5000 4.4 9.5 0.4632 3.9 7.8 0.5 3.0 5.4 0.5555
150 10.6 6.6 1.6061 13.7 9.7 1.4124 11.9 7.9 1.5063 9.3 5.4 1.722
300 9.4 3.2 2.9375 14.0 4.8 2.9166 11.8 3.9 3.0256 18.3 5.8 3.1555
Concentration Concentration found (ng/nl) Mean Concentration Standard Coefficient %
added found (ng/nl) Deviation of Difference
(ng/nl) DAY 1 DAY 2 DAY 3 DAY 4 Variation
0 - - - -
10 8.34 11.03 10.40 8.95 9.68 1.25 12.87 3.22
50 48.39 49.07 49. 70 49.31 49.12 0.55 1.12 1.77
150 160.35 146.81 149.81 159.69 154.09 6.93 4.50 2.73
300 295.15 301.72 300.27 295.30 297.51 3.21 1.08 0.83
Mean % C.V. = 8.0%
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Table 11(d) Inter - Assay OH - Nortriptyline
Concentration
added
(ng/ml)
Peak
OH-NOR
DAY I
Height
DD
(cm)
Peak Rt 
OH-NOR 
DD
DAY II 
Peak Height 
OH-NOR DD 
(cm)
Peak Rt 
OH-NOR 
DD
Peak
OH-NOR
DAY 3 
Height Peak Rt 
DD OH-NOR 
(cm) DD
Peak
OH-NOR
DAY 4 
Height 
DD
(cm)
Peak Rt 
OH-NOR 
DD
0
10 1.0 6.7 0.1493 0.9 9.6 0.0938 0.8 7.7 0.1039 0.9 6.2 0.1452
50 4.2 6.6 0.6264 4.5 9.5 0.4737 4.0 7.8 0.5128 3.3 5.4 0.6111
150 13.2 6.6 2.0000 14.4 9.7 1.4845 12.8 7.9 1.6202 10.3 5.4 1.9074
300 12.9 3.2 4.0313 14.8 4.8 3.0833 13.0 3.9 3.3333 20.5 5.4 3.7963
Concentration Concentration found (ng/ml) Mean Concentration Standard Coefficient %
added found (ng/ml) Deviation of Difference
(ng/ml) DAY 1 DAY 2 DAY 3 DAY 4 Variation
0 - - - “
10 12.21 12.35 12.17 11.29
50 47.64 49.11 48.76 48.13
150 149.65 146.92 147.88 150.62
300 300.50 301.61 301.20 299.96
12.01 0.48 4.00 20.10
48.41 0.65 1.34 3.18
148.76 1.67 1.12 0.83
300.82 0.73 0.24 0.27
C.V. = 1.7%
TABLE III 
PRECISION AND REPRODUCIBILITY
INTRA-ASSAY
Cone added Mean (n=4) concentration % Difference between
(ng/ml) found + S.D. (ng/ml) C.V. added and found
Concent, (ng/ml)
AMITRIPTYLINE
10 12.85 + 0.25 1. 95 28.50
50 49.08 + 3. 72 7.58 1.84
150 146.04 + 2.53 1. 73 2.64
300 302.04 + 8.53 2.82 0.86
Mean % C.V. = 3.i 5%
NORTRIPTYLINE
10 14.07 + 0. 76 5.40 40.70
50 47.87 + 2. 78 5.81 4.26
150 145.67 + 2.88 1.98 2.89
300 302.38 + 11.39 3. 77 0. 79
Mean % C.V . = 4.2%
lO-HYDROXY-AMITRIPTYLINE
10 11.69 + 0.36 3.08 16.90
50 49.08 + 3. 24 6.60 1.84
150 148.27 + 4.28 2.89 1.15
300 300.96 + 6.80 2.26 0.32
Mean % C.V . = 3. 7%
lO-HYDROXY-NORTRIPTYLINE
10 11.79 + 0.37 3. 14 17.90
50 46. 74 + 1.17 2.50 6.52
150 151.97 + 3.89 2.56 1.31
300 299.50 + :10. 71 3.58 0.18
Mean % C.V . = 3.0 %
Linear regression line for intra-assay precision
(a) for AMITRIPTYLINE i Y = .0051 x -.0186 and 
correlation coefficient (r) = 0.999
(b) for NORTRIPTYLINE: Y = .OlOOx - .0491 and
the correlation coefficient (r) = 0.999
(c) for 10-HYDROXY-AMITRIPTYLINE : Y = .0096X - .0303 and
the correlation coefficient (r) = 0.999
(d) for lO-HYDROXY-NORTRIPTYLINE : Y = 0.0116 x - .0606 and
the correlated coefficient (r) == 0.999
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TABLE III Contd.
INTER-ASSAY
AMITRIPTYLINE
Cone added 
(ng/ml)
Mean (n: 
found +
=4)
S.
concentration 
D. (ng/ml)
C.V.
%
Difference between 
added and found 
Concentration (%)
10 10.70 4 1.32 12.52 7.00
50 48.76 + 1.25 2.56 2.48
150 150.70 + 2.21 1.47 0.47
300 299.83 + 1.03 0.34 0.06
Mean % C.V. == 4.2%
NORTRIPTYLINE
10 9.08 + 1.59 17.51 9.20
50 48.98 + 0.92 1.88 2.04
150 153.47 + 4. 12 2.68 2.31
300 298.46 + 1.89 0. 63 0.51
Mean % C.V. == 5.7%
10-HYDROXYAMITRIPTYLINE
10 9.29 + 2.19 23.57 7. 10
50 48.49 + 1.49 3.07 3.02
150 153.88 + 6.50 4.22 2.59
300 298.34 Hh 2.95 0.99 0.55
Mean % C.V. =' 8.0%
10-HYDROXYNORTRIPTYLINE
10 12.01 + 0.48 4.00 20. 10
50 48.41 + 0.65 1.34 3.18
150 148.76 4* 1.67 1. 12 0. 83
300 300.82 + 0.73 0.24 0.27
Mean % C.V. == 1.7%
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4.2.2.3. Linearity
Measures of linearity as defined by the correlation 
coefficient of the regression lines for all drugs and the 
difference between added and found concentrations are given 
in intra-assay precision Table I (a), (b), (c), (d) and
Table III. In all cases the correlation coefficients were 
better than 0.999 and the intercepts did not differ greatly 
from the origin.
4.2.2.4. Recovery
The overall recovery was calculated in two different ways 
(Table IV)
First by comparing the peak heights of a series of spiked 
plasma samples after they had been taken through the entire 
procedure with a series of reference standards. Secondly, 
by comparing the slopes of the regression lines obtained 
from the two sets used in the first procedure. Using these 
methods in the concentration range 10-300 ng/ml, the mean 
overall recoveries were 90.7%, 92.6%, 83.9% and 90.5% for
amitriptyline, nortriptyline, 10-hydroxynortriptyline and 
10-hydroxyamitriptyline respectively.
4.2.2.5. Interference Study
Eight other members of the tricyclic drugs were tested for 
possible interferences with the measured substances. As can 
be seen from the chromatogram in Fig. 6, no other member of
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TABLE IV
RECOVERY
METHOD 1______________________ AMITRIPTYLINE____________________________
Concentration Amitriptyline peak height (cm) Recovery
(ng/ml) (mean of duplicates) (%)
Set A Set B
Authentic Standards Recovered
Blank N.D. N.D. -
10 0.50 0.53 105.00
50 2.35 2.45 104.25
150 8.00 7.50 93. 75
300 17.50 14.80 84.57
Mean overall % recovery .+ S.D. = 96.89% — 9.68
Method 2
Regression line for Set A : Y = .05835 x - .28183 , r = .9988
Regression line for Set B : Y = .04936 x + .02029 , r = .9999
04936Overall recovery =    x 100 = 84.59%
.05835
Mean recovery determined by both methods = 90.7%
METHOD 1 NORTRIPTYLINE
Concentration Nortriptyline peak height (cm) Recovery
(ng/ml) (mean of duplicates) (%)
Set A Set B
Authentic Standards Recovered
Blank N.D. N.D. -
10 0.90 0.85 94.44
50 4.00 4.35 108.75
150 14.20 13.55 94.42
300 30.40 26.90 88.48
Mean overall % recovery —  S,.D. = 96. 77% —  8.55
METHOD 2
Regression line for Set A : Y = .10162 - 0.06493, r = 0.999
Regression line for Set B : Y = .08992 - 0.04191, r = 0.9999
.08992Overall recovery =
.10162
X 100 = 88.49%
Mean recovery determined by both methods = 92.6%
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TABLE IV Contd.
METHOD 1___________________ 10-HYDROXY-AMITRIPTYLINE___________________
Concentration 10-hydroxy-amitriptyline peak height (cm) Recovery 
(ng/ml) (mean of duplicates) (%)
Set A Set B
Authentic Standards Recovered
Blank N.D. N.D. -
10 0.90 0.85 94.44
50 3.90 4. 15 106.41
150 13.45 12.80 96.16
300 30.20 25.80 85.43
Mean overall % recovery —  S.D. = 95.36% — 8.59
METHOD 2
Regression line for Set A: Y = .10050 x - .56109, r = .998
Regression line for Set B: Y = .08606 x - .05833, r = .9999
„  .08606 Overall recovery = x 100 = 85.63
.10050
Mean recovery determined by both methods = 90.5%
METHOD 1_____________10-HYDR0XY-N0RTRIPTYLINE_________________________
Concentration 10-hydroxy-nortriptyline peak height (cm) Recovery 
(ng/ml) (mean of duplicates) (%)
Set A Set B
Authentic Standards Recovered
Blank N.D. N.D. -
10 1.00 0. 85 85.00
50 4.55 4.25 93.40
150 15.40 13.60 88.31
300 34.50 27.80 80.58
Mean overall % recovery“  S.D. = 86.82% — 5.41
METHOD 2
Regression line for Set A: Y = .11480 x - .6196, r = .9983 
Regression line for Set B: Y = .09286 x - .1724, r = ,99988
Overall recovery = • 09286 ^ ^  55%
.11480
Mean recovery determined by both methods = 83.8%
* N.D. = Not detectable, below limit of detection.
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Fig. 6 Chromatogram of a small pooled human drug-free plasma 
spiked with tricyclic antidepressant drugs. Peak 1 = 10-hydroxy- 
nortriptyline; 2 = 10-hydroxyamitriptyline; 3= desmethyldoxepin;
4 and 5 = protriptyline and desipramine; 6,7 and 8 = 
trimipramine, cianopramine and nortriptyline; 9= doxepin; 10 and 
11 = amitriptyline and imipramine; 12 and 13 = chlomiprimine and 
chlorapramine.
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the tricyclics studied interfered with the determination of 
10-hydroxyamitriptyline or 10-hydroxynortriptyline.
Imipramine interfered with amitriptyline and likewise 
cianopramine and trimipramine interfered with nortriptyline, 
but it is unlikely that any of these combinations would be 
administered simultaneously.
Tranylcypromine which was given in combination with 
amitriptyline to some patients did not interfere and eluted 
with plasma peaks.
4.2.2.6. Plasma Levels
The described method has been successfully applied to the 
measurement of amitriptyline, nortriptyline, 10-hydroxyamit- 
riptyline and 10-hydroxynortriptyline in patients with 
neurotic and endogenous depression receiving oral doses of 
placebo, 50, 75, 100 or 150 mg of amitriptyline alone or in 
combination with tranylcypromine, (table V). The exact 
amount of dosage could not be revealed to us at this stage 
and therefore, results in table V are only indicative of the 
capability of the described method for the analysis of 
patient samples receiving the above doses of amitriptyline. 
Chromatograms from patients are shown in Fig. 7.
4.2.2.7. Discussion
As mentioned previously, HPLC procedures for the 
determination of tricyclic antidepressants generally 
involve extraction of the drugs from plasma or serum,
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TABLE V
TIME"
PATIENT 1 
CONCENTRATION (ng/ml)
PATIENT 2 
CONCENTRATION (ng/ml)
PATIENT 3 
CONCENTRATION (ng/ml)
PATIENT 4 
CONCENTRATION (ng/ml)
AMI NOR OH--AMI OH-NOR AMI NOR OH-AMI 0H-N0R AMI NOR OH-AMI OH-NOR AMI NOR OH-AMI OH -NOR
DAY 1 31.9 22.9 N D. 33.2 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 24.6 7.2 N.D. 22 4
DAY 14 54.5 42.2 N D. 60.1 36.7 55.7 10.6 84.5 N.D. N.D. N.D. N.D. 34.2 30.4 N.D. 115 .9
DAY 28 106.7 86.1 6 3 110.4 50.1 47.3 5.9 56.7 N.D. N.D. N.D. N.D. 36.3 50.4 7.4 114 .5
DAY 42 74.0 61.6 N D. 82.6 47.2 56.7 9.6 64. 3 N.D. N.D. N.D. N.D. 50.5 49.2 6.9 138 .7
AMI = AMITRIPTYLINE
NOR = NORTRIPTYLINE
OH-AMI = ÎO-HYDROXY-AMITRIPTYLINE
OH-NOR = 10-HYDROXY-NORTRIPTYLINE
* Blood samples were taken 10 hours after administration. 
+ N.D. = Not detectable, below limit of detection.
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Fig. 7 Chromatograms of plasma from a patient receiving 
amitriptyline and (c) a 100 mg oral dose of amitriptyline.
(a) a placebo and (b) a 50 mg oral dose of
followed by various modes of chromatography. Most recent 
publications, although different in many aspects, exhibit 
similar results in terms of validation and applications.
The use of on-line column switching with direct injection of 
plasma provides a new alternative for sample preparation of 
tricyclic drugs prior to analysis with HPLC.
Sample preparation procedures based on extraction are often 
tedious and time consuming, susceptable to errors and often 
can result in loss of sample because of incomplete 
extraction or formation of artifacts.
In chapter 2, the advantages of column switching as an 
on-line method for sample preparation are fully discussed. 
In setting up the system, a major consideration is the 
nature of packing material in the concentration column and 
the mobile phase passing through it during the sample 
enrichment process. They have to be selected in such a way 
that the drug is almost completely retained while the 
interfering substances in plasma are removed.
The packing eventually chosen was pellicular Corasil C^g 
(37-5CVum) with water as the mobile phase for enrichment. 
This allowed at least fifty injections of 25Qul of plasma. 
More injections resulted in the loss of resolution, band 
broadening and lesser recovery and hence lesser sensitivity. 
This may not allow automatic injection of sample batches 
exceeding fifty in number. Except for this limitation, 
direct injection/column switching proved to be a superior
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technique as virtually no sample preparation is necessary 
and the results obtained showed excellent precision and 
reproducibility with high recovery and limits of detection 
of between 5-10 ng/ml of each drug in plasma.
Detection at 215nm also gave a four-fold enhancement in 
sensitivity as compared to 254nm.
The method allowed separation and quantitation of 
amitriptyline and its three major metabolites, 
nortriptyline, 10-hydroxynortriptyline and 10-hydroxyamitrip- 
tyline. The large differences in concentrations added and 
found at the low concentration of 10ng/ml can be accounted 
for by the fact that the method is based on peak height 
measurements. At these concentrations a large difference in 
peak height ratio of drug/internal standard, hence 
concentration of the drug, is obtained for a very small 
difference, e.g. 1mm, in peak height measurement.
4.2.3. CONCLUSION
For routine analysis of the tricyclic drugs in plasma, a new 
method of analysis based on a direct injection/column 
switching technique was developed. The advantages of this 
method over conventional extraction methods is that it was 
less time consuming, needed a smaller volume of plasma, and 
gave better recovery. It has a comparable precision and 
detection limit with conventional extraction methods. The 
disadvantages are that the concentration column had to
217
be changed after every fifty injections and it needed more 
elaborate instrumentation i.e. two pumps and a column 
switching valve.
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HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHIC DETERMINATION OF 
AMITRIPTYLINE AND ITS METABOLITE 
NORTRIPTYLINE IN HUMAN PLASMA 
USING RAPID LIQUID EXTRACTION 
FOR SAMPLE CLEAN-UP
4.3. INTRODUCTION TO THE EXTRACTION METHOD FOR TRICYCLIC 
DETERMINATION
A new, sensitive and simple HPLC method for the 
determination of plasma levels of amitriptyline (AT) and 
nortriptyline (NT) is described. Plasma spiked with the 
drugs and internal standards, imipramine (IP) and 
desmipramine (DP) for AT and NT respectively was mixed with 
0. 1M NaOH and the drugs were extracted into 
hexane-isopropanol (99:1). After evaporation of the 
extracting solvent, the residue was taken up in methanol and 
an aliquot was injected for chromatography. The separation 
of the drugs was carried out on an adsorption column 300 x 
3.9mm commercially packed with p. Porasil, (lO^ im), using 
methanol containing 0.1% ammonia as the mobile phase at a 
flow rate of 1.5ml/min. The drugs were detected by 
absorption at 215nm. The limit of detection for AT and NT 
in plasma was 5 and lOng/ml respectively. Mean percentage 
coefficients of variation for intra-assay and inter-assay 
precision were respectively 3.2% and 8.6% for AT and 3.0% 
and 5.6% for NT. Linearity as measured by the correlation 
coefficient for the intra-assay linear regression lines was 
0.9999 for both drugs. The mean overall recoveries from 
plasma for AT and NT were respectively 80.8% and 71.0%. The 
assay described has been successfully applied to the 
determination of plasma levels of AT and NT in man after 
oral administration.
The advantages of this method over previously published 
methods are:
2 2 0
(a) a single extraction step with little adsorption 
onto the glass.
(b) use of two internal standards.
(c) detection at 215nm.
(d) simple mobile phase, and
(e) use of pre-column and guard column packed with 
Lichrosorb Si 100.
All these points have contributed to the sensitivity, 
reproducibility and reliability of the described method.
4.3.1. EXPERIMENTAL
4.3.1.1. Reagents
Amitriptyline, nortriptyline, imipramine, desipramine, all 
in the form of the HCL salt, and trimipramine as maleate 
were gifts from I.C.P. Dulbin. Hexane, methanol, 
acetonitrile and iso-propanol (all HPLC grade) were 
purchased from Fisons, England. Ammonia solution, sodium 
hydroxide, sodium acetate and zinc sulphate were obtained 
from B.D.H. Chemicals Ltd., Poole, England.
Trichlorocetic acid was purchased from May & Baker, 
Dagenham, England and perchloric acid from Riedel-de-Haen,
2 2 1
Germany.
For the preparation of the plasma samples dried human plasma 
(from the Blood Transfusion Service Board, Ireland) was 
dissolved in Millipore water (deionized water obtained by 
the MILLI-Q water purification system). The blank plasma 
obtained was examined for the presence of endogenous 
components which might interfere with the tricyclic drugs in 
the assay system. The reconstituted plasma was stored 
frozen and used within two weeks of preparation.
4.3.1.2. Instrumentation
The HPLC system consisted of Waters P-45 liquid 
chromatograph solvent delivery system equipped with a Waters 
U6K manual injector and fitted to a Shimadzu SPD-6A variable 
wavelength UV detector. The chromatograms were recorded on 
a Philips PM 8251 single pen recorder.
4.3.1.3. Chromatography
The chromatographic conditions for the separation were as 
follows, the stationary phase was an adsorption Porasil 
column (300 x 3.9mm) commercially packed with Porasil, 
(particle size lOjjm). Mobile phase was methanol containing 
0.1% ammonia, flow rate 1.5ml/min, recorder chart speed 0.5 
cm/min., detection wavelength 215nm and an injection volume 
of 70^1.
2 2 2
Under the described chromatographic conditions the following 
retention times were obtained, amitriptyline 3.1 min, 
nortriptyline 5.8 min,- imipramine 3.4 min, and desipramine 
7.5 min. (fig. 8) .
4.3.1.4. Preparation of Standards
Amitriptyline hydrochloride (11.23 mg) and nortriptyline 
hydrochloride (11.39 mg) were weighed and dissolved in 100ml 
of methanol to yield a stock solution of lOOug/ml 
amitriptyline and nortriptyline. This stock solution was 
then diluted to yield working standards ranging from 0.30 to 
6.0 p . g / m l . Imipramine hydrochloride (5.65mg) was weighed 
and dissolved in 50ml of methanol to yield a stock solution 
of 100 ^wg/ml of imipramine. Desipramine hydrochloride 
(11.37 mg) was weighed and dissolved in 100 ml of methanol 
to yield a stock solution of 100 ^ug/ml. These were then 
diluted with a methanol-water (1:1) mixture to yield a 
solution of 4 ^ug/ml imipramine and 20 ).l g / m l desipramine. 
Spiked plasma standards were then prepared each day by 
addition of 50 ^jal of the working standards and 50 ^ yil of the 
internal standards to 1.5ml of plasma to provide standards 
ranging from 10 to 200 ng/ml of the drugs in plasma.
4.3.1.5. Extraction Procedure
For several of the tricyclic drugs, irreversible adsorption 
onto glass is a problem.
Methods to prevent adsorption [42, 82-85], such as
silanization and siliconizing of glassware, replacement by 
plastic,
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Fig.8 Chromatograms of (a) a small pooled human drug free
plasma (b) the same plasma spiked with 10 ^ jjg/ml of each 
of the drugs and (c) spiked with 50 ng/ml of each of the 
drugs.
A = Amitriptyline, I = Imipramine, N = Nortriptyline and 
D = Desipramine.
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pretreatment of glassware with alkylamines or alkyl 
alcohols, or addition of these reagents to the solution for 
evaporation all gave variable results. In the present 
method plasma (1.5 ml) spiked with 50 of the working
standards and 50 i^l of the internal standard was mixed with 
0.4 ml of 0. 1M NaOH and vortex mixed for 20 seconds in 
polypropylene tubes. After the addition of 10ml of hexane: 
isopropanol (99:1), the drugs were extracted by vortexing 
the tubes for 1 min, followed by centrifugation for 15 mins 
at 500 g. The supernatant was then transferred into clean 
polypropylene tubes and placed in a water bath at 40°C and 
the solvent was evaportated under a gentle stream of oxygen 
free nitrogen. The residue was reconstituted, just before 
injection, in 100 ^ 1 of methanol and an aliquot of 70 ^ ul was 
injected for HPLC analysis. The major problem of adsorption 
onto glass was minimized by (a) the use of polypropylene 
tubes and (b) the presence of 1% isopropanol in the 
extraction mixture. The patient samples were treated 
exactly as described for standards except that in place of 
authentic standards, 50 ^ ul of methanol : water (1:1) and 
50 jjlI of internal standard was added prior to extraction.
4.3.1.6. CALIBRATION AND CALCULATION
The slope and intercept of the calibration curves were 
obtained by linear regression of the peak height ratios of 
drug/internal standard versus the concentration of the drug 
(internal standard method). For this method, based on 
extraction, imipramine and desipramine were used as internal
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standards for amitriptyline and nortriptyline respectively. 
The concentration of amitriptyline and nortriptyline in 
plasma is then calculated from the measured peak height 
ratios - (table Via and VIb and table Vila and Vllb).
4.3.2. RESULTS AND DISCUSSION
4.3.2.1. Limit of Detection
Under the procedural conditions, the limit of detection 
using a 1.5ml plasma sample and 70j.il injection from a 
reconstituted volume of 100^1 was between l-5ng/ml for 
amitriptyline in plasma. The variation in detection limit 
was due to day-to-day changes in operational conditions and 
detection system. The detection limit was taken as the 
amount of compound giving a signal to noise ratio greater 
than 3:1.
4.3.2.2. Precision
The data presented in table Via, VIb, Vila, Vllb and VIII 
demonstrate the within-batch (intra-assay) and between batch 
(inter-assay) variation of this method. Using this 
extraction procedure, variability was determined at five 
concentrations and in quadruplicate at levels of 10, 25, 50, 
100 and 200 ng/ml of each drug in plasma. Inter-assay 
variability was determined singly at the same five 
concentrations in four replicate runs. The precision of the 
method (mean coefficient of variation +\- standard 
deviation) for the values of the recovered determinate 
standards when calculated as unknown against the linear
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TABLE VI (a)
INTRA-ASSAY
AMITRIPTYLINE Peak Ratios
Concentration added
Peak Ht 
(cm)
Peak RT 
AT
Peak Ht
(cm)
Peak RT 
AT
Peak Ht
(cm)
Peak RT 
AT
Peak HT 
(cm)
Peak Rt 
AT
Mean Ratio 
AT
(ng/ml) AT IP IP AT IP IP AT IP IP AT IP IP IP
0
10
25
50
100
200
ND
0.4
0.8
2.3
2.9
9.6
ND
3.1
2.5
3.6
2.2
3.7
0.1290
0.3200
0.6389
1.3182
2.5946
ND
0.5
0.8
1.6
6.2
7.0
ND
3.2
2.3 
2.5 
4. 7 
2.7
0.1563 
0.3478 
0.6400 
1.3191 
2.5926
ND ND 
0.4 3.2 
0.6 1.8 
1.6 2.5 
2.9 2.2 
11.0 4.3
0.1250 
0.3333 
0.6400 
1.3182 
2.5581
ND ND 
0.3 2.2 
0.7 2.3 
1.1 1.7 
3.3 2.5 
6.0 2.3
0.1364
0.3261
0.6471
1.3200
2.6086
0.1367 
0.3318 
0.6415 
1.3189 
2.5885
Y == . 0130X + .0076 , (r) = .9999
Ht = Height
Rt = Ratio
N.D. = Not Detectable
Concentration
(ng/ml)
added Concentration 
1 2
found (ng/ml)
3 4
Mean concentration 
found (ng/ml)
Standard
Deviation
Coefficient of 
variation (%)
0
10
25
50
100
200
9.39
24.16
48.81
101.33
200.02
11.50
26.31
48.90
101.40
199.86
9.08
25.19
48.90
101.33
197.20
9.96 
24.63 
49.45 
101.47 
201.10
9.99
25.07
49.01
101.39
199.55
1.08
0.93
0.29
0.07
1.66
10.81
3.71
0.59
0.07
0.83
Mean % C.V. = 3.2%
H
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TABLE VI (b)
INTRA-ASSAY
NORTRIPTYLINE
Concentration added 1
Peak Ht 
NT DP 
(ng/ml) (cm)
Peak RT 
NT 
DP
2
Peak Ht 
NT DP 
(cm)
Peak RT 
NT 
DP
3
Peak Ht 
NT DP
(cm)
Peak RT 
NT 
DP
4
Peak HT 
NT DP
(cm)
Peak Rt 
NT 
DP
Mean Ratio 
NT 
DP
0
10
25
50
100
200
ND
0.2
SL
0.6
0.7
2.3
ND
7.5 
SL
4.6
2.6 
4.1
0.0267 
SL 
0.1304 
0.2692 
0.5610
ND
0.1
0.3
0.4
0.9
2.3
ND
3.7
4.5
3.0
3.2
4. 1
0.0270 
0.0667 
0.1333 
0.2813 
0.5610
ND ND 
0.1 4.4 
0.3 4.5 
0.4 3.0 
0.9 3.2 
3.0 5.3
0.0227 
0.0667 
0.1333 
0.2813 
0.5660
ND ND 
0.1 3.9 
0.3 4.7 
0.3 2.3 
1.2 4.5 
2.0 3.7
0.0256 
0.0638 
0.1304 
0.2667 
0.5405
0.0255 
0.0657 
0.1319 
0.2746 
0.5571
* SL = 
ND = 
Ht = 
Rt =
Sample Lost 
Not Detectable 
Height 
Ratio
Y == .0028X -.0051, (r) = .9999
Concentration added 
(ng/ml)
Concentration found (ng/ml)
1 2  3 4
Mean concentration 
found (ng/ml)
Standard
Deviation
Coefficient of 
variation (%)
0
10
25
50
100
200
11.32
SL
48.29
97.76
201.77
11.43 
25.69 
49.32 
102.07 
201.77
9.90
25.69
49.32
102.07
203.55
10.93
24.55
48.29
96.86
194.46
10.89
25.31
48.82
99.68
200.38
0.70
0.66
0.60
2.77
4.04
6.43
2.61
1.23
2.78
2.02
Mean % C.V. = 3 . 0 %
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TABLE VII (a)
INTER-ASSAY
Concentration added
Peak Ht Peak RT Peak Ht Peak RT Peak Ht Peak RT Peak HT Peak Rt
AT IP AT AT IP AT AT IP AT AT IP AT
(ng/ml) (cm) IP (cm) IP (cm) IP (cm) IP
AMITRIPTYLINE Day 1 Day 2 Day 3 Day 4
0
10 0.3 2.4 0.1250 0.5 3.9 0.1282 0.3 2.2 0.1364 0.4 3.9 0.1026
25 0.8 2.6 0.3077 1.2 3.6 0.3333 0.7 2.0 0.3500 1.2 4.7 0.2553
50 1.2 2.3 0.5217 1.8 3.0 0.6000 1.5 2.0 0.7500 1.4 2.7 0.5185
100 5.7 4.5 1.2667 4.4 3.6 1.2222 3.0 2.0 1.5000 7.0 6.4 1.0938
200 11.8 4.6 2.5652 7.5 3.0 2.5000 3.1 1.1 2.8182 11.9 5.4 2.2037
Concentration added Concentration found (ng/ml)
(ng/ml) Day 1 Day 2 Day 3 Day 4
0 0 0 0 0
10 12.90 10.43 8.11 8.78
25 26.98 26.91 23. 20 23.69
50 43.46 48.34 51.49 49.38
100 100.83 98.33 104.51 105.54
200 200.83 200.99 197.69 213.88
Mean
Mean concentration Standard Coefficient of
found (ng/ml) Deviation variation (%)
10.06 2.13 21.17
25.20 2.03 8.06
48.17 3.40 7.06
102.30 3.33 3.26
203.35 7.18 3.53
% C.V. = 8.6 %
Ut
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TABLE. Vll(b)
INTER-ASSAY
NORTRIPTYLINE Day 1 Day 2 Day 3 Day 4
Concentration added
Peak Ht Peak RT Peak Ht Peak RT Peak Ht Peak RT Peak HT Peak Rt
NT DP NT NT DP NT NT DP NT NT DP NT
(ng/ml) (cm) DP (cm) DP (cm) DP (cm) DP
0 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.
10 0.2 6.1 0.0328 0.15 5.1 0.0294 0. 1 2.8 0.0357 0.2 6.25 0.0320
25 0.4 4.9 0.0816 0.35 4.7 0.0745 0.3 3.3 0.0909 0.7 8.9 0.0787
50 0.9 5.4 0.1667 0.7 4.4 0.1591 0.5 2.9 0.1724 0.9 5.8 0.1552
100 2.2 7.3 0.3014 1.4 4.9 0.2857 1.3 4.0 0.3250 3.0 9.2 0.3261
200 4.9 8.0 0.6125 2.2 3.7 0.5946 1.8 2.5 0.7200 6.0 9.6 0.6250
Concentration added Concentration found (ng/ml) Mean concentration Standard Coefficient of
(ng/ml) Day 1 Day 2 Day 3 Day 4 found (ng/ml) Deviation variation (%)
0 - - -
10 8.83 9.46 11. 77 9.59 9.91 1.28 12.91
25 24.97 24.75 27.22 24.48 25.36 1.26 4.97
50 53.10 53.42 50.02 48.88 51.36 2.25 4.38
100 97.63 96.33 92.73 103.37 97.52 4.42 4.53
200 200.47 201.04 203.27 198.68 200.87 1.89 0.94
Mean % C.V. = 5.6%
TABLE VIII
PRECISION AND REPRODUCIBILITY
INTRA-ASSAY
AMITRIPTYLÌNE
Cone added Mean (n=5) concentration C.V. Difference between
(ng/ml) found + S.D. (ng/ml) % added and found
Concentration %
10 9.99 ± 1.08 10. 81 0. 10
25 25.07 + 0.93 3.71 0. 28
50 49.01 ±  0.29 0.59 1.98
100 101.39 + 0.07 0.07 1.39
200 199.55 + 1.66 0. 83 0. 23
Mean % C.V. = 3.2 %
NORTRIPTYLINE
10 10. 89 + 0.70 6.43 8.90
25 25.31 + 0.66 2.61 1.24
50 48.82 + 0.60 1.23 2. 36
100 99. 68 + 2.77 2. 78 0.32
200 200.38 + 4.04 2.02 0.19
Mean % C.V. = 3.0 %
INTERASSAY
AMITRIPTYLINE
10 10.06 + 2.13 21.17 0.60
25 25.20 + 2.03 8.06 0.86
50 48.17 + 3.40 7. 06 3.66
100 102.30 4* 3.33 3.26 2.30
200 203.35 + 7.18 3.53 1. 68
Mean % C.V. = 8.6 %
NORTRIPTYLINE
10 9.91 ± 1.28 .12.91 0.90
25 25.36 + 1.26 4.97 1.44
50 51.36 ± 2.25 4. 38 2. 72
100 97.52 + 4.42 4.53 2.48
200 200.87 ± 1.89 0. 94 0.44
Mean % C.V. = 5 . 6  %
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regression line were 3.2% and 8.6% for amitriptyline for 
intra- and inter-assay variation respectively. The values 
were 3.0% and 5.6% for nortriptyline for intra-assay and 
inter-assay respectively.
4.3.2.3. Linearity
Measures of linearity as defined by the correlation 
coefficient of the regression lines for both drugs and the 
difference between added and found concentrations are given 
in intra-assay precision (Table Via and VIb).
4.3.2.4. Recovery
The overall recovery was calculated in two different ways 
(Table VIII). First by comparing the peak heights of a 
series of spiked plasma standards after extraction with the 
peak heights of a series of unextracted authentic standards. 
Secondly, by comparing the slopes of the regression lines 
obtained from the two sets used in the first procedure. 
Using these methods in the concentration range 10-200 ng/ml, 
the mean overall recoveries were 80.8% and 71.0% for 
amitriptyline and nortriptyline respectively.
4.3.2.5. Plasma levels of Amitriptyline and Nortriptyline
The described method was successfully applied to the 
measurement of anitriptyline and nortriptyline in patients 
with neurotic and endogenous depression receiving oral doses 
of placebo, 50, 75, 100 or 150mg of anitriptyline. For
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TABLE V
RECOVERY
METHOD 1
Concentration Amitriptyline peak height (cm) Recovery
(ng/ml) (mean of duplicates) (%)
Set A 
Authentic
Set B
Standards Extracts
•jVBlank N.D. N.D. -
10 2. 1 1.6 76.19
25 5.2 3.7 71.15
50 10.5 8.5 80.95
100 22.4 17.9 79.91
200 45.7 38.0 83.15
Mean overall recovery — S.D,, = 78.27 - 4.21
METHOD 2
Regression line for set A: Y = .2294 x -.4063, r = 0.999
Regression line for set B: Y = .1911 x -.6473, r = 0.999
Overall recovery = .1911 x 100 = 83.30%
.2294
Mean recovery determined by methods 1+2 = 80.79%
NORTRIPTYLINE
METHOD 1
Concentration Nortriptyline peak height (cm) 
(ng/ml) (mean of duplicates)
Recovery
(%)
Set A Set B
Authentic Standards Extracts
Blank N.D. N.D.
10 0.80 0.60 75
25 2.05 0.40 68.28
50 4.05 3.05 75.30
100 8.55 5.25 61.40
200 18.00 13-|0 72.77
Mean overall recovery — S.D. = 70.55 — 5.22
METHOD 2
Regression line for set A: Y = .0901 x 2079, r = 0.999
Regression line for set B: Y = .0644 x 2329, r = 0.994
Overall recovery = .0644 x 100 = 71.48%
. 0901
Mean recovery determined by methods 1 + 2 = 71.02% 
* N.D. Not detectable.
233
quality control, each batch of samples received from the 
hospital contained a couple of split samples whose 
indentities were not revealed to us. The results of the 
split samples from patients are shown in Table X. These 
results indicated excellent precision of the described 
method.
4.3.2. CONCLUSION
The tricyclic drugs are lipophilic strong bases, thus at 
high pH's the free base can be extracted from an aqueous 
phase into an organic solvent such as hexane. This method 
which is based on a single extraction step is comparable or 
better in most of its features to other published methods. 
The features of the method are (a) a single extraction step 
with little adsorption onto the glass, achieved by using 
inexpensive polypropylene tubes wherever possible and the 
use of 1% iso-propanol in the extraction solvent which 
enhances recovery and reproducibility, (b) the use of the 
double internal standard for improving precision. (c) 
detection at 215 nm which improves sensitivity and was 
possible to use because of the simple mobile phase and the 
cleanliness of the extracts. (d) use of normal phase 
chromatography - the tricyclic antidepressants become 
ionized to some extent when they are in aqueous solution, 
that is they act as weak bases. The basic properties of 
these secondary and tertiary amines indicate that maximum 
separation potential would be attained with a mobile phase 
of pH9, since at higher pH's the ionization of these weak 
bases is suppressed.
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TADLE X
Plasma concentrations of At and NT in patients with neurotic and 
endogenous depression receiving oral doses of amitriptyline.
Samples were split Into two parts and their code revealed after 
analysis.
Concentration found (ng/m 1)
DOSAGE Part 1 Part 2
mg AT NT AT NT
100 58.2 107.4 66.0 102.9
100 76.4 62.4 85.5 66,9
100 12.8 17.5 12.8 17.5
75 169.9 44.4 150.1 44.4
75 21.9 31.0 21.9 31.0
PLACEBO N.D. N.D. N.D. N.D.
150 248.8 187. 8 226.6 211.4
PLACEBO N.D. N.D. N.D. N.D.
N.D. = NOT DETECTABLE (Below limit of detection).
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Fig. 9
Chromatograms of human plasma samples 10 hours after receiving a 
single oral dose of (1) Placebo and (2) tablets and containing 50 
mg of Amitriptyline and (3) 150 mg of amitriptyline.
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Use of a Lichrosorb Si 100 column means that a high pH 
mobile phase can be used but the column must be kept free of 
water. Peak tailing was minimized by the addition of 0.1% 
ammonia solution to the mobile phase. (e) use of A 
pre-column and guard column packed with silica in order to 
avoid formation of a void in the analytical column due to 
dissolution of silica in the mobile phase which could occur 
due to the high pH of this mobile phase. More recent 
publications [53, 73, 75] report recoveries of 90 - 100% for 
the extraction of amitriptyline and nortriptyline which 
involves time consuming extraction/back extraction and the 
use of higher volumes of plasma. Although the recovery of 
our extraction scheme is lower, the detection limits are 
similar (1-5 ng/ml) and the baseline is more stable in terms 
of noise and drift at the most sensitive detector setting. 
This can be attributed to the use of the lower detection 
wavelength (215 nm) for the measurement of the drugs. The 
use of the double internal standards imipramine and 
desipramine, not only improve precision but also offers the 
possibilities of determining other important tricyclic drugs 
using the described method. Some typical chromatograms are 
shown in fig. 8 + 9  and it can be seen that chromatograms of 
control plasma and patients plasma are quite similar with no 
interfering peaks in the region where the drugs and internal 
standards elute.
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4.4. COMPARISON
For the HPLC determination of amitriptyline and 
nortriptyline in human plasma, the two procedures for sample 
preparation are compared.
The first method used on-line, direct injection of plasma 
and a column switching technique followed by reverse bonded 
phase chromatography whereas the second is based on 
conventional liquid - liquid extraction and adsorption 
chromatography. Validation of both techniques showed 
excellent sensitivity, precision and reproducibility. For 
the method based on extraction the limit of detection was 
between 1-5 ng/ml of the drugs in plasma and the mean % 
coefficient of variation for intra and inter - assays was 
better than 8% for both drugs. The column switching/direct 
injection method showed a limit of detection of 5 ng/ml and 
the mean % coefficient of variation for intra and inter 
-assay better than 5%. This method shows obvious advantages 
in terms of speed and ease of sample handling. Both methods 
have been sucessfully applied to samples from patients 
receiving oral doses of amitriptyline and results were in 
good agreement.
As mentioned previously, HPLC procedures in the 
determination of tricyclic antidepressants generally 
involve extraction of drugs from plasma or serum, followed 
by various modes of chromatography. These extraction 
schemes are often tedious and time consuming, susceptible to 
errors and often can result in loss of sample because of 
incomplete extraction or formation of artifacts.
238
On the other hand, the use of on-line column switching with 
direct injection of plasma provides a new rapid alternative 
for sample preparation of tricyclic drugs prior to analysis 
with HPLC. The recovery of amitriptyline and nortriptyline 
was 90.7% and 92.6% respectively whereas using the 
extraction scheme recoveries were only 80.8% and 71.0%
Erni et al. [86] fully discuss the advantages of column 
switching as an on-line method for sample preparation and 
points out its many possibilities. In setting up the 
system, a major consideration is the nature of packing 
materials in the concentration column and the mobile phase 
passing through it during sample enrichment process. These 
have to be selected in such a way that the drug is almost 
completely retained while the interfering substances in 
plasma are removed.
The packing eventually chosen was pellicular Corasil C.. Q1 O
(37-50 ^m) . Water was chosen as the mobile phase for 
enrichment since it gave good recovery and eliminated the 
need for buffer salts which can cause precipitation of 
plasma proteins. This allowed at least 30 or 50 injections 
of 250 i^l plasma. More injections resulted in the loss of 
resolution, band broadening and lesser recovery hence lesser 
sensitivity. This may not allow automatic injection if 
total number of samples exceed thirty or fifty. Except for 
this limitation, direct injection/column switching proved to 
be a superior technique as virtually no sample preparation 
was necessary.
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HPLC DETERMINATION OF ANTIHISTAMINES IN BIOLOGICAL FLUIDS
CHAPTER 5
5.1. INTRODUCTION TO ANTIHISTAMINES
Drugs that are customarily classified as antihistamines have 
in common the property of antagonising the actions of 
histamine that are now recognised as involving H^ 
receptors. They could therefore be termed 'H^ - receptor
antagonists'. Their development began in 1937 when Bovet 
discovered that an adrenaline antagonist
thymoxyethyldiethylamine also antagonised the actions of 
histamine. A large series of related compounds were then 
prepared to obtain increased potency and specificity and 
lower toxicity. In 1942, antergan was prepared and this 
became the first antihistamine to be used in medicine and 
found to be of value. This was followed by mepyramine in 
1944 which even today has retained its position among the 
drugs used in the treatment of allergies. At about the same 
time in the U.S.A. another parent compound was developed
i.e. tripelennamine which has also remained in use today. 
From this start many other type of antihistamines have been 
developed and it is worth noting that two other important 
drug groups i.e. neuroleptic phenothiazines and tricyclic 
antidepressants had their origins in research into 
antihistamines.
Chemically, antihistamines are a diverse group of compounds. 
The only common feature is that they all possess at least 
one tertiary nitrogen atom and have an aromatic portion 
consisting of two phenyl rings. They are all weak bases,
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consequently they are well absorbed, widely distributed in 
tissues and cross the blood, brain and placental barriers 
readily. They are rapidly eliminated in the urine partly 
unchanged and partly after metabolism in the liver. 
Antihistamines can be divided into groups on the basis of 
their chemical structures as follows, ethylenediamine, 
imidazoline and piperidine derivatives, oxyethylamines 
arylalkylamines and phenindine derivatives.
The main use of antihistamines that is directly related to 
their antagonistic activity at - receptors is in the
relief of histamine - mediated effects in allergic and 
anaphylactic reactions. Thus they are useful for the 
symptomatic relief of urticarial lesions, angioneurotic 
oedema, hay fever and serum sickness. Antihistamines are 
also useful in treating reactions to venoms which contain 
histamine and substances causing histamine release in 
tissues (e.g. certain insect stings).
In the treatment of allergic skin rashes antihistamines may 
be applied topically in ointments or creams. Those with 
local anaesthetic activity are particularly effective in 
allying itching. Other actions include antinauseant and 
antiemetic activity, relief of vertigo and nausea in 
Menieres Syndrome and other labyrinthine disorders, the 
treatment of Parkinson's disease and sedative activity.
Side effects may be drowsiness, atrophine like effects e.g. 
dryness of the mouth and the mucosa of the upper respiratory
251
tract. A variety of other effects have been reported 
including anorexia, nausea, vomiting, diarrhoea, dizziness, 
tinnitus and disorders of perceptors.
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High Performance Liquid Chromatographic 
Determination of Tripelennamine in 
bovine plasma and milk using a 
Column Switching Technique.
5.2.1. INTRODUCTION
A new, sensitive and selective HPLC method for the 
determination of tripelennamine, an antihistamine, in bovine 
plasma and milk is described which uses direct injection and 
a column switching valve. The method is based on the 
enrichment of the drug on a small reverse phase 
concentration column, packed with Corasil RP, 37-50 /im. The 
enriched drug is then eluted from the concentration column, 
in back flush mode, and separated on a bonded phase 
Techsphere CN column, 3 ^ m, using an isocratic acetonitrile 
0.05 M acetate buffer (70:30 v/v) mobile phase. 
Tripelennamine was detected by absorption at 246 nm. The 
validation of the method showed excellent sensitivity, 
precision and reproducibility. The limit of detection, 
using a 250 ^ 1 direct injection of biological sample was 2 
ng/ml. The mean percentage coefficient of variation for 
intra-and inter-assay were 5.6% and 7.4% respectively. The 
linearity, as measured by the correlation coefficient of the 
intra-assay linear regression curve and calibration curves 
throughout the analyses was consistently better than 0.999. 
The mean overall recovery from plasma was 78% and from milk 
was 73.5%. The method showed obvious advantages over 
existing methods in terms of speed and convenience of sample 
handling. The method has been successfully applied to the 
samples from cattle receiving an intravenous injection of a 
formula containing tripelennamine.
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TRIPELENN AMINE
P R O T R IP T Y L IN E
Fig. 1 Chemical structure for Tripelennamine and 
the internal standard Protriptyline.
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Tripelennamine 2 - [ benzyl (2 - dimethylaminoethyl) amine ] 
pyridine, (fig 1) is an antihistamine which acts as a 
competitive antagonist of histamine at receptors [1].
Tripelennamine is used to control allergic manifestations in 
humans and animals and it has also been used as a stimulant 
in cows who refuse to stand because of various disorders 
[2]. The recommended dosage of tripelennamine for an adult 
is 50 to 100 mg once or twice daily, it is administered to 
other animals e.g. cattle in certain pharmaceutical 
preparations and in animal feed. In humans, pharmacological 
effects due to the drug are evident within 15 to 30 minutes 
and maximal effects are reported 1 to 2 hours after dosage. 
The duration of action is 4 to 6 hours. The drug is rapidly 
absorbed from the gastrointestinal tract and the tissues are 
normally free of it in about 6 hours. The majority of 
tripelennamine is biotransformed primarily in the liver, 
although some metabolic conversion has been noted in the 
lung and kidney [3]. Tripelennamine is then excreted in the 
urine and in bile. Chadhuri et al, [4] isolated four 
metabolites from human urine (fig 2), the drug is 
metabolised by N-demethylation and aromatic hydroxylation 
followed by conjugation with glucuronic acid.
Methods employed for the determination/detection of 
tripelennamine include, UV spectrophotometry [5,6] 
fluorimetry [5], and chromatographic methods. These 
chromatographic methods include thin layer chromatography 
[6-8] to detect tripelennamine in urine when screening for 
drug abuse. Gas liquid chromatography (GLC) with flame
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CH,
C H , N(CH 3)
N-oxide of tripelennamine.
CH,— N-
CH,
N'
CH,
Quaternary ammonium N-glucuronide of tripelennamine
> —  glucuronyl
R=C H ^  ; 0-g lucuron ide of liydroxytripelennamine.
R = II; O-glucuronide of hydroxydesmethy 1 tri pelennamine
Fig. 2: Metabolites of tripelennamine.
257
ionization detection for the identification of the drug in 
urine [6,7] and to determine tripelennamine residues in 
bovine milk [2] and in pharmaceutical formulations [9]. GLC 
has also been used with nitrogen specific detection [10,11] 
to determine tripelennamine in the blood of addicts taking a 
combination of pentazocine and tripelennamine known as "T's 
and Blues".
Spectrophotometric methods and all but one of the GC methods 
mentioned above while giving adequate sensitivity for 
measurement of tissue levels in cases of massive overdose 
[5,13] or among "T's and Blues" addicts [6,12] do not allow 
quantitation in the low nanogram region which is required 
for bioavailibility studies. Only the method described by 
Luders et al. [2] achieves this. GC with flame ionization 
detection is used giving a limit of detection of 10 ppb for 
a 2nl injection, however a major drawback of this method is 
the very lengthy and elaborate extraction procedure used 
requiring specially made tubes. This would render it 
impracticable for routine monitoring in the laboratory.
Although GC methods have been the most use for quantitative 
determination of tripelennamine, high performance liquid 
chromatographic methods have been reported for the 
determination of basic antihistamines including 
tripelennamine [14] in animal feed, human urine and waste 
water [15]. In one of these methods [15], after liquid - 
liquid partitioning of the drug and silica gel column 
clean-up, levels of 500ng/ml of the drug could be 
determined.
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However, this method suffers from the same drawback as the 
GC method [2], i.e. lengthy sample preparation technique.
The objective of the present study was to develop a HPLC 
method for the determination of tripelennamine in bovine 
plasma and milk that was sensitive, selective and 
reproducible and yet convenient in terms of sample handling 
and speed of analysis. In the following section a technique 
will be described which fully meets the objectives set out 
above. Each sample is processed and chromatographed inside 
15 minutes, giving a limit of detection of 2ng/ml.
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5.2.2. EXPERIMENTAL
5.2.2.1. Reagents and Solvents
Tripelennamine hydrochloride was obtained from Sigma 
Chemical Company, Dorset, England. Protriptyline
hydrochloride (internal standard) (IS), was obtained as a 
gift from Jervis Street Hospital, Dublin. Methanol and 
acetonitrile (HPLC grade) were purchased from Fisons, 
Loughborough, England and sodium acetate (AnalaR grade) was 
purchased from BDH Chemicals Ltd., Poole, England. Pure 
water was obtained by the Milli-Q water purification system. 
Drug free bovine plasma and milk were provided by Bimeda 
Chemicals Ltd., Dublin, stored frozen at -4°C and thawed at 
room temperature prior to use. The control plasma and milk 
showed no interference from endogenous components when 
examined for possible interferences with tripelennamine in 
the assay system.
5.2.2.2. Instrumentation
The HPLC system consisted of two Waters Assoc. (Milford, MA, 
USA) P-45 liquid chromatograph solvent devilvery systems 
equipped with a Waters U6K (Milford, MA, USA) manual 
injector and a Rheodyne (California, USA) 7000, 6 port
switching valve. A Shimadzu (Tokyo, Japan) SPD -6A variable 
wavelength UV detector was used and the chromatograms were 
recorded on a Philips (Endhoven, Holland) PM 8251 single pen 
recorder.
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5.2.2.3 . Preparation of Standards
Tripelennamine HC1 (11.43mg) was weighed and dissolved in 
100ml of methanol to yield a stock solution of 100^ig/ml. 
This stock solution was then diluted with methanol-water 
(1:1) to yield working standards of the following 
concentrations 0.04, 0.1, 0.2, 0.5, 1.0, 1.5, 3.0 and
6.0jag/ml. Protriptyline HCI (11.39mg) was weighed and 
dissolved in 100ml of methanol to yield a stock solution of 
lOOjig/ml. This was then diluted with a methanol-water (1:1) 
mixture to obtain a working internal standard solution of 
4jjg/ml. Spiked plasma standards ranging in concentration 
from 2 to 50ng/ml of the drug were prepared in each assay 
day by spiking 1ml of plasma with 50ul of working standards 
(0.04 - 6.0ug/ml) and 50ul of IS (4ug/ml) solution.
Spiked milk samples ranging from 5-300ng/ml of the drug in 
milk were prepared by spiking 1ml of milk with 50ul of the 
working standards (0.1 - 6.0 p q / m l )  and 50ul of IS (4 ^ jg/ml) 
solution. It should be noted that tripelennamine, although 
stable for at least 5 years at room temperature should be 
protected from light as on exposure it slowly darkens [1] 
and appears to undergo light catalyzed oxidation to yield 
benzaldehyde and 2-[2- (dimethylamino) ethylamino] pyridine.
Samples from cattle undergoing treatment were spiked with 
50jj1 of methanol-water (1:1) mixture to compensate for any 
changes in the composition of the sample, plus 50ul of IS 
(4jag/ml) .
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5 .2 .2 .4 . Chromatography
The instrument arrangement for the chromatography was
exactly as described in section 4.2.1.5. The
chromatographic conditions for the separation were as 
follows: mobile phase pump A: water; concentration column:
(10 x 1.5mm) dry packed in-house with Corasil (Waters Assoc. 
USA) RP 18, 37-50 .^im packing; wash time: 3.0 min.; flow
rate: 0.8 ml/min. Mobile phase pump B: acetonitrile - 0.05 M 
acetate buffer (70:30 v/v) pH 7.2; analytical column:
Techsphere (HPLC Technology, Cheshire, UK) 3CN (10 cm x 4.6
mm); flow rate: 0.8 ml/min, detection wavelength: 246 nm;
recorder chart speed: 0.5 cm/min and an injection volume of
250^1 of plasma or milk sample.
Under the described chromatographic conditions the mean 
retention times were 5.2 min and 6.8 min for tripelennamine 
and protriptyline respectively (fig. 3).
5.2.2.5. Column Switching Procedure
5.2.2.5.1. (a) Plasma
The column switching procedure described in section 4.2.1.5. 
was adopted for use in the present study. The bovine plasma 
was more viscous than human plasma and the wash time was 
therefore extended to 3.0 minutes per sample to avoid 
cloggin gof the pre-column and the resulting high back 
pressure. It was possible to inject up to thirty samples 
per concentration column. Chromatography deteriorated where 
sample injections exceeded thirty.
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10 10 10
(a) (b) (c)
Fig. 3: Chromatograms of (a) drug free bovine plasma,
(b) drug free plasma spiked with 2ng/ml of
tripeIennamine and the internal standard and
(c) drug free plasma spiked with 25ng/ml of 
tripeIennamine and the internal standard.
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Because of the relatively high amount of fats in milk it was 
not possible to directly inject the milk samples onto the 
concentration column. Their subsequent elution from this 
column onto the analytical column gives rise to the presence 
of interfering peaks on the chromatogram. Removal of the 
fats from the milk was attempted using three different 
procedures:
(a) Extraction of the fats into hexane (6ml), followed by 
centrifugation.
(b) Addition of 50 ^ 1 of a 0.1 M HC1 solution followed by 
extraction of the fats into hexane followed by 
centrifugation. After removal of the hexane, 50 ^ ul of
0.1 M NaOH is added to the lower milk layer.
(c) Centrifugation of the milk sample so that the fats rise 
to the top.
Spinning of the milk sample in a centrifuge at 1200 g to 
separate fats from the sample proved to be as effective as 
extraction of the fats into hexane. Upon centrifugation of 
milk samples three distinct layers were formed. The top
layer was the fat and the bottom layer was precipitated 
protein. Hence care was taken to inject the middle layer 
for chromatrography. The analysis of separated fat and
protein showed no detectable amount of tripelennamine (at
5.2.2.5.2. (b) Milk
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a spiked level of 300 ng/ml tripelennamine in milk) in 
either fat or protein.
5.2.2.6. Calibration and Calculation
Evaluation of the assay was carried out using five point 
calibration standards in the concentration range 2-50 ng/ml 
of tripelennamine in plasma and six point calibration 
standards in the concentration range 5-300 ng/ml of the drug 
in milk. The slope and intercept of the calibration curves 
were obtained by linear regression of the peak height ratios 
of drug / IS versus the concentration of the drug (internal 
standard method). These calibration curves were then used 
to interpolate the concentration of tripelennamine in bovine 
plasma and milk from the measured peak height ratios.
5.2.3. RESULTS AND DISCUSSION
In this study, the extension of the use of column 
switching/direct injection was investigated for the clean-up 
of milk samples. With some modification i.e. centrifugation 
of the samples for removal of fats prior to injection, this 
proved successful. On line sample clean-up followed by 
chromatographic analysis proved to be a rapid, sensitive and 
selective method for the determination of tripelennamine in 
the low nanogram range in milk, giving a comparable if not 
better limit of detection than more elaborate clean-up 
procedures, [2]. The use of column switching as a method 
for analysis of organopesticides in milk has been
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reported previously using a silica pre-column for sample 
clean-up [16]. Fats from the milk are adsorbed onto the 
pre-column while the organopesticides are eluted onto the 
analytical column. In a regeneration phase the fats are 
then backflushed off the pre-column using 1% isopropanol in 
hexane, followed by hexane leaving it ready for the next 
injection.
For the determination of tripelennamine in plasma on line 
solid phase extraction gave good sample clean-up coupled 
with a low limit of detection. In all the previously 
described methods liquid - liquid extraction prior to 
analysis was used with some of the procedures being somewhat 
lengthy. Monteford et al. [5] evaluated the extraction
efficiencies of various solvents for extraction of 
tripelennamine from plasma and these are shown in Table 1.
TABLE 1
SOLVENT % RECOVERY OF TRIPELENNAMINE
Ethyl Acetate 47
Diethyl Ether 75
Toluene 68
n-butyl chloride 40
Chloroform 62 '
Methylene Chloride 62
Ethylene Chloride 60
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(a)
1 ml of milk 
50 ^1 of drug
50 ^ 1 of I.S.
Centrifuge for 
15 mins at 3000 r.p.m 
Fats to top
Pellet of proteins to bottom
(b)
5 ml of milk 
0.5 ml of 6N NaOH
Extract twice with
30 ml of 20%
methylene chloride -
ether
Combine Extracts
Add 5 ml of HCL
solution (1 to 9)
Inject middle layer (250 ^ 1) 
onto concentration column
Wash for 2 minutes
t IAnalyse
Shake for 2 mins. and 
allow layers to 
separate ,
Drain bottom layer 
into centrifuge tube
Add another 5 ml of 
HCL and repeat 
extraction
I
Combine extracts
Add 3 ml of 6N NaOH
Add 5 ml of 20% 
methylene chloride 
ether solution
Shake vigourously
I
Centrifuge
Fig. 4: Extraction of tripelennamine 
from milk using (a) a 
column-switching procedure 
and (b) the liquid-liquid 
extraction employed 
by Luders et al [ 2 ] ,
Transfer organic 
phase to tapered tube
Evaporate solvent
IDissolve residue in
9 to 7 ^ 1 of 
dimethyl formamide
IMix and centrifuge
Adjust volume to
10 j i l  and analyse.
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5.2.3.1. Limit of Detection
Under the described procedural conditions, the limit of 
detection using a 250 ^ 1 direct injection of plasma or milk 
was 2 ng/ml of tripelennamine in the biological fluid. The 
detection limit was taken as the amount of compound giving a 
signal-to-noise ratio greater than 3:1.
5.2.3.2. Precision
The data presented in table II, III and IV demonstrates the 
within batch (intra-assay) and between batch (inter-assay) 
variation of the method. Intra-assay variability was 
determined at five concentrations in quadruplicate at levels 
of 2,5,10,25 and 50 ng/ml of the drug in plasma. 
Inter-assay variability was determined singly at the same 
five concentrations in four replicate runs. The precision 
of the method (mean coefficient of variation) for the values 
of the recovered determinate standards when calculated as 
unknowns against the generated linear regression line were 
5.6% and 7.4% for intra- and inter-assay respectively.
A full validation was not carried out for milk samples as 
the precision of the assay for milk was found to be very 
similar to that of plasma.
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TABLE II
TRIPELENNAMINE
INTRA-ASSAY - PLASMA
Concentration
added
(ng/ml)
Peak HT 
(cm)
Peak RT
T
P
Peak HT 
(cm)
Peak RT
T
P
Peak HT
(cm)
Peak RT
T
P
Peak HT 
(cm)
Peak RT
T
P
Mean Ratio
T
PT P T P T P T P
0 N.D. N.D. N.D. N.D.
2 0.2 5.1 0.0392 0.2 4.9 0.0408 0.15 4.5 0.0333 0.15 3.9 0.0385 0.0380
5 0.4 4.7 0.0851 0.4 4.7 0.0851 0.4 4.7 0.0851 0.5 5.2 0.0962 0.0879
10 1.1 6.1 0.1803 0.8 4.6 0.1739 0.8 4.5 0.1778 0.7 4.1 0.1707 0.1757
25 2.4 5.4 0.4444 2.0 4.7 0.4255 2.1 4.8 0.4375 1.9 4.4 0.4318 0.4348
50 3.2 4.0 0.8000 3.2 4.0 0.8000 2.6 3.2 0.8125 4.4 5.0 0.8800 0.8231
Y = 0.0164 x + 0.0102 r = .999
C on c ent ration 
added 
(ng/ml)
Concentration found (ng/ml) Mean Concentration 
found (ng/ml)
Standard
Deviation
Coefficient of 
Variation %
1 2 3 4
0
2
5
10
25
50
1.77
4.57
10.38
26.48
48.16
1.87 
4.57 
9. 99 
25.33 
48.16
1.41
4.57
10.22
26.06
48.92
1.73 
5.24 
9. 79 
25.71 
53. 04
1.70
4.74
10.09
25.89
49.57
0.199
0.335
0.259
0.491
2.340
11.71
7.07
2.57
1.90
4.72
Mean % C.V. = 5.6%
N.D. = not detectable
HT = height
RT = ratio
T = Tripelennamine
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TABLE III
INTER-ASSAY - PLASMA
TRIPELENNAMINE
DAY 1 DAY 2 DAY 3 DAY 4
Concentration
added
(ng/ml)
Peak HT 
(cm)
Peak RT
T
P
Peak HT 
(cm)
Peak RT
T
P
Peak HT 
(cm)
Peak RT
T
P
Peak HT 
(cm)
Peak RT
T
PT P T P T P T P
0 N.D. N.D. N.D. N.D.
2 0.3 9.3 0.0323 0.3 8.7 0.0345 0.4 11.2 0.0357 0.2 6.6 0.0303
5 0.7 9.5 0.0737 0.7 8.5 0.0824 1.0 10.3 0.0971 0.3 4.1 0.0732
10 1.4 9.1 0.1538 1.5 8.4 0.1786 2.1 12.9 0.1628 0.7 5.3 0.1321
25 3.3 8.8 0.3750 3.1 8. 1 0.3827 3.9 10.2 0.3824 1.4 4.5 0.3111
50 7.1 9.4 0.7553 6.1 8.1 0.7531 8.4 10.1 0.8317 2.8 4.4 0.6364
Concentration
added
(ng/ml)
Concentration found (ng/ml) Mean Concentration 
found (ng/ml)
Standard
Deviation
Coefficient of 
Variation %
1 2 3 4
0 N.D.
2 2.10 1.42 2.13 1.95 1.9 0.330 17.37
5 4.85 4.65 5.88 5.37 5.2 0.552 10.62
10 10.16 11.14 9.90 10.06 10.3 0.561 5.45
25 24.83 24.90 23.32 24.34 24.4 0.729 2.99
50 50.06 49.88 50. 77 50.28 50.2 0.385 0.77
Mean % C.V. = 7.4%
N.D. = not detectable
HT = height
RT = ratio
T = Tripelennamine
TABLE IV
PRECISION (REPEATABILITY AND REPRODUCIBILITY)
Concentration added Mean (n=4) concentration C.V, Difference between 
(ng/ml) found — S.D. (ng/ml) % added and found
concentration %
INTRA-ASSAY
2 1.7 ~ 0.20 11.7 15.0
5 4.7 - 0.34 7.1 5.2
10 10.1-0.26 2.6 0.9
25 25.9 -  0.49 1.9 3.2
50 49.6 - 2.34 4.7 0.9
Mean % C.V. =5.6%
INTER-ASSAY
2 1.9 -  0.33 17.4 5.0
5 5.2 - 0.55 10.6 4.0
10 10.3 ~ 0.56 5.5 3.0
25 24.4 - 0.73 2.0 2.4
50 50.2 - 0.39 0.8 0.4
Mean % C.V. = 7.4 %
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MILK SAMPLES - TRIPELENNAMINE
Duplicate Standards
Standard Curve
Concentration
ng/ml
Peak Ratios Mean Ratio Concentrations found
ng/ml
10
25
75
0.5 
5.7 
0.55 
6 . 1
0.6
3.4
0.6
3.2
1.5
3.4
1.4 
3.2
4.4
3.4 
4.3
3.2
= .0877 
= .0902
= 0.1765 
= 0.1875
= 0.4412 
= 0.4375
= 1.2941
= 1.3438
0.0890
0.1820
0.4394
1.3190
6.32
11.34
25. 24
72. 76
150 9.7
3.5
11.1
4.2
= 2.7714
= 2.6428
2.7071 147.74
300 15.0 
2.7
20.0
3.6
= 5.5555
= 5.5555
5.5556 301.60
Slope = .0185 I = -.0279, r = .99988
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5.2.3.3. Linearity
Measures of linearity as defined by the correlation 
coefficients (r) of the regression lines generated based on 
duplicate calibration curves obtained for plasma and milk 
were consistantly better than 0.999.
5.2.3.4. Recovery
In order to establish the recovery, two calibration curves 
based on the external standard method, were set up. One 
calibration curve was based on spiked plasma samples in the 
concentration range 2-50 ng/ml and the other was based on 
working reference standards in the same concentration range. 
The overall recovery was calculated by comparing the slopes 
of the regression lines generated for the two sets. The 
same procedure was applied to the milk samples in the 
concentration range 5-300 ng/ml tripelennamine. The overall 
recovery was also calculated by direct comparison of the 
peak heights. The results obtained are shown in Table V.
5.2.4. APPLICATIONS OF THE METHOD
The described method has been successfully applied to the 
samples from cattle receiving an intravenous injection of a 
formula containing tripelennamine.
2 7 3
TABLE V
RECOVERY FROM PLASMA
CONCENTRATION TRIPELENNAMINE PEAK HEIGHTS (cm) RECOVERY
(ng/ml) (mean of duplicates) %
Set A: Working Set B: Standards extracted
standards from plasma/milk
2* 0.9 0.7 78
5 0.9 0.7 78
10 1.9 1.5 79
25 4.5 3.5 79
50 9.1 7.1 77
Mean overall recovery = 78%
Regression line for Set A : Y = 0.1805X 4- 0.0480, r = 0.9999
Regression line for Set B : Y = 0.1407X 4- 0.0402, r = 0.9999
Overall recovery = ^ x 100 = 78%
0.1805
Mean recovery determined by the two methods: 78%
RECOVERY FROM MILK
5 0.50 0.35 70
10 0.85 0.65 77
25 2.30 1.75 76
75 7.90 5.70 72
150 15.75 11.90 76
300 31.00 22.60 73
Mean overall recovery = 74%
Regression line for Set A: Y = 0.1040 x -0.0821, r = 0.999
Regression line for Set B: Y = 0.0761 x -0.0113, r = 0.999
Overall recovery = ^ ^  x 100 = 73%
0.1040
Mean recovery determined by the two methods: 73.5%
* More sensitive detector setting.
Results of the analysis of plasma and milk samples are shown 
in Table VI and VII. Chromatograms from the actual plasma 
and milk samples are included in figures 5 and 6. As can be 
seen, these chromatograms resemble the chromatograms 
obtained from spiked samples and no interferences were 
observed from endogenous components of plasma or milk.
5.2.5. CONCLUSION
For routine anlaysis of tripelennamine in bovine plasma and 
milk, a new method of analysis based on direct 
injection/column-switching technique was developed. Plasma 
samples could be injected directly while milk samples had to 
be spun first, to separate fat, prior to injection. The 
method is rapid and eliminates the need for lengthy and 
tedious liquid-liquid extraction procedures with good 
recovery and low running cost. The method achieves a low 
limit of detection which compares with some reported GC 
methods which employ long and elaborate extraction 
procedures. The chromatrography was selective, i.e. there 
were no interferences from endogenous plasma components, and 
sharp peaks were obtained for the drug and the internal 
standard. This procedure illustrates the extension of the 
use of the column switching technique for clean up of 
biological fluids other than plasma.
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TABLE VI - Results of plasma samples from cattle undergoing 
treatment with a complex, containing 
tripelennamine.
Concentrations of 
Tripelennamine in Plasma (ng/ml)
Cow 1 Cow 2 Cow 3 Cow 4 Cow 5
Time after dosage
0 min (pre-■treatment) N.D. N.D. N.D. N.D N.D.
15 mins 18.3 21. 6 12 . 6 14.3 15.6
30 mins 27.2 27.5 18.2 15.5 23.6
45 mins 25.6 30. 6 17.9 16. 5 32.8
1 hr 14.8 24. 7 15.9 22.8 23.9
2 hr 9.7 15.7 12.1 18.1. 17.2
4 hr 3.0 S.L.
6 hr N.D. 3.9 *
12 hr N.D. N.D.
24 hr N.D. N.D.
* Samples not given
N.D. = not detectable 
S.L. = sample lost
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TABLE VII - Results of milk samples from cattle undergoing 
treatment with a complex, containing 
tripelennamine.
Concentration found of tripelennamine (ng/ml)
Cow No. 1 2 10 22 536 545
Sample
Number
0 N.D. N.D. N.D. N.D. N.D. N.D.
1 75.83 71.26 83.41 156.57 90.58 46.06
2 68.15 21.45 48.90 47.89 28.22 18.78
3 17.08 7.17 8.05 9.58 6.80 10.18
4 6.08 4.17 5.67 N.D. N.D. N.D.
5 N.D. N.D. N.D. N.D. N.D. N.D.
N.D. = not detectable.
2 1 1
I M INS J
Fig. 5: Chromatograms from cow 1 showing levels of
tripeIennamine in plasma (a) pre-dose,
(b ) 30 mins. after dosage , (c ) 4 hours after
dosage and (d) 24 hours after dosage.
Each cow received a 15mg/kilo intravenous 
dose of a complex containing tripeIennamine.
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- I ------------- 1---------- 1
6 a 10 8 10
(MINS.)
Fig. 6: Chromatograms of (a) Bovine drug free milk,
(b) drug freemilk spi ked with the internal 
standard and 5ng/ml tripeIennamine and
(c) milk of a cow 30 mins. after receiving 
an intravenous injection of a formula 
containing t r i.pe I ennami ne.
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High Performance Liquid Chromatographic 
Determination of Setistine 
in plasma using a Column 
Switching Technique.
5.3.1. INTRODUCTION TO SETISTINE
Setistine (fig 7) is an antihistamine, developed recently in 
Eastern Europe. No literature is available at present. It 
bears structural similarity to clemestine (fig 7) which is 
used as the internal standard.
CLEMASTINE
CH,
/
c — o ch 2ch2 — n ,
Cl
SETISTINE
Fig. 7: Chemical Structures of Setistine
and the Internal Standard Clemastine.
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5.3.2. EXPERIMENTAL
5.3.2.1. Reagents and Solvents
Setistine and clemastine were obtained from The Institute 
of Clinical Pharmacology, Dublin. Methanol and acetonitrile 
(HPLC grade) were purchased from Fisons, Loughborough, 
England and sodium acetate (AnalaR grade) was purchased from 
BDH Chemicals Ltd., Poole, England. Pure water was obtained 
by the Milli Q water purification system. Drug free human 
plasma was obtained from the Blood Transfusion Board, Dublin 
and stored at -4^C.
5.3.2.2. Prepa ration of Standards
Setistine (10mg) was weighed and dissolved in methanol to 
yield a stock solution of 100 ug/ml. This stock solution 
was then diluted with methanol to yield working standards in 
the range 0.1 to 1 ug/ml. Clemastine (10mg) was weighed 
and dissolved in 100 ml ■ of methanol to yield a stock 
solution of 100 ug/ml. This was then diluted with methanol 
water (1:1) to obtain a working internal standard solution 
of 2 ug/ml. Spiked plasma samples ranging in concentration 
from 5 to 50 ng/ml of the drug in plasma were prepared in 
each assay day by spiking 1 ml of plasma with 50 ul of the 
working standards (0.1 to lug/ml) and 50 ul of internal 
standard (2ug/ml) solution. Samples from patients 
undergoing treatment were spiked with 50 ul of a methanol - 
water solution (1:1) to compensate for any change in the 
samples plus 50 ul of internal standard (2ug/ml).
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5.3.2.3. Instrumentation and Chromatography
The HPLC system consisted of two Waters Assoc. P-75 liquid 
chromatograph solvent delivery systems equipped with a 
Waters U6K manual injector and a Rheodyne 7000 six port 
switching valve. A Shimadzu SPD-6A variable - wavelength UV 
detector was used and the chromatograms were recorded on a 
Philips PM 8251 single pen recorder. A Perkin-Elmer 
fluorescence spectrometer with flow cell was used. Under 
these chromatrogaphic conditions the mean retention times 
were 5.9 min and 7.0 min for setistine and clemastine 
respectively. The instrumental arrangement is as described 
in section 4.2.1.5. The addition the fluorescence detector 
in line with the UV detector was used.
The chromatographic conditions for the detection were as 
follows: mobile phase pump A, water with 1% acetonitrile,
concentration column (10 x 1.5 mm) dry packed in house with 
Corasil RP 18, (37-50 /im) packing. The mobile phase from
pump A was passed through the concentration column for 90 
seconds (wash time) at a flow rate of 1 ml/min. Mobile 
phase pump B, acetonitrile -0.05M acetate buffer adjusted to 
PH 6.5 with acetic acid (60:40 v/v). Analytical column: 
Techsphere 3CN (10cm x 4.6mm) flow rate: 0.8 ml/min;
detection wavelength: 225nm; injection volume: 300 ul of
plasma. Under the described chromatographic conditions the 
mean retention times were 5.9 min and 7.0 min for setistine 
and clemastine respectively (fig 8).
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I MINS t
Fig. 8: Chromatograms showing (a) drug free human
plasma (b) drug free plasma spiked with 
5ng/ml of setistine and the internal standard 
and (c) drug free plasma spiked with 25ng/ml 
of setistine and the internal standard.
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5.3.2.4. Column Switching Procedure
The column switching procedure is described in section
4.2. 1.5. The injection volumn was increased to 300 ^ 1 in an 
attempt to lower the limit of detection.
5.3.2.5. Off-line Solid-Phase Extraction using Sep-pak
A Sep-pak cartridge was placed above each tube. Each
cartridge was conditioned using 2 volumes of methanol
followed by 2 volumes of deionized water. 1 ml of each
plasma standard was then added to the cartridge and eluted
using different solvents as outlines in Table VIII. Each
was eluted with 3 x 2  ml portions of the relevant solvent
and the extracts then combined and evaporated to dryness.
The residue was then reconstututed in the mobile phase prior
to injection. The recoveries are shown in table VIII.
Other cartridges were also investigated but C-^ g gave the 
best recovery among the packings tried.
If any residual silanol groups were present on the packing 
these could irreversibly bind the drug. To prevent this 
happening (a) diethylamine and (b) octylamine were added to 
the 1st portion of methanol but this did not improve 
recovery. Recovery may be improved by the addition of 0.1% 
acetic acid, but this results in dirty chromatograms.
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TABLE VII!
Results for recovery using a C^g cartridge.
ELUENT % RECOVERY
Methanol 46.0
Acetonitrile 42.0
Methanol/Chloroform 22 .9
Methanol/Water 6.4
Diethylamine in Methanol 40.3
Octylamine in Methanol 36.3
Addition of Acetic Acid 
to Methanol
75.4
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Evaluation of the assay using the column-switching procedure 
was carried out using four-point calibration standards in 
the concentration range 5 to 50 ng/ml of the drug in plasma. 
The slope and the intercept of the calibration curves were 
obtained by linear regression of the peak height ratios of 
drug/internal standard versus the concentration of the drug 
(internal standard method).
The internal standard (I.S.) used was clemastine a drug 
which bears structural resemblance to setistine and which 
has a suitable retention time (t = 7.0 min). Thesev r /
calibration curves were then used to interpolate the 
concentrations of drug in patient plasma from the measured 
peak - height ratios.
5.3.3. DISCUSSION
5.3.3.1. Off-line Solid Phase Extraction
The Sep-pak column extraction procedure has several steps 
that can cause variability. Firstly, it is essential that 
the columns be activated thoroughly with 100% methanol, a 
two-column volume wash will achieve this. The columns then 
need to have all traces of methanol removed by using another 
2 column volume wash of distilled, deionized water. The 
plasma standard is then loaded onto the column and proteins 
removed by washing the column with water. A wash with 
methanol-water (50:50) is then included. Finally using 0.1% 
acetic acid methanolic solution the drugs are then eluted 
from the column in 3 x 2 ml portions.
5.3.2.6. Calibration and Calculation
287
The rigid silica substrate enables the user to apply either 
positive or negative pressure to draw the sample rapidly 
through the cartridge without damaging the material.
5.3.3.1.1. Protein Binding Study
The peak heights obtained for a series of authentic 
standards were compared with the peak heights obtained for a 
series of plasma standards in the range of 5 - 50 ng/ml.
Similar recoveries for both indicated that the loss in 
recovery of the drug from the Sep-pak is not due to protein 
binding.
5.3.3.1.2. Cartridge Selection
Sep-pak cartridges containing Cg and CN packing were also
investigated with a new to improving recovery but C., _ provedlo
to be the best among the packings tried. The use of 
Bond-Elut cartridges did not improve recovery.
5.3.3.1.3. Detector Settings
Using this off-line solid phase extraction procedure the 
lowest detector setting which could be achieved was .02 AUFS 
because of the co-extraction of interferents from the 
cartridge. This proved to be a severe limitation in the 
case of the present study since a limit of quantitation of 5 
ng/ml was desired and this requires a setting of .005 AUFS.
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The amount of interfering peaks in the chromatogram may be 
due to the dimension of the sep-pak cartridge since we also 
recorded similar types of chromatograms with larger size 
concentration columns used in column switching procedures in 
our laboratory. Smaller size commercial cartridges are now 
available. A sample chromatogram is shown in figure 9.
Typical Non-polar Extraction Procedure
porus
frits < LI i
sorbent bed
- A r -  - Q
0
A '. Ai
I T
6
JU~ '
A
A
A
Fig. 10,
1. Activation of Sorbent
2. Removal of activation solvent
3. Application of sample
4 . Removal of interferences (I)
5. Elution of the concentrated, purified drug (D)
289
s
I
Fig. 9 Chromatogram obtained 
for a drug free human 
plasma spiked with 
lOOng/nl of setistine 
using a Bond-elut 
cartridge for sample 
clean up.
( M I N S . )
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5.3.3.2. Column switching
5.3.3.2.1. Concentration column packings
The following packings were investigated in the 
concentration column, Vydak cyano (30 yum), Corasil RP C^g 
(37-50 ^ m) and Separalyte CQ (40 /lm). Smaller size packings 
were not investigated. With regard to recovery of setistine 
and cleanliness of chromatograms C1Q proved the best among 
the packings tried. An injection volumn of 300 1 of plasma
was used and this allowed thirty consecutive injections 
before changing the concentration column.
5.3.3.2.3. Wash time and Flow-rates
The sharpest peaks and cleanest chromatograms were obtained 
for a wash period of 90 seconds at 1 ml/min.
5.3 .3.2.3. Limit of Detection
Using a 300 j i l  direct injection of plasma and under the 
procedural conditions outlined, the limit of detection for 
setistine in plasma was 5 ng/ml. Using the off-line 
extraction procedures and for a 75 ^ul injection from a 
reconstituted volume of 100 jul, the limit of detection was 
500 ng/ml because of the limitation in detector setting 
outlined above.
The assay was then validated for the column switching 
procedure since this proved to be superior in terms of 
selectivity, sensitivity, precision and reproducibility.
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5.3.3.2.4. Precision
Intra-assay variability was determined at four 
concentrations and in quadruplicate at levels of 5, 10, 25
and 50 ng/ml of the drug in plasma. Inter-assay variability 
was determined singly and at the same four concentrations 
infour replicate runs. The precision of the method (mean 
coefficient of variation) for the values of the recovered 
determinate standards when calculated as unknowns against 
the linear regression lines for intra-assay and inter-assay 
were 2.4% and 1.2% respectively (tables IX, X and XI).
5.3.3.2.5. Linearity
A measure of linearity as defined by the correlation 
coefficient of the regression line for the intra-assay was 
better than 0.999 and the intercept did not differ greatly 
from the origin.
5. 3.3.2.6. Recovery
The overall recovery was calculated in two different ways. 
First by comparing the peak heights of a series of spiked 
plasma samples after they had been taken through the entire 
procedure with a series of reference standards. Secondly, 
by comparing the slopes of the regression lines obtained 
from the two sets used in the first procedure. Using these 
methods in the concentration range 5-50 ng/ml, the mean 
overall recovery was 86.5% (Table XII).
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TABLE IX
INTRA-ASSAY - PLASMA
Concentration
added
(ng/ml)
Peak HT 
(cm)
Peak RT
S
C
Peak HT 
(cm)
Peak RT
S
C
Peak HT 
(cm)
Peak RT
S
C
Peak HT 
(cm)
Peak RT
S
C
Mean Ratio
S
CS C S C S C S C
0
5
10
25
50
0.4
0.7
2.3
3.2
8.5
8.2
9.7
7.1
0.0471
0.0854
0.2371
0.4507
0.4
0.7
1.9
3.1
8.6
8.2
8.4
6.9
0.0465 
0.0854 
0.2262 
0.4493
0.4
0.8
2.0
3.4
8.8
8.8
8.9
7.5
0.0455
0.0909
0.2247
0.4533
0.3
0.6
1.8
3.3
6.6 
7.1 
7.7 
7.6
0.0455
0.0845
0.2338
0.4342
0.0462
0.0866
0.2305
0.4469
Y = 0.00895 + .00096 r = .9997
Concentrat ion 
added
(ng/ml)
C one ent r at ion found (ng/ml) Mean Concentration 
found (ng/ml)
Standard
Deviation
Coefficient 
Variation %
1 2 3 4
0
5 5.15 5.08 4.97 4.97 5.05 0. 09 1.78
10 9.42 9.42 10.03 9.32 9.55 0.32 3.35
25 26.36 25.14 24.97 25.99 25.62 0.67 2.62
50 50.20 50.04 50.49 48.36 49.77 0. 96 1.93
Mean % C.V. = 2.4%
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TABLE x
INTER-ASSAY - PLASMA
SETISTINE
DAY 1 DAY 2 DAY 3 DAY 4
Concentration
added
(ng/ml)
Peak HT 
(cm)
Peak RT
S
C
Peak HT 
(cm)
Peak RT
S
C
Peak HT 
(cm)
s C
CO
1
O CM
1
00
0 . 6 7.7
1 . 6 8.5
2.7 CM
Peak RT
S
C
Peak HT 
(cm)
Peak RT
S
C
0
5
10
25
50
0.4 9.5
0.7 8.8
1.6 8.0
3.7 9.7
0.0421
0.0795
0.2000
0.3814
0 6 12 8
1 0 11 8
2 5 12 5
4 7 12 2
0.0469
0.0847
0.2000
0.3852
0.0366 
0.0779 
0.1882 
0.3750
0.3
0.7
1.6
3.4
7.5 
8.3
7.5 
8.0
0.0400
0.0843
0.2133
0.4250
Concentration
added
(ng/ml)
Concentration found (ng/ml) Mean Concentration 
found (ng/ml)
Standard
Deviation
Coefficient 
Variation %
1 2 3 4
0
5 4.82 4.90 4.75 4.87 4.84 0.07 1.45
10 9.76 9.94 10.27 10.05 10.01 0.21 2.10
25 25.70 25.27 25.01 25.15 25.28 0.30 1.19
50 49.71 49.88 49.96 49.92 49.86 0.11 0.22
Mean % C.V. =1.2%
PRECISION (REPEATABILITY AND REPRODUCIBILITY)
TABLE XI
Concentration added Mean (n=4) concentration C.V. Difference between 
(ng/ml) found - S.D, (ng/ml) % added and found
concentration %
INTRA-ASSAY (REPEATABILITY)
0
5 5.05 - 0.09 1.8 1.0
10 9.55 -  0.33 3.4 4.5
25 25.62 - 0.67 2.6 2.5
50 49.77 - 0.96 1.9 0.5
Mean % C.V. = 2.4%
[-ASSAY (REPRODUCIBILITY
0
5 4.84 - 0.07 1.5 3.2
10 10.01 ~  0.21. 2.1 0. 1
25 25.28 - 0.30 1.2 l.i:
50 49.86 ~ 0.11 0.2 0.2!
Mean % C.V. = 1.2%
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TABLE XII
RECOVERY FROM PLASMA 
METHOD I
Concentration Peak Heights (cm) Recovery
(ng/ml) (mean of duplicates) (%)
Set A Set B
Working Standards Standards
Extracted from 
plasma
0 -
5 0.4 0.38 93.75
10 0.75 0.70 93.33
25 1.8 2.00 90.00
50 3.9 3.25 83.33
Mean overall recovery = 90.10%
METHOD II
Regression line for set A : y = .0779X - 0.0393
Regression line for set B : y = .0645X + 0.1291
Overall recovery = % = 0.0645 x 100 = 82.80%
0.0779
Mean recovery determined by two methods = 86.5%.
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TABLE XIII 
RESULTS OF SETISTINE ANALYSIS
Comparison of on-line and off-line solid phase extraction
ON-LINE OFF-LINE 
BOND - ELUT
LIMIT OF 
DETECTION 
ng/ml
5 500
INTRA-ASSAY 
PRECISION 
MEAN % C.V.
INTER-ASSAY 
PRECISION 
MEAN % C.V.
2.5
2 . 2
NOT
VALIDATED
% DIFFERENCE 
BETWEEN 
ADDED & FOUND 
(intra-assay)
0.12 - 4.5
% DIFFERENCE 
BETWEEN 
ADDED & FOUND 
(inter-assay)
0.1 - 1.9
RECOVERY 87.7% 46.0%
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5.3.3. CONCLUSION
When the described method was applied to plasma from 
patients receiving an 8  mg oral dose of the drug. However, 
it was found that the highest level in plasma was 5 ng/ml 
after 1  hour, the other amounts were not quantifiable so in 
this regard the method as it stands at present is not 
adequate for bioavailability studies of setistine. A more 
sensitive dectection system is required.
Fluorescence detection was investigated but did not lower 
the detection limit. The limit of detection using the 
fluorescence detector was 2 0  ng/ml.
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HPLC DETERMINATION OF 
DIAZEPAM AND ITS METABOLITES 
IN PLASMA.
A COMPARISON OF DIRECT/INJECTION 
COLUMN SWITCHING WITH CONVENTIONAL 
LIQUID-LIQUID EXTRACTION
CHAPTER 6 .
6.1. INTRODUCTION TO BENZODIAZEPINES
Benzodiazepine derivatives are widely used as 
tranquillisers, hypnotics, anticonvulsants, muscle relaxants 
and in the treatment of acute alcohol withdrawal [1]. Used 
singly they appear to be relatively safe but care must be 
exercised when they are taken in conjunction with other 
drugs [2]. They are clinically effective at low doses 
ranging from 1 to 25mg and this results in blood 
concentrations in the range 10 - 500 ng/ml. Metabolism of 
the drugs is extensive and many of the metabolites are 
pharmacologically active [3-6]. Thus it is essential that 
any assay method be both sensitive and specific and capable 
of monitoring the parent drug and the metabolites. Methods 
for the analysis of these drugs have been extensively 
reviewed [6 -1 0 ].
The 1-4 benzodiazepines can be structurally generalised by 
the formula shown in fig. 1  where substitution with different 
groups leads to different benzodiazepines. All the members 
of importance contain a 5 phenyl ring, a halogen or nitro 
group at position 7 and in some cases an additional halogen 
in the R. position. These compounds with a substituent at 
position 7 on ring A are highly pharmacologically active. 
Substitution with electron withdrawing groups increases this 
activity but substitution with electron donating groups 
reduces it. Substitution with a methyl group at position 1 
(in ring B) generally increases the activity while side 
chains or bulky groups at the same position have the 
opposite effect. Any substitution in the para position in 
ring C causes a complete disappearence of biological 
activity [ 1 1  ] .
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The structure of chlordiazepoxide differs from other 
benzodiazepines in that it is an N - oxide with a methyl 
amino group in position 2  and no alkyl group at position 1  
(Fig. 2).
Fig 1 Fig 2
Benzodiazepine Structure Chlordiazepoxide
Structure
Benzodiazepine
R 1 R 2 R3 R4
Diazepam ch3 H H Cl
Desmethyl diazepam H H H Cl
Temazepam CH3 OH H Cl
Oxazepam H OH H Cl
Nitrazepam H H H N° 2
Flurazepam -(CH2 )-NEt2 H F Cl
Lorazepam H OH Cl Cl
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Benzodiazepines are basic drugs and in the free form are 
lipid soluble and water insoluble, the salts of the drugs, 
however, are water soluble.
Because the benzodiazepines are such a widely prescribed 
group of drugs many years of work and research has gone into 
the development of sensitive and specific assays for their 
determination. Results of benzodiazepine assays can be used 
to evaluate and care for a toxic patient (clinical 
toxicology), to check on a patients drug compliance with the 
prescribed regimen (compliance) and to adjust the drug 
dosage or schedule to achieve maximum therapeutic benefit 
(pharmacokinetics). For clinical toxicological testing, a 
rapid method that measures total active drug is very useful. 
The precision of the method is less important in this case 
and a between assay CV of 10 to 15% can be tolerated. For 
compliance testing, measurement of a single representative 
compound, either parent drug or metabolite suffices. 
However the precision required for perodic monitoring of a 
patient for compliance in somewhat greater than for clinical 
toxicological studies. A between-day assay C.V. of 5 to 10% 
would be acceptable for this purpose [1 2 ].
Pharmacokinetic studies are the most demanding in terms of 
specificity and precision. Because each bioactive 
metabolite may have a different distribution and excretion 
pattern and biological half-life, each one should be 
measured individually. Furthermore the monitoring of 
changes resulting from dosage adjustments requires a between 
assay CV of 5% although a CV as large as 10% can often be 
tolerated. [1 2 ]
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Many different analytical methods have been reported for the 
determination of benzodiazepines in pharmaceutical 
preparations, serum and other body fluids. These include 
spectrophotometry [13-15], colorimetry [16], TLC [17-19], 
radioimmunoassay [20,21], with polarography [22-27], GLC 
[6 , 11, 28-46] and HPLC [47-61] being the most widely
applied. Spectrophotometry is not specific and only gives 
information about the overall concentration of a drug 'and 
its metabolites, and radioimmunoassay is limited not only by 
the low linear range available but also by the cross 
reaction of diazepam with antibodies specific for desmethyl 
diazepam and by the time (24 hrs) needed to complete the 
assay [2 0 ].
Polarography requires large amounts of serum and lacks the 
selectivity required for metabolic studies. The
polarographic reduction waves of the 1-4 benzodiazepines, 
corresponding to the C=N group have been used mostly for 
trace analysis[62]. Metabolism of the benzodiazepines leads 
to structural changes distinct from this group and hardly 
affects its electron density. Therefore electroanalytical 
methods based on these reduction waves possess little 
selectivity [63]. Nitrazepam, clonazepam and flunitrazepam 
structures do contain a readily reducible N 0 2  
group which can be modified to electroinactive - NH2  and 
-N-C-CH^ groups on metabolism. Some improvement in 
selectivity can be obtained by introducing a solvent 
extraction step prior to differential pulse polarographic
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analysis. A recent publication [64] describes solvent 
extraction for flurazepam and its metabolites but the method 
was found to be somewhat time-consuming.
On-line electrochemical detection of 1,4 benzodiazepines has 
been investigated in both oxidative [69] and reductive 
modes, the latter being used in conjunction with reversed 
phase HPLC for the separation and determination of nanogram 
amounts of nitrazepam, diazepam and chlordiazepoxide in 
mixtures [6 6 ]. Such on-line methods, when linked with HPLC, 
result in optimization of the selectivity and time of 
analysis of the overall analytical method. Additional 
selectivity over U.V. detection using electrochemical 
detection in either mode can be obtained by control of the 
detector potential.
A very widely applied technique for benzodiazepine analysis 
is gas - chromatography. Many of the earlier GC methods 
depended on the acid hydrolysis of the benzodiazepines to 
their corresponding benzophenones [7] followed by gas-liquid 
or thin layer chromatography. Unfortunately hydrolysis of 
several of the benzodiazepines results in the formation of 
the same benzophenone [6,67] so that the individual parent 
drugs cannot be identified. More lately the technique most 
extensively used has been GLC with electron captive 
detection. De Silva et al, [11] have described a
comprehensive extraction scheme using GLC - ECD for the
determination of the compounds in blood. However the
procedure has major disadvantages such as lengthy
purification steps and the necessity for relatively large 
sample volumes (up to 2ml). Rutherford [40] has described a
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rapid micro method using GLC - ECD for the determination of 
diazepam and its metabolites in plasma. The method involves 
a direct solvent extraction followed by GLC. A similar 
procedure is also reported [68] and extended to include the
Fig. 3 Metabolic Pathway for Diazepam
2 4
1 Diazepam (7 - chloro - 1,3 dihydro - 1 - methyl - 5
phenyl - 2H - 1,4 benzodiazepine - 2 - one)
2 Desmethyl diazepam (7 - chloro - 1,3 dihydro - 5 - phenyl
- 2H - 1,4 - benzodiazepine - 2 - one)
3 Temazepam (7 - chloro - 1,3 dihydro - 3 hydroxy - 1 
methyl - 5 phenyl 2H - 1, 4 - benzodiazepine - 2 - one)
4 Oxazepam (7 - chloro - 1,3 dihydro - 3 hydroxy - 5 phenyl
- 2H, - 1,4 benzodiazepine - 2 - one)
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quantitative determination of flurazepam and its major 
metabolite N-desalkylflurazepam.
With regard to the analysis of diazepam and its metabolites 
(Fig 3) earlier methods pointed to GC - ECD as the method of 
choice [29, 30, 31, 39, 40] for its determination and that
of its main metabolites, oxazepam, temazepam and 
desmethyldiazepam. Although GC - ECD is inherently more 
sensitive than HPLC analysis with U.V. detection for the 
analysis of diazepam and desmethyldiazepam per se, the 
analysis of temazepam and oxazepam requires silylation to 
the trimethylsilyl ether derivative not only for enhanced 
sensitivity and chromatographic behaviour but also to ensure 
thermal stability, especially of oxazepam. The procedural 
details required make the simultaneous analysis of all four 
metabolites by EC - GLC [28] a difficult process.
Due to convenience and ease of operation HPLC has now become 
the method of choice for the analysis of the 
benzodiazepines. Use of electrochemical detection or U.V. 
absorbance in the 230 - 260 nm range gives sensitivity in
the nanogram range.
Most of the current HPLC methods for benzodiazepines use 
reverse phase columns with U.V. detection and mobile phases 
consisting of organic solvents mixed with water or weakly 
acidic buffers. [9]. Using reverse phase chromatography 
drugs of varying polarity can be separated and the columns 
require little maintenance. The most popular column packing 
material for benzodiazepine analysis is chemically
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bonded silica containing octadecyl or octyl
(Cg)groups, although hexyl (Cg) an^ cyano - bonded R.P. 
columns as well as ordinary silica have also been used. 
Radial compression columns have been used for the 
determination of diazepam and its metabolites [69], these 
columns afford short analysis time and can be operated at 
lower pressures. The most common solvent system used as 
mobile phase is a mixture of acetonitrile or methanol and an 
aqueous acetate or phosphate buffer or water [69]. 
Combinations of two organic solvents and an aqueous buffer 
have also been employed to achieve optimum conditions for 
the separation of closely related solutes such as diazepam 
[53, 69, 70], chlordi azepoxide [70, 71] and their
metabolites.
Before analysis, however, the benzodiazepines must be 
extracted from the biological medium in which they occur. 
They are usually extracted as neutral molecules with a range 
of organic solvents under weakly alkaline conditions [7]. 
Some workers have found it unnecessary to alkalize samples 
since the pK values for the benzodiazepines are considerably 
below the physiological pH. A wide range of solvents have 
been used, some workers choose diethyl ether, ethyl acetate 
and chloroform in that order [7] while others prefer a 
relatively non-polar solvent such as methylene chloride. 
One advantage of the low boiling point solvents is that they 
can be readily evaporated for recovery of the drugs. A 
single extraction step is sufficient for all benzodiazepines 
except oxazepam and lorazepam. Owing to their lower lipid 
solubility they need a double extraction. [72]
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Solid phase extraction techniques using disposible C^g 
bonded phase columns (Bond - Elut) have been applied to the 
isolation of the benzodiazepines from biological fluids, 
specifically to clonazepam [59], temazepam [60] and in 
particular to the determination of diazepam and its 
metabolites [56]. These columns selectively retain 
benzodiazepines and their metabolites from biofluids at a pH 
of 9.0. The compounds are then eluted with methanol, making 
sample preparation more convenient than the traditional 
solvent extraction procedure. These methods give good 
sensitivity, selectivity and recoveries, allow a smaller 
volume of plasma to be used but are expensive.
More recently Koenigbauer et al. have developed a method for 
trace analysis of diazepam using on-line preconcentration 
[61]. However, the method requires ultracentrifugation of 
plasma prior to injection and does not simultaneously assay 
all three metabolites.
6.2 Introduction to a column switching/direct injection 
method for determination of diazepam and its metabolites
The following work describes an on-line solid phase 
extraction scheme for the determination of diazepam and its 
metabolites. It uses a switching valve to allow direct 
injection of plasma onto a concentration column where the 
drugs are enriched and held. They are then eluted in 
backflush mode onto the analytical column for separation and 
quantitation. This method is compared to a conventional 
extraction procedure in terms of speed of analysis, 
precision, accuracy, sensitivity and specificity.
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6.2.1. EXPERIMENTAL
6 .2.1.1. Reagents
Diazepam, temazepam, oxazepam, desmethyl-diazepam,
nitrazepam and salicylic acid were obtained as a gift from 
the Institute of Clinical Pharmacology, Dublin. Methanol, 
acetonitrile, diethyl ether (all HPLC grade) were obtained 
from Lab-Scan Ireland Ltd. Chloroform and sodium hydrogen 
phosphate were obtained from Riedel-de -Haen (Hanover, 
F.R.G.). Sodium carbonate, sodium bicarbonate and sodium 
hydroxide were obtained from May and Baker (Dagenham U.K.) 
Ammonia solution and phosphoric acid were purchased from 
BDH, Poole U.K.
For the preparation of the plasma samples, dried human 
plasma (from the Blood Transfusion Service Board, Dublin , 
Ireland) was dissolved in deionised water (obtained by the 
Milli-Q-water purification system). The control plasma 
obtained was examined for the presence of endogenous 
components which might interfere with the benzodiazepines in 
the assay system. The reconstituted plasma was stored 
frozen and used within two weeks of preparation.
6 .2.1 .2. Intrumentation
The HPLC system consisted of two Waters Assoc. (Milford, MA. 
USA. ) P-45 liquid chromatographic systems equipped with a
Rheodyne 7125 injector fitted to a Shimadzu (Tokyo, Japan) 
SPD-6 A variable wavelength U.V. detector. The chromatograms
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were recorded on a Philips (Eindhoven, The Netherlands) PM 
8251 single pen recorder. A Rheodyne (CA ; USA) 7000 six - 
port switching valve was used.
6 .2.1.3. Chromatography
The instrumental arrangement for the chromatography is 
described in section 4.2.1.5. The chromatographic conditions 
for the separation were as follows.
Mobile phase pump A: Water; concentration column (10 x
1.5mm) dry packed with Separalyte (Analytichem 
International) RP Cg packing (40um) in our laboratory; wash 
time, 2.0 min; flow rate: lml/min. Mobile phase pump B:
methanol - 2mM NaH2 P04  buffer (50:50, V/V) adjusted to pH3 
with phosphoric acid; stationary phase: Lichrosorb 10 RP8 ,
5um (HPLC Technology, Macclesfield, U.K.) (25cm x 4.6mm),
flow rate: 1 .6 ml/min, recorder chart speed: 1 2 0 mm/hr,
detection wavelength: 246nm, injection volume: 50ul or 250^ il 
of plasma. Under the described chromatographic conditions 
the mean retention times were as follows, oxazepam 10.5 
min, temazepam 12.5 min, desmethyl - diazepam 15.5 min and 
diazepam 20.5 min (fig 4).
Prep a ration o f Stand a r d s_^
Oxazepam (10 mg), temazepam (10 mg), desmethyl diazepam 
( 1 0  mg) and diazepam ( 1 0  mg) were weighed and dissolved in 
1 0 0  ml of methanol to yield a stock solution of 1 0 0  ;ug/ml of 
each drug. This stock solution was then diluted with
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Fig. 4: Chromatograms obtained for (a) human drug
free plasma, (b) the same plasma spiked with 
25ng/ml of each drug (2 50;i.l injection,
0.02 AUFS) and (c) spiked with 250ng/ml of 
each drug (50^il injection 0.02 AUFS)
1 = oxazepam, 2 = temazepam, 3 = desmethy1-diazepam,
4 = diazepam.
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water - methanol (1 :1 ) to yield working standards ranging
from 0.5 to 50 ^ g/ml. Spiked plasma standards ranging from 
25 to 2500 ng/ml of the drugs were then prepared in each 
assay day by spiking 1 ml of plasma with 50 j i l  of the
working standards.
6 .2.1.5. Column Switching Procedure
Prior to injection 50 ¿il of a 4mg/ml solution of salicylic 
acid is added to the spiked plasma samples (this frees the 
bound drugs from plasma), and the sample is centrifuged for 
5 minutes. It is then injected through the injector port
and washed by water from pump A onto the concentration
column. The drugs are held on the concentration column 
while the other components in plasma are eluted to the
drain. Meanwhile the eluent from pump B is passing through
the analytical column and on to waste. On switching the
valve the eluent from pump B elutes the drugs - which have 
been enriched on the concentration column - in backflush 
mode onto the analytical column where they are separated.
With regard to optimising the analytical procedure in terms 
of precision, accuracy, reproducability, recovery,
sensitivity and selectivity, variations in the following
experimental parameters were investigated.
Concentration Column packing - (i) recovery
- (ii) protein
binding study.
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(a) Concentration Column packing - (i) recovery
- (ii) protein
binding study.
(b) Sample pre-treatment prior to injection
(c) Concentration column size
(d) Sample injection volume
(e) Wash time and flow rate
(f) Analytical column
Concentration Column Packing
The concentration column packing should be chosen in such a 
way that the drugs are completely retained while interfering 
substances from plasma are removed. The following packings 
were tested in the concentration column, CN and DIOL from a 
Sep-pak (50-lOQum), Lichroprep CN (40jam), u Bondapak C^g 
(40^ im) and Separalyte Cg (40ym). Smaller size packings were 
not investigated as from a previous study it had been found 
that they did not allow direct injection of plasma [73]. 
The recovery of the four drugs i.e. diazepam and its three 
metabolites from each of the packings was calculated by 
comparing the peak heights of a standard injected directly 
onto the analytical column with the peak heights obtained 
for the recovered authentic standards using the valve (Table 
1).
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The only packing which gave good recovery of the most polar 
metabolite i.e. oxazepam was the Cg packing. This was then 
chosen for the assay. Other packings gave better results in 
terms of cleanliness of chromatograms for blank plasma but 
CQ gave adequate sample clean up.
TABLE 1
% Recovery of the Authentic Standards 
from the Concentration Column
Peak Heights (cm)
C18 C 8 CN Diol
Oxazepam
6.2 55.8% 11.0 99% 0 . 6__ 5.4% 0.6 . 5.4%
1 1 . 1 1 1 . 1 1 1 . 1 1 1 . 1
Temazepam
7.4 91.3% 8.0 98.7% 0 . 2  2.5% 0.3 3.7%
8 . 1 8 . 1 8 . 1 8 . 1
Desmethyl
Diazepam 12.7 96.2% 14.0 106% 1 . 6  7.5% 1.4 10.6%
13.2 13.2 13 .2 13.2
Diazepam
9.3 97.9% 10.4 109% 1 . 6  _ 16.8% 1.0 10.5%
9.5 9.5 9 . 5 9.5
Calculation: Peak Height of Recovered
Authentic Standard x 100 = % RecoveryPeak Height of Authentic / 0 J
standard
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6.2.1.5.2. Protein Binding Study
Having chosen the concentration column packing, ideally the 
drug should have a greater affinity for this packing than 
for the proteins of plasma, otherwise recovery of the drug 
from plasma will be very poor. In the present study when 
the peak heights obtained for the recovered authentic 
standards were compared with the peak heights for the 
recovered plasma standards from the concentration column it 
was found that the recovery of diazepam from plasma was only 
35% (table II). This is an expected result since it is well 
known that the benzodiazepines and in particular diazepam 
are extensively protein bound. Other workers have reported 
the use of proteolytic enzymes i.e. subtilisin carbergensis 
[47] or subtilisin A [74] to overcome this problem in tissue 
and plasma, however, this renders the procedure somewhat 
elaborate. We searched for a cheaper and more convenient 
solution to the problem of protein binding.
It was found that the addition of 5Qul of a 4mg/ml solution 
of salicylic acid which is very strongly protein bound frees 
the diazepam and improves recovery of the drug to 1 0 0 % but 
does not interfere with the assay as it is washed off the 
concentration column bound to plasma. Use of a lower 
concentration of salicylic acid does not give full recovery 
or reproducible results (table III).
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Table II
Protein binding studies using Cg packing in 
the concentrated column.
Peak Heights (cm)
Drug
No valve
authentic
standard
Valve +
authentic
standard
Valve +
plasma
standard
Overall % 
recovery
Oxazepam 6.5 5.9 5.3 81.5
Temazepam 4.5 4.1 3.3 73.3
Desmethyl
Diazepam
7.6 6.9 6.4 84.2
Diazepam 5.5 4.8 1.9 34.5
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Table III
Use of Salicylic acid to improve 
recovery of the drugs from plasma.
Peak Heights in cm
II III IV
Authentic 13.7 9.6 9.7 6.5
No Salicylic 10.1 6 . 6  7.4 2.9
acid
2.0 mg/ml 10.1 6 . 6  8.5 4.1
Salicylic
acid
4.0 mg/ml 11.2 7.6 8.7 4.8
Salicylic
acid
6.0 mg/ml 11.4 7.6 8.7 4.8
Salicylic
acid
I = Oxazepam
II = Temazepam
III = Desmethyl-Diazepam
IV = Diazepam
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6.2.1.5.3. Sample Pretreatment Frior to Analysis
One of the major drawbacks in using a direct injection of 
plasma is the build up of backpressure due to accumulation 
of particular matter from plasma and the resultant clogging 
of frits. Also proteins from plasma may precipitate on the 
concentration column when they come into contact with the 
buffer salts and organic solvents from the mobile phase. 
With a view to overcoming these problems protein 
precipitation prior to injection using a range of 
precipitating agents was examined, as outlined by Blanchard 
et al [75] (Table IV).
Table IV 
Table of Precipitating Agents
Precipitant Volume added per ml 
of plasma
10% Trichloroacetic 
acid
0 . 2  ml
Methanol 1 . 0  ml
Ethanol 1 . 0  ml
1:1 10% ZnS04 :0.1M NaOH 0.4 ml
1:1 6 % Na2 W04 :0.7N H 2 S04 0 . 6  ml
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For each precipitant, the required volume was added to 1ml 
of plasma and the resulting mixture vortexed for twenty 
seconds and then allowed to settle for fifteen minutes. 
This mixture was then centrifuged at 3,500 rpm for fifteen 
minutes and 250 ^ul of the supernatant injected onto the 
concentration column. However protein precipitation did not 
give good results. Precipitation with acid leads to 
ionization of the basic benzodiazepines and results in their 
not being held on the CQ packing, also addition of the acid
O
gives dirty chromatograms.
The organic solvents proved to be very efficient at 
deproteinizing the plasma, giving clean chromatogams for 
blank plasma. However, the organic solvent of the 
supernatant is a strong eluent i.e. MeOH or EtOH and result 
in almost complete elution of the drug from the 
concentration column immediately after injection. Also the 
large volume of the organic solvent required for efficient 
deproteinization leads to dilution of the drugs.
Precipitation with base and heavy metal i.e. ZnSO^ and NaOH 
leads to co-precipitation of the drugs with the plasma 
proteins. Best recovery, sensitivity and reproducibility 
were achieved using direct injection of plasma. The 
problems associated with direct injection i.e. build up of 
back-pressure etc. can be minimized by using backflush mode.
6.2.1.5.4. Concentration Column Size
The size of the concentration column is also an important 
experimental consideration in the chromatographic system.
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Two different sizes were investigated
(i) 2.5 x 0.4 cm (large)
(ii) 1.1 x 0.15 cm (small)
It was found that a large concentration column allows a 
larger injection volume without a decrease in the lifetime 
of the column but a longer wash time is necessary. This is 
because the plasma has further to travel on the larger 
column. This leads to band broadening and the greater 
volume of packing in the larger column retains more
interferents from plasma giving dirty chromatograms. The 
"small" concentration column was chosen since, while giving 
good recovery of the drugs, less wash time is required for 
plasma clean-up and it is more economical as less packing is 
used.
6 .2.1.5.5. Sample Injection Volume
For the higher concentration of diazepam and its metabolites 
in plasma a 50 ;ul injection of plasma gives an adequate 
limit of detection. For lower concentrations a larger 
injection volume is required. A direct injection of 250 ^ ul 
allows quantitation at the 25 ng/ml level. Larger volume
injections are possible but these will significantly lower 
the lifetime of the concentration column.
6 .2.1.5.6 . Wash Time and Flow Rate
One of the applications of column switching is sample
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clean-up, however, for an efficient sample clean-up the wash 
phase must be optimized. A good washing solvent should 
eliminate interferences and larger molecules present in the 
sample and prevent contamination of the analytical column. 
Water was found to best meet these requirements. Variations 
in wash time and flow rate do not affect the chromatography 
to a large extent. Best results in terms of cleanliness of 
chromatogram and peak shape were obtained for a 2 . 0  minute 
wash time at lml/min. These conditions allow adequate 
sample clean-up with little or no band broadening. Longer 
wash times do not cause breakthrough of the drugs. 
Breakthrough volume was estimated to be 20 mis.
6 .2.1.5.7. Analytical Columns
Using a range of mobile phases at various pH's, separation 
of diazepam and its metabolites was attempted using a 
Nucleosil C^g (HPLC Technology), a Lichrosorb C^g (HPLC 
Technology), a Resolve C^g (Waters) a Techsphere Phenyl 
(HPLC Technology) , a Pierce Cg and a Lichrosorb Cg (HPLC 
Technology) column. The C^g columns did not provide the 
selectivity required to separate diazepam and its 
metabolites in a reasonable analysis time. The phenyl 
column retained the drugs for too short a time resulting in 
their co-elution with endogenous compounds from plasma 
(Fig 5). Best results were achieved using a Lichrosorb Cg 
( 1 0  /im) .
6 .2.1.6 . Calibration and Calculation
Evaluation of the assay was carried out using 7 - point
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F i g .  5: Chromatograms show ing  s e p a r a t i o n  o f  oxazepam ( 1) ,
temazepam ( 2 ) ,  d e sm e th y l - d ia zep am  (3) and d iazepam 
(4) on (a) A Nova-pak C , 8 column (b)  A n u c l e o s i l  C , R
n « i u  _ u ± 9 . . i  . • >
calibration standards in the range 25 - 2500 ng/ml of the 
drugs in plasma. The slope and intecept of the calibration 
curves were obtained by linear regression of the peak 
heights versus the concentration of the drug. These 
calibration curves were then used to interpolate the 
concentration of the drug in plasma from the measured peak 
heights (External standard method).
No internal standard was used, nitrazepam has a suitable 
retention time but interferents eluting with similar 
retention times were found in some plasma samples.
6.2.2. RESULTS AND DISCUSSION
6.2.2.1. Limit of Detection
For the higher concentrations (250 - 2500 ng/ml) a 50 ;ul 
direct injection of plasma was used. For the lower
concentrations (25 - 125ng/ml) a 250 ¿il direct injection was 
used. Using a 250 u^l direct injection of plasma and under 
the procedural conditions outlined, the limit of detection 
for each of the four drugs was 25 ng/ml. The detection 
limit was taken as the amount of compound giving a signal to 
noise ratio greater than 3:1.
6 .2.2.2. Precision
Intra-assay variability was determined at seven 
concentrations and in quadruplicate at levels of 25, 50,
125, 250, 750, 1500, 2500 ng/ml of each drug in plasma.
Inter-assay variability was determined singly and at the 
same seven concentrations in four replicate runs. The 
precision of the "column-switching method" (mean coefficient 
of variation) for the recovered determinate standards when 
calculated as "unknowns" against the linear regression lines 
for intra-assay and inter-assay were, respectively, 0 . 6  and 
2 .8 % for diazepam, 0.5% and 2 .8 % for desmethyl diazepam, 
1.4% and 3.2% for temazepam and 2 .0 % and 1.9% for oxazepam. 
(Tables V and VI (a), (b), (c) and (d) and Table VII).
6 .2.2.3. Linearity
Measures of linearity as defined by the correlation 
coefficient of the regression lines of intra-assay for all 
drugs were better than 0.999 and the intercepts did not 
differ greatly from the origin.
6 .2.2.4. Recovery
The overall recovery was calculated in two different ways. 
First by comparing the peak heights of a series of spiked 
plasma samples after they had been through the entire 
procedure (either column switching or extraction) with a 
series of reference standards. Secondly by comparing the 
slopes of the regression lines obtained from the two sets
i.e. the reference and the processed samples. Using these 
methods in the concentration range 25-2500 ng/ml the mean 
overall recoveries were 100.8%, 98.5%, 101.5%, 104.1% for
diazepam, desmethyl diazepam, temazepam and oxazepam 
respectively using the column switching procedure (Table
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Table Vf a)
Intra - Assay Slope = .0122
I = - .0153
Diazepam r = .9999
C one ent r at ion 
ng/ml 
added
1 2 3 4 Mean S.D. % CV % Differ
between
added
and
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
25 0.30 25.77 0.30 25.77 0.30 25.77 0. 30 25.77 0.30 25.77 0.0 0.0 3.08
50 0.60 50.29 0.60 50.29 0.60 50.29 0.60 50.29 0.60 50.29 0.0 0.0 0.56
125 1.50 123.84 1.50 123.84 1.50 123.84 1.50 123.84 1.50 123.84 0.0 0.0 0.93
250 3.00 246.42 3.00 246.42 3.00 246.42 3.00 246.42 3.00 246.42 0.0 0.0 1.43
750 9.00 736.76 9.00 736.76 9.00 736.76 9.00 736.76 9.00 736.76 0.0 0.0 1.77
1500 18.00 1472.26 18.00 1472.26 18.50 1513.12 18.50 1513.12 18.25 1492.69 23.59 1.58 0.49
2500 32.00 2616.38 30.50 2493.80 31.00 2534.66 30.00 2452.93 30.88 2524.85 69.79 2.76 1.00
Peak H = Peak Height (cm) Mean % C.V. = 0.6%
S.D. = Standard Deviation
C.V. = Coefficient of Variation
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Table VÇb)
Iatra - Assay Slope = 0.0221
I = 0.0003
Desmethyl Diazepam r = 0.9999
Concentration
added
ng/ml
1 2 3 4 Mean S.D. % CV % Differ
between
added
and
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
25 0.55 • 24.91 0.55 24.91 0.55 24.91 0.55 24.91 0.55 24.91 0 0 0.36
50 1.10 49.83 1.10 49.83 1.10 49. 83 1.10 49.83 1. 10 49.83 0 0 0.34
125 2.75 124.59 2.75 124.59 2.75 124.19 2.75 124.59 2.75 124.59 0 0 0.33
250 5.50 249.19 5.50 249.19 5.50 249.19 5.50 249.19 5.50 249.19 0 0 0.32
750 17.00 770.25 17.00 770.25 16.50 747.60 16.50 747.60 16.75 758.93 13.08 1.72 1.19
1500 33.00 1495.21 33.50 1517.86 34.00 1540.52 33.50 1517.86 33.50 1517.86 18.50 1.22 1.19
2500 55.00 2492.02 54.50 2469.36 54.50 2469.36 54.50 2469.36 54.63 2475.26 11.33 0.46 0.99
Peak H = Peak Height (cm) Mean % C.V. =0.5%
S.D. = Standard Deviation
C.V. = Coefficient of Variation
3
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Table V(c)
Intra - Assay Slope = .0189
I = - .0840
Temazepam r = .9999
Concentration
added
ng/ml
1 2 3 4 Mean S.D. % CV % Differ.
between
added
and
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
25 0.40 25.56 0.40 25.56 0.40 25.56 0.40 25.56 0.40 25.56 0.0 0.0 2.24
50 0.90 51.95 0.90 51.95 0.80 46.67 0.90 51.95 0.88 50.90 2.64 5.19 1.80
125 2.25 123.23 2.25 123.23 2.25 123.23 2.25 123.23 2.25 123.23 0.0 0.0 1.42
250 4.50 240.02 4.50 240.02 4.50 240.02 4.50 240.02 4.50 242.02 0.0 0.0 3.19
750 14.50 769.99 14.00 743.59 14.00 743.59 14.00 743.59 14.13 750.46 13.20 1.76 0.06
1500 28.50 1509.15 28.00 1482.75 28.50 1482.75 28.00 1509.15 28.25 1495.95 15.24 1.02 0.27
2500 48.50 2565.08 47.50 2512.29 47.50 2459.49 46.50 2512.29 47.50 2512.29 43.11 1.72 0.49
Peak H = Peak Height (cm) Mean % C.V. = 1.4%
S.D. = Standard Deviation
C.V. = Coefficient of Variation
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Table V(d)
Ixitra - Assay Slope = .0283
I .0317
Oxazepam r = .99999
Concentration
added
ng/ml
1 2 3 4 Mean S.D. % cv % Diff
between
added
and
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
Peak
H
Cone.
found
25 0.70 25.90 0.60 22.36 0.70 25.90 0.70 25.90 0.68 25.19 1.77 7.03 0.76
50 1.40 50.67 1.30 47.13 1.40 50.67 1.40 50.67 1.38 49.79 1.77 3.55 0.06
125 3.50 125.00 3.50 125.00 3.50 125.00 3.50 125.00 3.50 125.00 0.0 0.0 0.00
250 7.00 248.88 7.00 248.88 7.00 248.88 7.00 248.88 7.00 248.88 0.0 0.0 0.45
750 21.50 762.08 21.00 744.39 21.00 744.39 21.00 744.39 21.13 748.99 8.85 1.18 0.13
1500 42.00 1487.65 42.50 1505.35 42.50 1505.35 41.50 1469.95 42.13 1492.25 16.95 1.14 0.52
2500 72.00 2549.46 70.50 2496.37 71.00 2514.06 70.00 2478.67 70.88 2509.64 30.22 1.20 0.35
Peak H = Peak Height (cm) Mean % C.V. =2.0%
S.D. = Standard Deviation
C.V. = Coefficient of Variation
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Table VI(a)
Inter - assay - Diazepam
Concentration
added
ng/ml
Day 1 Day 2 Day 3 Day 4 Mean
Concentration
found
S.D. %C.V. % Differei 
between 
added + 
foundP.H.
Cone.
found
P.H.
Cone.
found
P.H.
Cone.
found
P.H.
Cone.
found
25 0.30 24.81 0.25 25.71 0.30 27.26 0.20 25.39 25.79 1.05 4.07 3.16
50 0.60 50.25 0.50 50.20 0.55 49.93 0.50 53.02 50.85 1.45 2.85 1.70
125 1.50 126.56 1.25 123.67 1.25 113.42 1.25 122.10 121.44 5.66 4.66 2.85
250 3.00 253.75 2.50 246.13 2.75 249.47 2.50 237.22 246.64 7.01 2.84 1.34
750 8.50 720.09 7.50 735.95 8.50 770.10 8.00 743.79 742.48 20.88 2.81 1.00
1500 18.00 1525.60 15.50 1519.66 16.50 1496.59 16.00 1480.61 1505.62 20.84 1.38 0.37
2500 29.50 2500.69 25.50 2499.30 27.50 2494.29 27.50 2539.80 2508.52 21.03 0.84 0.34
Mean % C.V. = 2.8%
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Coefficient of Variation
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Table VI(b)
Inter - assay Desmethyl - diazepam
Concentration
added
ng/ml
Day 1 Day 2 Day 3 Day 4 Mean
Concentration
found
S.D. %c.v. % Différé: 
between 
added + 
foundP.H.
Conc.
found
P.H.
Conc.
found
P.H.
Conc.
found
P.H.
Conc.
found
25 0.60 26.16 0.55 24.88 0.60 25.43 0.60 23.32 24.95 1.21 4.15 0.20
50 1.10 48.08 1.10 50.00 1.10 48. 73 1.30 52.06 49.72 1.75 3.52 0.56
125 3.00 131.37 2.75 125.35 2.75 125.64 3.00 121.87 126.06 3.93 3.12 0. 85
250 5.50 241.00 5.50 250.94 5.50 253.82 6.50 265.59 252.84 10.12 4.00 1.14
750 16.50 723.18 16.50 753.33 16.00 743.24 18.50 758.34 744.52 15.55 2.09 0.73
1500 35.00 1534.17 32.50 1484.07 32.00 1489.01 36.00 1476.95 1496.05 25.89 1.73 0.26
2500 57.00 2498.60 55.00 2511.67 54.00 2514.44 61.00 2503.52 2507.06 7.30 0.29 0.28
% C.V. = 2.8%
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Coefficient of Variation
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Table VICe)
Inter - assay Temazepam
Concentration
added
ng/ml
Day 1 Day 2 Day 3 Day 4 Mean
Concentration
found
S.D. %C.V. % Differei 
between 
added + 
foundP.H.
Cone.
found
P.H.
Cone.
found
P.H.
Cone.
found
P.H.
Cone.
found
25 0.50 26.88 0.40 26.84 0.50 24.18 0.50 25.26 25.79 1.31 5.08 3.16
50 0.90 48.64 0.80 50.21 0.90 47.69 1.00 48.96 48.88 1.04 2.13 2.24
125 2.25 122.08 2.00 120.32 2.25 127.04 2.50 120.06 122.38 3.24 2.65 2.10
250 4.50 244.50 4.00 237.16 4.50 259.28 5.50 262.25 250.80 11.96 4.77 0.32
750 14.00 761.34 12.50 733.74 13.50 788.24 16.00 759.93 760.81 22.26 2.93 1.44
1500 27.00 1468.61 27.00 1580.85 25.00 1461.13 31.50 1494.59 1501.30 54.94 3. 66 0.09
2500 46.50 2529.50 42.00 2457.17 42.50 2492.66 52.50 2489.94 2492.07 29.60 1.19 0.32
Mean % C.V. = 3.2%
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Coefficient of Variation
3
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Table VI(d)
Inter - assay C.S. Oxazepam
Concentration
added
ng/ml
Day 1 Day 2 Day 3 Day 4 Mean
Concentration
found
S.D. %C.V. % Differei 
between 
added + 
foundP.H.
Cone.
found
P.H.
Cone.
found
P.H.
Cone.
found
P.H.
Cone.
found
25 0.70 24.49 0. 70 25.66 0. 80 25.52 0.70 24.16 24.96 0.75 3.01 0.16
50 1.40 49.78 1.40 50.11 1.40 47.50 1.50 49.59 49.12 1.13 2.30 1.76
125 3.50 125.65 3.50 123.49 3.50 124.45 4.00 129.05 125.66 2.43 1.93 0.53
250 7. 00 252.10 7.00 245.77 7.00 252.69 8.00 256.19 251.69 4.34 1.72 0.68
750 21.00 757.91 21.50 752.40 21.50 783.96 23.50 748.85 760.78 15.90 2.09 1.44
1500 42.00 1516.61 42.50 1486.12 40.50 1480.12 46.50 1479.90 1490.69 17.52 1.18 0.62
2500 68.50 2474.02 72.00 2516.82 68. 00 2487.71 79.00 2512.90 2497.90 20.46 0.82 0.09
Mean % C.V. = 1.9%
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Coefficient of Variation
Diazepam
Table VII
Precision and Reproducibility
Concentration added 
(ng/ml)
Mean (n=4) Concentration 
found + S.D.
(ng/ml)
C.V.
X
Difference 
between 
added + 
found
INTRA-ASSAY PRECISION (REPEATABILITY)
25 25.77 + 0.0 0.0 3.08
50 50. 29 ± 0.0 0.0 0.58
125 123.84 + 0.0 0.0 0.93
250 246.42 + 0.0 0.0 1.43
750 736.76 + 0.0 0.0 1. 77
1500 1492.69 + 23.59 1.58 0.49
2500 2524.85 + 69. 79 2.76 1.00
Mean % C. V. = 0. 6%
INTER-ASSAY REPRODUCIBILITY
25 25.79 + 1.05 4. 07 3. 16
50 50.85 ± 1.45 2.85 1.70
125 121.44 + 5.66 4.66 2.85
250 246.64 + 7.01 2. 84 1.34
750 742.48 + 20.88 2.81 1.00
1500 1505.62 + 20.84 1.38 0.37
2500 2508.52 + 21.03 0.84 0.34
Mean % C.V. = 2.8%
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Desmethyl diazepam
Table VII contd
Concentration added 
(ng/ml)
Mean (n=4) Concentration 
found + S. D .
(ng/ml)
C.V.
%
Difference 
between 
added + 
found
INTRA-ASSAY PRECISION (REPEATABILITY)
25 24.91 + 0.0 0.0 0.36
50 49.83 + 0.0 0.0 0.34
125 124.59 + 0.0 0.0 0.33
250 249.19 + 0.0 0.0 0.32
750 758.93 + 13.08 1.72 1.19
1500 1517.86 + 18.50 1.22 1.19
2500 2475.26 4* 11.33 0.46 0.99
Mean % C,,V. = 0..5%
INTER-ASSAY REPRODUCIBILITY
25 24.95 + 1.21 4.85 0.20
50 49.72 + 1.75 3.52 0.56
125 126.06 + 3.93 3. 12 0.85
250 252.84 + 10.12 4.00 1.14
750 744.52 + 15.55 2.09 0.73
1500 1496.05 + 25.89 1.73 0.26
2500 2507.06 + 7.30 0. 29 0.28
Mean % C.V. = 2.8%
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Table VII contd
Temazepam Precision and Reproducibility
Concentration added 
(ng/ml)
Mean (n=4) Concentration 
found + S.D. 
ng/ml
C.V. Difference 
% between 
added + 
found 
Concentration (%)
INTRA-ASSAY PRECISION (REPEATABILITY)
25 25.56 + 0.00 0. 00 2. 24
50 50.90 + 2.64 5. 19 1.80
125 123.23 + 0.00 0 . 00 1.42
250 242.02 + 0.00 0 . 00 3.19
750 750.46 + 13.20 1.76 0.06
1500 1495.95 ± 15.24 1.02 0.27
2500 2512.29 + 43.11 1. 72 0.49
Mean % C. V. = 1..4%
INTER-ASSAY REPRODUCIBILITY
25 25.79 + 1.31 5. 08 3. 16
50 48.88 + 1.04 2.13 2.24
125 122.38 + 3.24 2.65 2. 10
250 250.80 + 11.96 4. 77 0.32
750 760.81 ± 22.2.6 2.93 1.44
1500 1501.30 + 54.94 3.66 0.09
2500 2492.07 + 29.60 1. 19 0.32
Mean % C.V. =3.2%
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Oxazepam Precision and Reproducibility
Table VII contd
Concentration added 
(ng/ml)
Mean (n=4) Concentration 
found + S. D.
(ng/ml)
C.V.
%
Difference 
between 
added + 
found (%) 
Concentration
INTRA-ASSAY PRECISION (REPEATABILITY)
25 25.19 ± 1.77 7.03 0.76
50 49.79 + 1.77 3.55 0.06
125 125.00 + 0.00 0.00 0.00
250 248.88 + 0.00 0.00 0.45
750 748.99 + 8.85 1. 18 0. 13
1500 1492.25 + 16.95 1.14 0.52
2500 2509.64 + 30.22 1 .'20 0.35
Mean % C. V. = 2.0%
INTER-ASSAY REPRODUCIBILITY
25 24.96 + 0.75 3. 01 0. 16
50 49. 12 4 1.13 2.30 1.76
125 125.66 + 2.43 1.93 0.53
250 251.69 ± 4.34 1.72 0.68
750 760.78 + 15.90 2.09 1.44
1500 1490.69 ± 17.52 1.18 0.62
2500 2497.86 + 20.46 0.82 0.09
Mean % C.V. = 1.9%
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Table VIII 
Recoveries - Diazepam
Method 1
PEAK HEIGHTS
Concentration
ng/ml
Authentic Standards Recovered Standards % Recovery
1 2 Mean 1 2 Mean
25 0.3 0.3 0.3 0.3 0.3 0.3 100 %
50 0.6 0.6 0.6 0.6 0.6 0.6 100 %
125 1.5 1.5 1.5 1.5 1.5 1.5 100 %
250 3.0 3.0 3.0 3.0 3.0 3.0 100 %
750 9.0 9.5 9.25 9.0 9.0 9.0 94.7%
1500 19.0 19.0 19.0 18.0 18.0 18. 0 94.7%
2500 30.0 30.0 30.0 32.0 30.5 31.25 104.2%
Mean Percentage Recovery + SD =99.1%
Method 2
Regression line for set A: y = 0.0121 X + 0.0576 
Regression line for set B: y = 0.0124 X - 0.1304
% Recovery = x 1QQ = 102i48%
Mean recovery by both methods = 100.79%
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Table Vili contd
Recovery - Desmethyl - diazepam
Method 1
PEAK HEIGHTS
Concentration
ng/ml
Authentic Standards Recovered Standards % Recovery
1 2 Mean 1 2 Mean
25 0.5 0.5 0. 5 0 .45 0.45 0.45 90
50 0.9 0.9 0. 9 0.9 0.9 0.9 100
125 2.3 2.2 2. 25 2.25 2.25 2. 25 100
250 5 0 5.0 5. 0 4 .3 4.7 4.5 90
750 14 .4 14.1 14. 25 14 .0 14.5 14. 25 100
1500 29 1 28.4 28. 75 27 .9 28. 6 28. 25 98.3
2500 44 44 44 44 44 44 100
Mean Percentage Recovery = 96.9%
Method 2
Regression line for set A: y = 0.0179 X + 0.3926 
Regression line for set B: y = 0.0179 X + 0.2562
Recovery = 0-0179 10Q = looy
0.0179 /o
Mean recovery by both methods = 98.5%
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Table Vili contd
Recoveries Temazepam
Method 1
PEAK HEIGHTS
Concentration
ng/ml
Authentic Standards Recovered Standards % Recovery
1 2 Mean 1 2 Mean
25 0.5 0.5 0.5 0.4 0.5 0.45 90
50 0.9 0.9 0.9 0.9 0.9 0.9 100
125 2.5 2.0 2.25 2.25 2.25 2.25 100
250 5.0 5.0 5.0 4.5 4.5 4.5 90
750 14. 0 14.5 14. 25 14.5 14.0 14.25 100
1500 28.5 29 28. 75 28.5 28. 0 28. 25 98.3%
2500 44.0 44.0 44. 0 46.5 47.5 47 106.8 %
Mean Percentage Recovery = 97.9%
Method 2
Regression line for set A: y = 0.0179 X + .3926 
Regression line for set B: y = 0.0188 X - .0568
% Recovery = 0.01880.0179 1U5. d/o
Mean recovery by both methods = 101.47%
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Table VIII contd
Recoveries Oxazepam
Method 1
PEAK HEIGHTS
Concentration
ng/ml
Authentic Standards Recovered Standards % Recovery
1 2 Mean 1 2 Mean
25 0.6 0. 7 0.65 0.7 0.6 0.65 100
50 1.3 1.4 1. 35 1.4 1.3 1.35 100
125 3.5 3.5 3.5 3.5 3.5 3.5 100
250 7.0 7.5 7.25 7.0 7.0 7.0 96.6
750 21.5 20.5 21.0 21.5 21 21.25 101. 2
1500 42.5 41.5 42 42 42.5 CNCN 100.6
2500 65 65 65 70 71 70.5 108.5
Mean Percentage Recovery = 100.99%
Method 2
Regression line for set A: y = 0.0263 X + 0.5504
Regression line for set B: y = 0.0282 X - 0.0318
% Recovery = x 100 = 107.22%
Mean % recovery by both methods = 104.11%
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6.2.2.5. Interference Study
Seven other members of the benzodiazepines were tested for 
possible interference with the measured substances. As can 
be seen from the chromatogram in Fig 6  no other member of 
the benzodiazepines tested interfered with the determination 
of temazepam and desmethyl-diazepam. Lorazepam interfered 
with oxazepam and midozalam interfered with diazepam. 
Flurazepam and medazepam did not elute under these 
chromatographic conditions. Members of the tricyclics were 
also tested for possible interference but did not elute at 
similiar retention times to any of the drugs under study.
6.2.3. CONCLUSION
For routine monitoring of diazepam and its metabolites the 
on-line solid phase extraction technique described achieves 
a high recovery rate (>98%) for all four drugs. The method 
circumvents the need for lengthy liquid-liquid extraction 
and overcomes the problem of protein binding which often 
lowers the recovery for these compounds due to their being 
extensively protein bound. The addition of salicylic acid 
to preferentially bind the plasma proteins releases the 
benzodiazepines from the concentration column for subsequent 
analysis on the analytical column. This is a procedure 
which may be applied to other protein bound drugs and is a 
simple alternative to their release by hydrolysis using 
enzymes.
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5Fig. 6: Chromatogram obtained for members of the
benzodiazepines showing interference with 
diazepam and its metabolites. 1 = 7— 
aminonitrazepam, 2 = clonazepam, 3 = nitrazepam, 
4 = lorazepam, 5 = oxazepam, 6 = temazepam,
7 = desmeChyl-diazepam, 8 = diazepam,
9 = nridozalem.
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The precision and accuracy of the method are excellent as 
denoted by the coefficients of variation and the percentage 
differences between added and found amounts of the drugs 
indicated above. The limit of detection may be improved by 
the use of a larger injection volume but this will shorten 
the lifetime of the concentration column considerably.
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HPLC Determination of 
Diazepam and its metabolites 
in Plasma using an 
Extraction Technique.
6.3. INTRODUCTION TO THE EXTRACTION TECHNIQUE
A sensitive high-performance liquid chromatographic 
(HPLC) method for the determination of plasma levels of 
diazepam and its metabolites in human plasma is 
described. The drugs were extracted from plasma into 
diethyl ether. After evaporation of the solvent, the 
residue is reconstituted in the mobile phase and 
quantified by HPLC on a reverse phase Lichrosorb Cg 
column using methanol - phosphate buffer (50:50) as the 
mobile phase with U.V. detection at 246 nm. The limit 
of quantitation was 25ng/ml in plasma, using a 1ml 
plasma sample and a 25 u^l injection from a 
reconstituted volume of 100 >ul. The mean overall 
recoveries of the drugs from plasma were 67.7%, 77.8%,
78.7% and 75.3% for diazepam, desmethyl diazepam, 
temazepam and oxazepam respectively. Mean percentage 
coefficients of variation for intra-assay and 
inter-assay precision respectively were 5.2% and 1.9% 
for diazepam, 4.1% and 2.8% for desmethyl diazepam, 
5.1% and 3.2% for temazepam and 3.6% and 2.1% for 
oxazepam.
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6.3.1. EXPERIMENTAL
Reagents, Instrumentation, Chromatography and Preparation of 
standards were as described in section 6 .2 .1 .
6 .3.1.1. Extraction Procedure
Plasma (1ml) spiked with 50 a^l of each drug was mixed with 
100 mg of a 3 : 1 dry mixture of NaHCOg and Na2 C03  by
vortexing for 20 sec. After the addition of diethyl ether 
(7ml), the drugs were extracted by vortex mixing for 60
seconds followed by centrifugation for 10 minutes at 700g. 
The organic phase was then transferred into a clean 
poly-propylene tube which is placed in a water bath at 40^ 
and the solvent evaporated under a gentle stream of oxygen 
free nitrogen. The residue was reconstituted in 100 ^ j1 of 
the mobile phase directly prior to injection and 25 j i l
injected for analysis onto the analytical column. The 
chromatograms are shown in fig 7.
6 .3.1.2. Calibration and Calculation
Evaluation of the assay was carried out using seven-point
calibration standards in the concentration range 25 - 2500 
ng/ml of the drugs in plasma. No internal standard was 
used.
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IFig. 7: Chromatograms obtained for (a) human drug
free plasma, (b) the same plasma spiked with 
25ng/ml of each drug and (c) spiked with 
250ng/ml of each drug. The injection volume 
is 25ul from a reconstituted volume of 
l O O u l .
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The majority of methods used for extracting benzodiazepines 
from biological fluids have been based on the partitioning 
of the drugs in favour of an organic solvent from a (usually 
alkaline) buffered aqueous solution. Organic solvents 
employed for this purpose have included n-hexane [76], 
toluene [77,78], chloroform [79,80], octanol [81], diethyl 
ether [82,83,84], n-butyl chloride [85,86] or n-butylacetate 
[87,40]. Mixed solvents have also been used for this 
purpose. In an article by Clifford and Smyth [7] over half 
of the extraction methods reviewed had been made using 
diethyl ether. Specifically for diazepam and its 
metabolites diethyl ether has been the solvent of choice 
with one publication reporting the use of a 
benzene-methylene chloride mixture which gave poor recovery.
Among the solvents tested in our own laboratory were 
ethyl-acetate, methylene chloride - toluene mixture (1:9), 
diethyl ether and chloroform. Ethyl acetate gave reasonable 
recovery but the chromatograms were not clean, also some of 
the samples emulsified upon vortexing. Interfering peaks 
eluting with similar retention times to temazepam and 
desmethyl diazepam were recorded from extracts using 
methylene chloride - toluene. Use of chloroform causes 
solid material to separate out resulting in low recovery of 
the drugs.
6.3.1.3. Extraction Solvent
350
Diethyl ether was chosen as the extracting solvent as it is 
easily evaporated. Its limited polarity reduces the amount 
of endogenous material it extracts from biological fluids 
and being less dense than water, it is removed from 
centrifuged mixtures with less contamination from the 
aqueous layer than occurs with a denser liquid.
6 .3.1.4. Choice of Buffer for extraction
Having chosen diethyl ether as the extracting solvent 
various buffers were investigated. In a review of 
extraction techniques by Stevens [58], he points to ether 
extraction of aqueous ammonical solutions as giving the 
cleanest extracts. The extraction procedure used by him is 
shown in Fig 8 .
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2 0 0  ;ul of plasma
700 1 of distilled water
1 0 0  Ail of ammonia solution (sp.gr. 0.880) 
5 ml of diethyl ether
Shake for 15 mins
Centrifuge at 3,600 r.p.m. for 2 min
Upper clear colourless organic layer 
is removed
Evaporate to dryness
Reconstitute in 50 ;ul of methanol
Inject total volume for analysis
Fig 8 : Extraction procedure for the
benzodiazepines used by 
Stevens [58].
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A necessary pre-requisite for successful extraction is the 
maintenance of the blood proteins in a water-soluble form, 
any protein precipitation tends to adsorb drug molecules and 
reduce recoveries [8 8 ]. The relatively large ammonical 
constituent/blood ratios employed ensured that all mixtures 
remain clear and free of solid matter during extraction. 
However, when we repeated this procedure in our laboratory 
we could not obtain clear chromatograms under the 
chromotographic conditions described in the assay.
Previously other workers in our laboratory had found LiCl to 
be useful for the clean up of plasma samples during 
extraction. However, in the present study we found a 
mixture of Na2 CO^ and NaHCO^ to be the most effective for 
sample clean up and good recovery of all four drugs.
6 .3 .1.5. Single vs Double Extraction
In order to improve the recovery of the drug and its 
metabolites a double extraction using diethyl ether may be 
carried out. This was found to improve recovery by up to 
15%, however, it lengthens the procedure somewhat. A single 
step procedure was employed in this study.
6.3.2. RESULTS AND DISCUSSION
6.3.2.1. Limit of Detection
Under the procedural conditions the limit of detection, 
using a 25 ul injection from a reconstituted volume of 100 
_ul, was 25 ng/ml for each of the four drugs in plasma.
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6 . 3 . 2 . 2 .  Precision and Accuracy
Intra-assay variability was determined at seven 
concentrations in quadruplicate at levels of 25, 50, 125,
250, 750, 1500 and 2500 ng/ml of each drug in plasma.
Inter-assay variability was determined singly and at the 
same seven concentrations in four replicate runs. The 
precision of the method (mean coefficient of variation) for 
the values of the recovered determinate standards when 
calculated as "unknown" against the linear regression lines 
for intra-assay and inter-assay were respectively 5.2% and 
1.9% for diazepam, 4.1% and 2.8% for desmethyl diazepam, 
5.1% and 3.2% for temazepam, 3.6% and 2.1% for oxazepam. 
(Tables IX (a), (b), (c) and (d), X (a), (b), (c) and (d)
and Table XI).
6 . 3.2.3. Linearity
The correlation coefficients under intra-assay precision 
were better than 0.999 and the intercepts did not differ 
significantly from zero.
6 .3.2.4. Recovery
The recoveries of the four drugs was calculated as described 
in the column switching method. Using this method in the 
concentration range 25 - 2500 ng/ml, the mean overall
recoveries were 67.7%, 77.8%, 78.7% and 75.3% for diazepam, 
desmethyl diazepam, temazepam and oxazepam respectively. 
(Table XII).
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Table IX(a)
Intra-assay Extraction Diazepam
Slope = .0197
Intercept = - .1814
Concentration
added
ng/ml
1 2 3 4 Mean S.D. % CV % Diff
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
25 0.30 24.46 0.30 24.46 0.30 24.46 0.30 24.46 0.30 24.46 0 0 2.16
50 0.80 49.86 0.80 49.86 0.80 49.86 0. 80 49.86 0.80 49.86 0 0 0.28
125 2.40 131.15 2.50 136.23 2.60 141.31 2.40 131.15 2.48 135.21 4. 86 3.59 8.17
250 4.40 232.76 4.80 253.09 4.80 253.09 5.20 273.41 4.80 253.09 16.60 6.56 1.24
750 14.80 761.15 15.60 801.80 12.00 618.89 12.00 618.89 13.60 700.18 95.32 13.61 6.64
1500 27.20 1391.15 27.20 1391.15 31.60 1614.70 31.60 1614.70 29.40 1502.92 129.07 8.59 0.20
2500 48. 00 2447.92 52.00 2651.15 51.20 2610.51 48.00 2447.92 49.80 2539.38 106.90 4.21 1.58
r = .999 Mean % C.V. = 5.2%
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Coefficient of Variation
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Table IXÇb)
Intra-assay Extraction Desmethyl Diazepam
Slope = .0297
Intercept = .0593
Concentration
added
ng/ml
1 2 3 4 Mean S.D. % CV % Diff
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
25 0.80 24.96 0.80 24.96 0.80 24.96 0.80 24.96 0. 80 24.96 0. 0 0.00 0.17
50 1.50 48.55 1.50 48.55 1.50 48.55 1.50 48.55 1.50 48.55 0.0 0.00 2.90
125 3.70 122.68 3.90 129.42 3.70 122.68 3.70 122.68 3.75 124.36 3.37 2.71 0.50
250 7.20 240.62 7.20 240.62 8.00 267.58 8.40 281.05 7.70 257.47 20.22 7.85 3.00
750 23.60 793.25 25.20 847.16 20.00 671.94 21.20 712.37 22.50 756.18 78.88 10.43 0.82
1500 47.20 1588.49 45.20 1521.10 43.60 1467.18 43.60 1467.18 44.90 1510.99 57.58 3.81 0.73
2500 71.20 2397.21 76.00 2558.96 76.00 2558.96 71.20 2397.21 73. 60 2478.08 93.39 3.77 0.88
r = .9999 % C.V. = 4.1%
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Coefficient of Variation
357
Table IXÇc)
Intra-assav Extraction Temazepam
Slope = 0.0306
Intercept = - .0138
Concentration
added
ng/ml
1 2 3 4 Mean S.D. % cv % Diff
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
25 0.80 25.31 0.80 25.31 0.80 25.31 0.80 25.31 0.80 25.31 0.00 0.00 1.22
50 1.60 50.18 1.60 50.18 1.60 50.18 1.60 50.18 1.60 50.18 0.00 0.00 0.36
125 4.00 124.80 4.20 131.02 4.00 124.80 3. 80 118.58 4.00 124.80 5.08 4.07 0.16
250 7.20 224.30 8.00 249.17 8.00 249.17 8.60 267.83 7.95 247.62 17.86 7.21 0.95
750 25.20 783.96 27.60 858.58 20.80 647.15 22.00 684.46 23.90 743.54 96.00 12.91 0.86
1500 44.40 1380.93 48.80 1517.74 49.20 1530.17 50.80 1579.92 48.30 1502.19 85.19 5.67 0.15
2500 76.80 2388.32 84.00 2612.19 84.80 2637.06 76.80 2388.32 80.60 2506.47 136.81 5.46 0.26
R = .99999 % C.V. = 5.1%
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Coefficient of Variation
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Table IX(d)
Slope = .0355
Intercept = .1513
Intra-assay Extraction Oxazepam
Concentration
added
ng/ml
1 2 3 4 Mean S.D. % cv % Diff
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
25 1.00 23.94 1.00 23.94 1.00 23.94 1.00 23.94 1.00 23.94 0 0 4.24
50 2.00 52.15 2.00 52.15 2.00 52.15 2.00 52.15 2.00 52.15 0 0 4.30
125 4.10 111.39 4.50 122.67 4.50 122.67 4.60 125.49 4.43 120.70 6.25 5.18 3.44
250 8.40 232.69 9.20 255.25 9.60 266.54 9.60 266.54 9.20 255.25 15.96 6.25 2.10
750 28.00 785.59 28.00 785.59 26.00 729.17 27.60 774.30 27.40 768.66 26.86 3.49 2.49
1500 54.40 1530.31 56.00 1575.44 50.80 1428.75 50.80 1428.75 53.00 1490.81 73.99 4.96 0.61
2500 92.80 2613.54 81.60 2297.60 88.80 2500.70 90.40 2545.84 88.40 2489.42 136.03 5.46 0.42
r = .9999 % C.V. = 3.6%
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Coefficient of Variation
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Table X Ça)
Inter-assay Extraction Diazepam
Concentration
added
ng/ml
1 2 3 4 Mean S.D. %c.v. % Diff
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
Conc.
found
25 0.30 24.77 0.40 25.57 0.60 24.82 0.50 25.87 25.26 0.55 2. 18 1.04
50 0.80 51.63 0.80 50.44 1.10 49.41 1.00 51.67 50.79 1.08 2.13 1.58
125 2.20 126.84 2.00 125.03 2.70 128.10 2.50 129.09 127.27 1.75 1.38 1.82
250 4.40 245.03 4.00 249.36 5.20 251.06 4.40 227.15 243.15 10.96 4.51 2.74
750 13.60 739.27 11.60 721.79 15.20 742.90 14.40 743.25 732.30 10.55 1.44 2.36
1500 27.20 1469.89 24.00 1492.59 30.40 1490.49 29.20 1507.08 1490.01 15.31 1.03 0.67
2500 47.20 2544.33 40.80 2536.92 51.20 2513.50 48.80 2518.64 2528.35 14.65 0.58 1.13
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Coefficient of Variation
C.V. = 1.9%
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Table X(b)
Inter-assay Extraction Desmethyl - diazepam
Concentration
added
ng/ml
1 2 3 4 Mean S.D. %C.V. % Diff
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
Conc.
found
25 0.70 24.74 0.70 24.93 0.80 24.42 0.90 24.02 24.53 0.40 1.63 1.88
50 1.40 50.65 1.30 49.19 1.40 45.64 1.80 53.84 49.83 3.40 6.82 0.34
125 3.40 124.69 3.20 126.01 4.10 141.10 3.90 123.42 128.81 8.27 6.42 3.05
250 6.80 250.56 6.40 255.40 7.20 250.71 7.60 246.02 250.67 3.83 1.53 0.27
750 20.40 754.02 18.40 740.58 21.20 745.72 22.40 736.42 744.19 7.58 1.02 0.77
1500 40.00 1479.61 37.20 1500.71 42. 80 1509.44 46.40 1531.67 1505.36 21.55 1.43 0.36
2500 68.00 2516.16 62.00 2503.43 70.40 2485.32 75.20 2485.96 2497.72 14.89 0.60 0.09
Mean % C.V. = 2.8%
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Coefficient of Variation
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Table X(c)
Inter-assay Extraction Temazepam
Concentration
added
ng/ml
1 2 3 4 Mean S.D. %C.V. % Diff
between
added
and
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
Conc.
found
25 0. 70 25.08 0.70 25.04 1. 00 23. 12 0.90 25.55 24.70 1. 08 4.37 1.20
50 1.40 50.91 1.40 50.95 1.70 47.12 1.80 52.56 50.39 2.31 4.58 0.78
125 3.40 124.71 3.40 124.97 4.50 143.12 4.20 124.59 129.35 9.18 7.10 3.48
250 6.80 250.17 6.80 250.80 7.60 249.43 8.00 238.64 247.26 5.77 2.33 1.10
750 20.00 737.23 19.60 724.51 22.00 743.21 24.00 718.83 730.95 11.23 1.54 2.54
1500 40.00 1475.21 40.80 1509.09 44.00 1497.58 51.20 1535.15 1504.26 24.94 1.66 0.28
2500 68.80 2537.91 68.00 2515.72 73.20 2498.85 83.60 2507.53 2515.00 16. 75 0.67 0.60
Mean C.V. = 3.2%
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Cofficient of Variation
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Table X(d)
Inter-assay Extraction Oxazepam
C one ent r at ion 
added 
ng/ml
1 2 3 4 Mean S.D. %C.V. % Diff
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
P.H. Conc.
found
Conc.
found
25 0.80 24.82 0.70 24.39 0.90 23.88 0.90 24. 92 24.50 0.47 1.92 2.00
50 1.60 51.17 1.50 50.67 1.70 47.59 1.90 50.87 50.08 1.67 3.33 0.16
125 3.80 123.63 3.80 126.22 4.80 139.45 4.80 126.13 128.86 7.16 5.56 3.09
250 7.60 248.80 7.60 251.05 8.40 246.13 9.60 250.70 249.17 2.25 0.90 0.33
750 22.80 749.45 22.80 750.37 25.60 755.82 28.00 728.21 745.96 12.16 1.63 0.54
1500 45.60 1500.43 45.60 1499.35 50.80 1502.57 57.20 1486.00 1497.09 7.51 0.50 0.19
2500 76.00 2501.74 76.00 2498.00 84.00 2486.39 97.60 2534.46 2505.15 20.61 0.82 0.21
Mean % C.V. = 2.1%
P.H. = Peak Height (cm)
S.D. = Standard Deviation
C.V. = Coefficient of Variation
Table XI
Extraction
Diazepam
Concentration added 
(ng/ml)
Mean (n=4) 
found 4 
(ng/ml)
Concentration 
; S.D.
C.V.
%
Difference 
between 
added 4 
found
INTRA-ASSAY PRECISION (REPEATABILITY)
25 24.46 4 0.00 0.00 2.16
50 49.86 4 0.00 0.00 0.28
125 135.21 4 4.86 3.59 8. 17
250 253.09 ± 16.60 6.56 1.24
750 700.18 4 95.32 1.3.61 6.64
1500 1502.92 4 129.07 8.59 0.20
2500 2539.38 4 106.90 4.21 1.58
Mean % C.,V. = 5. 2%
INTER-ASSAY REPRODUCIBILITY
25 25.26 4 0.55 2. 18 1.04
50 50.79 4 1.08 2.13 1.58
125 127.27 4 1.75 1.38 1. 82
250 243.15 4 1,0.96 4.51 2.74
750 732.30 4 10.55 1.44 2.36
1500 1490.01 4 15.31 1.03 0.67
2500 2528.35 4 14.65 0.58 1.13
Mean % C.V. = 1.9%
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Table XI eontd
Extraction
Temazepam
Concentration added 
(ng/ml)
Mean (n=4) Concentration 
found + S. D .
(ng/ml)
C.V.
%
Difference 
between 
added + 
found
INTRA-ASSAY PRECISION (REPEATABILITY)
25 25.31 + 0.00 0.0 1.22
50 50.18 + 0.00 0.0 0.36
125 124.80 + 5.08 4.07 0.16
250 247.62 + 17.86 7.21 0.95
750 743.54 + 96.00 12.91 0.86
1500 1502.19 ± 85. 19 5.67 0.15
2500 2506.47 + 136.81 5.46 0.26
Mean % C..V. = 5. 1%
INTER-ASSAY Reproducibility
25 24.70 + 1.08 4.37 1.20
50 50.39 + 2.31 4.58 0.78
125 129.35 + 9. 18 7.10 3.48
250 247.26 + 5.77 2.33 1. 10
750 730.95 + 11.23 1.54 2.54
1500 1504.26 + 24. 94 1.66 0.28
2500 2515.00 + 16.75 0.67 0.60
Mean % C.V. = 3.2%
364
Table XI contd
Extraction
Desmethyl Diazepam
Concentration added 
(ng/ml)
Mean (n=4) Concentration 
found + S.D.
(ng/ml)
C.V.
%
Difference 
between 
added + 
found
INTRA-ASSAY PRECISION (REPEATABILITY)
25 24.96 ± 0.00 0.00 0.17
50 48.55 ± 0.00 0.00 2.90
125 124.36 + 3.37 2.71 0.50
250 257.47 + 20.22 7.85 3.00
750 756.18 + 78.88 10.43 0.82
1500 1510.99 + 57.58 3.81 0.73
2500 2478.08 4* 93. 39 3.77 0.88
Mean % C..V. = 4. 1%
INTER-ASSAY REPRODUCIBILITY
25 24.53 + 0.40 ] .63 1.88
50 49.83 + 3.40 6.82 0.34
125 128.81 + 8.27 6.42 3.05
250 250.67 + 3.83 1.53 0.27
750 744.19 + 7.58 1.02 0. 77
1500 1505.36 + 21.55 1.43 0.36
2500 2497.72 + 14.89 0.60 0.09
Mean % C.V. = 2.8%
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Table XI
Extraction
Oxazepam
Concentration added 
(ng/ml)
Mean (n=4) Concentration 
found + S. D .
(ng/ml)
C.V.
%
Difference 
between 
added + 
found
INTRA-ASSAY PRECISION (REPEATABILITY)
25 23.94 + 0.00 0.00 4.24
50 52.15 + 0.00 0.00 4. 30
125 120.70 + 6.25 5.18 3.44
250 255.25 + 15.96 6.25 2. 10
750 768.66 + 26.86 3.49 2.49
1500 1490.81 + 73.99 4.96 0.61
2500 2489.42 + 136.03 5.46 0.42
Mean % C.,V. = 3,.6%
INTER-ASSAY REPRODUCIBILITY
25 24.50 + 0.47 1.92 2.00
50 50.08 + 1.67 3.33 0. 16
125 128.86 + 7.16 5.56 3.09
250 249.17 + 2.25 0.90 0.33
750 745.96 + 12. 16 1.63 0.54
1500 1497.09 + 7.51 0.50 0. 19
2500 2505.15 + 0.82 0.82 0.21
Mean % C.V. = 2.1%
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Table XII
Extraction Recoveries
Method 1
DIAZEPAM
Concentration Added 
ng/ml
Peak Heights (cm) % Recovery
Authentic
standards
Recovered
standards
25
(1)
0.6
(2)
0.6
Mean
0.6
(1)
0,4
(2)
0.4
Mean
0.4 66.7
50 1.3 1.3 1.3 0.9 0.7 0.8 61.6
125 3.2 3.4 3.3 2.2 1.8 2.0 60.6
250 6.8 6.0 6.4 4.4 3.6 4.0 62.5
750 18.0 18.4 18.2 13.2 11.2 12.2 67.0
1500 38.4 39.2 38.8 27. 2 23.6 25.4 65.5
2500 61.6 61.6 61.6 47.2 40.8 44.0 71.4
Mean % Recovery = 65.0%
Method 2
Regression line for set A: 0.0249 X + 0.1131
Regression line for set B: 0.0175 X - 0.2892
% Recovery = 0.0175 x 100 = 70.35%
0.0249
Mean recovery by both methods = 67.7%
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Table XII contd
Extraction Recoveries
DESMETHYL DIAZEPAM
Method 1
Concentration Added 
ng/ml
Peak Heights (cm) % Recovery
Authentic
standards
Recovered
standards
(1) (2) Mean (1) (2) Mean
25 0.9 0.9 0.9 0. 7 0.7 0.7 77.77
50 1.7 1.8 1.75 1.4 1.3 1.35 77.14
125 4.5 4.5 4.5 3.4 3.2 3.3 73.33
250 9.2 9.6 9.4 6.8 6.4 6.6 70.21
750 24.4 24.4 24.4 20.4 18.4 19.4 79.51
1500 50.0 50.8 50.4 40.0 37.2 38.6 76.58
2500 81.6 81.6 81.6 68.0 62.0 65.0 79.65
Mean % Recovery = 76.31%
Method 2
Regression line for set A: 0.0327 X + 0.3603
Regression line for set B: 0.0259 X + .0226
% Recovery = 0.0259 x 100 = 79.24%
0.0327
Mean recovery by both methods = 77.8%
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Table XII çontd
Extraction Recoveries
Method 1
TEMAZEPAM
Concentration Added 
ng/ml
Peak Heights cm) % Recovery
Authentic
standards
Recovered
standards
(1) (2) Mean (1) (2) Mean
25 0.9 0.9 0. 9 0.7 0.7 0.7 77.8
50 1.8 1.8 1.8 1.4 1.4 1.4 77.8
125 4.4 4.8 4.6 3.4 3.4 3.4 73.9
250 9.2 9.2 9.2 6.8 6.8 6.8 73.9
750 25. 2 25.2 25. 2 20.0 19.6 19.8 78. 6
1500 52.0 50.8 51.4 40.0 40.8 40.4 78.6
2500 85.2 85. 2 85.2 68.8 68.0 68.4 80.3
Mean % Recovery = 77.25%
Method 2
Regression line for set A: 0.0340 X + 0.1734
Regression line for set B: 0.0272 x - 0.1017
% Recovery = 0.0272 x 100 = 80.10%
0.0340
Mean recovery by both methods = 78.7%
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Table XIX
Extraction Recoveries
Method 1
OXAZEPAM
Concentration Added 
ng/ml
Peak Heights (cm) % Recovery
Authentic
standards
Recovered
standards
(1) (2) Mean (1) (2) Mean
25 0.9 1.0 0.95 0.7 0.7 0.7 73.68
50 2.0 2.0 2.0 1.6 1.5 1.55 77.50
125 5.3 5.4 5.35 3.8 3.8 3.8 71.03
250 10.8 10.8 10.8 7.6 7.6 7.6 70.37
750 29.2 29.2 29.2 22.8 22.8 22.8 78.08
1500 60.0 61.2 60.6 45.6 45.6 45.6 73.55
2500
J
.00.0 99.2 99.6 76.0 76.0 76.0 76.30
Mean % Recovery = 74.4%
Method 2
Regression line for set A: 0.0399 X + 0.1507
Regression line for set B: 0.0304 X - 0.0059
% Recovery = 0.0304 x 100 = 76.27%
0.0399
Mean recovery by both methods = 75.3%
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6.4. COMPARISON
The aim of any sample preparation technique is the isolation 
of the drug from the biological medium in which it occurs in 
a way that is selective and provides the drug in solution in
a quantity appropriate for detection. In this study we
compared an on-line solid phase extraction procedure (method 
A) with a liquid-liquid extraction procedure (method B).
Both methods provide a comparable limit of detection i.e 
25ng/ml, but for method A a sample volume of only 250 j^a1 is
required, for method B, 1 ml of plasma is used. This is an
important factor in pharmacokinetic studies of diazepam and 
its metabolites in small animals.
The reproducibility of the assays using the two methods as 
denoted by the % C.V. under intra-assay precision show that 
method A is superior in terms of precision. It is a simple 
one step procedure so that losses due to such factors as 
incomplete extraction and losses during evaporation are 
eliminated rendering it more precise. The reproducibility 
of the extraction procedure could be improved by the use of 
an internal standard but this highlights yet another 
advantage of the column switching procedure i.e the 
elimination of the search for a suitable internal standard, 
giving adequate reproducibility using external
standardisation.
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Recovery is around 100% using this on-line solid phase 
extraction procedure. It is much less using liquid - liquid 
extraction e.g. 67.7% for diazepam, 77.8% for desmethyl 
diazepam, 78.7% for temazepam and 75.3% for oxazepam.
Column - switching procedures may take longer to develop 
than extraction procedures but are much less time consuming 
to operate. The fewer steps and methods used in any given 
protocol, the simpler, more convenient, cost effective and 
less time-consuming it is. Simple protocols lead to 
increased accuracy, selectivity, reproducibility and safety.
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SUMMARY
A new high-performance liquid chromatographic method for the determination of amitriptyline 
md its metabolites, nortriptyline, 10-hydroxynortriptyline and 10-hydroxyamitriptyline, in plasma 
is described which uses direct injection and a column-switching valve. The method is based on the 
Bnrichment of drugs on a reversed-phase concentration column, packed with Corasil RP. The enriched 
drugs were then separated, using back-flush mode on a bonded-phase CN column using an isocratic 
acetonitrile-acetate buffer (60:40, v /v) mobile phase. The validation of the method showed excellent 
sensitivity, precision and reproducibility. The limit of detection, using a 250-//1 direct injection of 
plasma, was between 5 and 10 ng/ml for each of the four drugs. The mean coefficient of variation for 
intra- and inter-assay was better than 5%. The method showed obvious advantages over conventional 
extraction procedures in terms of speed and ease of sample handling. The method has been success­
fully applied to the samples from patients receiving oral doses of amitriptyline.
INTRODUCTION
Tricyclic antidepressants, TCAs (Fig. 1), are widely used in the treatment of 
patients who are suffering from depression. The concentration of these drugs in 
plasma and the effect on depression symptoms is controversial [ 1 ] but it is very 
important that their therapeutic levels be monitored so that therapy can be made 
optimal. Several reports have shown that there are large individual variations in 
plasma concentrations among patients receiving the same dosage of these drugs 
[2-4],
Most existing methods for the determination of TCAs have been reviewed [ 5,6 ]. 
Gas chromatography (GC) using a variety of detection systems has been applied.
0378-4347/87/$03.50 ©  1987 Elsevier Science Publishers B.V.
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Fig. 1. Chemical structure of amitriptyline and its metabolic pathway.
hese include flame-ionization detection (FID) [7-10], election-capture detec- 
on (ECD) [ 10-13],nitrogen-phosphorusdetection (NPD) [14-16] andmass 
agmentography [ 17 ]. Since 1975 there has been extensive development of high- 
erformance liquid chromatography (HPLC) as a method of determination for 
lasma levels of tricyclics and currently rivals GC-NPD as the method of choice
18-26],
Common to all these methods is the need for the extraction of the drugs, which 
re lipophilic strong bases, from the biological medium at high pH. Although 
ngle-step extraction may be sufficient for some applications, usually a three- 
;ep extraction procedure is used with overall recovery of ca. 60-80% while the 
jcovery for each individual step is around 90%.
Recently, sample clean-up using solid-phase extraction techniques has become 
opular. The approach, which overcomes the need for lengthy extraction tech- 
iques has been successfully applied to the TCAs [ 20,21,27,28 ]. Measurement of 
iiese drugs in plasma based on solid-phase extraction on disposable C18 bonded- 
hase columns yielded results in agreement with those obtained using a three- 
tep extraction procedure [27,28],
This application involves the use of a switching valve which allows on-line 
ample loading and isolation of the analytes on a “concentration column”, fol- 
)wed by rapid elution and direct analysis on the analytical column. The use of 
olumn-switching techniques has become a major area of interest and its appli- 
ation to drug analysis in biological samples has been the subject of a number of 
ecent publications [ 29-34 ].
IXPERIMENTAL
leagen ts
10-Hydroxynortriptyline, 10-hydroxyamitriptyline and desmethyldoxepin were 
btained as a gift from the Laboratory of Clinical Pharmacology and Toxicology, 
iroot Ziekengasthuis, ’s-Hertogenbosch, The Netherlands. Doxepin andprotrip- 
yline were obtained from Jervis Street Hospital (Dublin, Ireland) and the other 
nembers of the tricyclics were obtained as gifts from I.C.P. Dublin. Hexane, 
nethanol, acetonitrile and isopropanol (all HPLC grade) were purchased from 
i'isons (Loughborough, U.K.). Ammonia solution, sodium hydroxide, sodium 
icetate and zinc sulphate were obtained from BDH (Poole, U.K.). Trichloro- 
icetic acid was purchased from May and Baker (Dagenham, U.K.) and perch- 
oric acid from Riedel-de-Haen (Hannover, F.R.G.).
For the preparation of the plasma samples, dried human plasma (from the 
Blood Transfusion Service Board, Dublin, Ireland) was dissolved in deionised 
vater (obtained by the Milli-Q water purification system). The control plasma 
>btained was Rxamined for the presence of endogenous components which might 
nterfere with the tricyclic drugs in the assay system. The reconstituted plasma 
vas stored frozen and used within two weeks of preparation.
rn strumen ta tion
The HPLC system consisted of two Waters Assoc. (Milford, MA, U.S.A.) P- 
15 licmid chromatoeranh solvent delivery systems equipped with a Waters U6K
Fig. 2. Operation of column-switching valve for sample enrichment.
manual injector and fitted to a Shimadzu (Tokyo, Japan) SPD-6A variable- 
wavelength UV detector. The chromatograms were recorded on a Philips (Eind­
hoven, The Netherlands) PM 8251 single-pen recorder. A Rheodyne (CA, U.S.A.) 
7000 six-port switching valve was used.
Chromatography
The instrument arrangement for the chromatography is shown in Fig. 2. The 
chromatographic conditions for the separation were as follows. Mobile phase pump 
A: water; concentration column (10x1.5 mm) dry-packed with Corasil (Waters 
Assoc.) RP C18 packing (37-50//m) in our laboratory; wash time, 1.5 min; flow- 
rate, 0.8 ml/min. Mobile phase pump B: acetonitrile - 0.05 M acetate buffer (60:40, 
v/v) pH 7; stationary phase, Techsphere (HPLC Technology, Macclesfield, U.K.) 
3CN (10 cmX4 mm); flow-rate, 0.9 ml/min; recorder chart-speed, 0.5 cm/min; 
detection wavelength, 215 nm; injection volume, 250 ¡A of plasma. Under the 
described chromatographic conditions the mean retention times (Fig. 3) were as 
follows: 10-hydroxynortriptyline, 6.0 min; 10-hydroxyamitriptyline, 7.5 min; nor­
triptyline, 10.0 min; amitriptyline, 12.5 min.
Prepara tion  o f  standards
Amitriptyline hydrochloride (11.32 mg), nortriptyline hydrochloride (11.39 
mg), 10-hydroxyamitriptyline hydrochloride (11.25 mg) and 10-hydroxynortrip­
tyline hydrochloride (11.31 mg) were weighed and dissolved in 100 ml of meth­
anol to yield a stock solution of 100 //g/ml amitriptyline, nortriptyline, 10- 
hydroxyamitriptyline and 10-hydroxynortriptyline. This stock solution was then 
diluted with water-methanol (1:1) to yield working standards ranging from 0.2 
to 6 fig/ml.
Desmethyldoxepin (11.4 mg) was weighed and dissolved in 100 ml of methanol 
to yield a solution of 100 /zg/ml. This was then diluted with a methanol-water
ixture to yield a solution of 10 /¿g/ml desmethyldoxepin. Spiked plasma stan- 
irds ranging from 10 to 300 ng/ml of the drugs in plasma were then prepared in 
ich assay day by spiking 1 ml of plasma with 50 ¡A of the working standards and 
) //I of the internal standards. Patient and blank plasma samples were spiked 
ith 50 fil of methanol-water mixture to compensate for any changes in the com- 
ssition of plasma.
o lumn-sw itch ing p r o c edu r e
Fig. 2 shows a simple six-port switching valve. The spiked plasma sample is 
ijected through the injector port and washed by the water from pump A onto the 
mcentration column. The drugs are held on the concentration column while the 
ther components in plasma are eluted to the drain. Meanwhile the eluent from 
amp B is passing through the analytical column and out to waste. On switching 
le valve, the eluent from pump B elutes the drugs, which have been held on the 
ancentration column, in back-flush mode onto the analytical column where they 
re separated.
ESULTS AND DISCUSSION
In using the column-switching valve the following variations in sample han- 
ling were studied: sample pretreatment; concentration column packing; wash 
ime; flow rates; and analytical column.
'ample p r e t r ea tm en t  
Protein precipitation prior to injection was tried using (i) acid precipitation 
sing perchloric acid or trichloroacetic acid and (ii) base precipitation of pro- 
eins with sodium hydroxide and zinc sulphate. The proteins were precipitated 
y addition of the reagent to plasma in tubes which were centrifuged for 15 min; 
he supernatant was injected for analysis. Direct injection with no sample pre- 
reatment was also tried. For all concentrations, acid precipitation gave the low- 
st recovery, probably due to ionization of the basic tricyclic drugs in the acid 
olution which were then eluted with the water from pump A and not retained on 
he concentration column. Base precipitation also gave poor recovery probably 
lue to co-precipitation of the drugs with plasma. The strong acids and base also 
lissolved the packing in the concentration column. Over the range of packings 
ried therefore, best recovery, sensitivity and reproducibility was achieved using 
i 250-/A direct injection of plasma. However, as it has been outlined in other 
mblications [29], direct injection is not without its problems. These problems 
nclude (i) deterioration in the performance of the concentration column due to 
>recipitation of plasma proteins when they come into contact with the solvents 
Torn pump B, i.e. the mobile phase, and (ii) build up of back-pressure due to 
iccumulation of particulate matter in plasma which can be minimized by using 
;he backflush mode.
Concentration co lum n  pack ings  
The following packings were tried in the concentration column: LiChrosorb 
RP C18, 10 fj,m; Hypersil phenyl, 10 ¿¿m; Vydak cyano, 30 /¿m; Corasil RP C18, 37-
Fig. 3. Chromatograms of (A ) a small pooled human drug-free plasma, (B ) the same plasma spiked with 10 ng/ml of each of the drugs and (C) 
plasma of a patient receiving a 50-mg oral dose of amitriptyline. Peaks: 1 =  10-hydroxynortriptyline; 2 =  10-hydroxyamitriptyline; 
3 =  desmethyldoxepin (internal standard); 4 =  nortriDtvline: 5 =  amitriDt.vlinfi.
0 fim. The main factor is the size of the packing particles. Packings with particle 
ize 10 pim do not allow direct injection since the small-size particles act as an 
fficient filter and after one to two injections become clogged with particulate 
latter from plasma.
Using 10-//m packings, acid or base precipitation must be used and, as outlined 
bove, these gave poor recovery. A 30-/mi Vydak cyano packing allowed direct 
ijection; however, the column capacity was only 150 [A of plasma. No enhance- 
lent in sensitivity was achieved by using larger injection volumes.
Corasil RP packing, 37-50 f im particle size, proved to be the best among the 
ackings tried. Although injection volumes of greater than 250 fA of plasma pro- 
ided enhanced sensitivity, it limited the number of injections per concentration 
olumn. An injection volume of 250 //l plasma allowed for at least fifty consecutive 
ijections.
Vash tim es and flow -rates
Wash times were varied from 1 to 10 min and flow-rates from 0.5 to 1.5 ml/min. 
Variation in these factors did not affect the chromatograms obtained to a large 
xtent, but the sharpest peaks and cleanest chromatograms were obtained with 
wash time of 90 s and a flow-rate of 0.8 ml/min. Shorter wash times result in 
ery large plasma peaks and longer wash times give rise to band broadening.
)ther CN co lumns
Separation of the drug and its metabolites may also be achieved using other 
IN columns. A //Bondapak CN column (300x3.9 mm) was tried but it was nec- 
ssary to vary both the composition of the mobile phase from 60:40 to 70:30 ace- 
onitrile-acetate buffer and also to vary the molarity of the buffer from 0.05 to 
.03 M in order to obtain separation. However, the peaks obtained were some­
what broadened and not as well resolved.
Calibration and ca lculation  
Evaluation of the assay was carried out using four-point calibration standards 
a the concentration range 10-300 ng/ml of drugs in plasma. The slope and inter- 
ept of the calibration curves were obtained by linear regression of the peak- 
¡eight ratios of drug/internal standard versus the concentration of the drug 
internal standard method).
The internal standard (I.S.) used was desmethyldoxepin which had a suitable 
etention time (£R=8.5 min). These calibration curves were then used to inter- 
olate the concentrations of drugs in patient plasma from the measured peak- 
Leight ratios.
dmit o f  d e te c t ion
Using a 250-//1 direct injection of plasma, and under the procedural conditions 
utlined, the limit of detection for each of the four drugs was between 5 and 10 
Lg/ml in plasma. The variation in detection limit was due to day-to-day changes 
n operational conditions and detection system. The detection limit was taken as 
he amount of compound giving a signal-to-noise ratio greater than 3:1.
lub
Fig. 4. Chromatogram of a small pooled human drug-free plasma spiked with tricyclic antidepressant 
drugs. Peaks: 1 =  10-hydroxynortriptyline; 2 =  10-hydroxyamitriptyline; 3 =  desmethyldoxepin; 4 and 
5 =  protriptyline and desiprimine; 6, 7 and 8 =  trimiprimine, cianoprimine and nortriptyline; 
9 =  doxepin; 10 and 11 =  amitriptyline and imipramine; 12 and 13 =  chlomiprimine and chloripramine.
Prec is ion
Intra-assay variability was determined at four concentrations in quadruplicate 
at levels of 10, 50, 150 and 300 ng/ml of each drug in plasma. Inter-assay vari­
ability was determined singly and at the same four concentrations in four repli­
cate runs. The precision of the method (mean coefficient of variation) for the 
values of the recovered determinate standards when calculated as “unknowns” 
against the linear regression lines for intra-assay and inter-assay were, respec­
tively, 3.3 and 3.8% for amitriptyline, 4.5 and 3.3% for nortriptyline, 3.8 and 4.9% 
for 10-hydroxyamitriptyline and 3.1 and 5.0% for 10-hydroxynortriptyline.
jASM A c o n c e n t r a t i o n s  o f  a m i t r i p t y l i n e  a n d  i t s  m e t a b o l i t e s  i n  h u m a n
VMPLES
\BLE I
e text for dosage. Blood samples were taken 10 h after administration. N .D .= n ot detectable (below 
nit of detection).
itient Compound Concentration (ng/ml)
Day 1 Day 14 Day 28 Day 42
Amitriptyline 31.9 54.5 106.7 74.0
Nortriptyline 22.9 42.2 86.1 61.6
10- Hydroxyamitriptyline N.D. N.D. 6.3 N.D.
10 - Hydroxy nortriptyline 33.2 60.1 110.4 82.6
Amitriptyline N.D. 36.7 50.1 47.2
Nortriptyline N.D. 55.7 47.3 56.7
10-Hydroxyamitriptyline N.D. 10.6 5.9 9.6
10-Hydroxynortriptyline N.D. 84.5 56.7 64.3
Amitriptyline N.D. N.D. N.D. N.D.
Nortriptyline N.D. N.D. N.D. N.D.
10-Hydroxyamitriptyline N.D. N.D. N.D. N.D.
10-Hydroxynortriptyline N.D. N.D. N.D. N.D.
Amitriptyline 24.6 34.2 36.3 50.5
Nortriptyline 7.2 30.4 50.4 49.2
10-Hydroxyamitriptyline N.D. N.D. 7.4 6.9
10-Hydroxynortriptyline 22.4 115.9 114.5 138.7
inearity
Measures of linearity as defined by the correlation coefficient of the regression 
nes of intra-assays for all drugs were better than 0.999 and the intercepts did 
ot differ greatly from the origin.
e co v e r y
The overall recovery was calculated in two different ways. First by comparing 
le peak heights of a series of spiked plasma samples after they had been taken 
irough the entire procedure with a series of reference standards. Secondly, by 
)mparing the slopes of the regression lines obtained from the two sets used in 
le first procedure. Using these methods in the concentration range 10-300 ng/ml, 
le mean overall recoveries were 90.74,92.63,83.85 and 90.50% for amitriptyline, 
ortriptyline, 10-hydroxynortriptyline and 10-hydroxyamitriptyline, respectively.
i t e r f e r en c e  s tudy
Eight other members of the tricyclic drugs were tested for possible interfer- 
tices with the measured substances. As can be seen from the chromatograms in 
ig. 4, no other member of the tricyclics studied interfered with the determination 
f 10-hydroxyamitriptyline or 10-hydroxynortriptyline. Imipramine interfered
1 UU
with amitriptyline and likewise cianopramine and trimipramine interfered wit! 
nortriptyline, but it is unlikely that any of these combinations would be admin 
istered simultaneously. Tranylcypromine which was given in combination wit! 
amitriptyline to some patients did not interfere and eluted with the plasma peak
Plasma levels
The described method has been successfully applied to the measurement o 
amitriptyline, nortriptyline, 10-hydroxyamitriptyline and 10-hydroxynortripty 
line in patients with neurotic and endogenous depression receiving oral doses o 
placebo, 50, 75,100 or 150 mg of amitriptyline alone or in combination with tran 
ylcypromine (Table I). The exact amount of dosage could not be revealed to ui 
at this stage and, therefore, results in Table I are only indicative of the capability 
of the described method for the analysis of patient samples receiving the abov< 
doses of amitriptyline (Fig. 3C).
CONCLUSION
For routine analysis of the tricyclic drugs in plasma, a new method of analysis 
based on direct-injection column-switching technique was developed. The advan 
tages of this method over conventional extraction methods is that it was less time 
consuming, needed a smaller volume of plasma and gave better recovery. It has i 
comparable precision limit with conventional extraction methods. As comparec 
to off-line solid-phase extraction [20,21 ] methods, it is less time-consuming anc 
more selective, i.e. no unidentified peaks were observed with less running cost 
The disadvantages are that the concentration column had to be changed aftei 
every fifty injections and it needed more elaborate instrumentation, i.e. two pumps 
and a column-switching valve.
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Applications of column-switching techniques in biopharmaceutical 
analysis
II. High-performance liquid chromatographic determination of 
tripelennamine in bovine plasma and milk
DARIOUSH DADGAR* and A N N A  POWER
School o f Chemical Sciences, N ational Institute for  H igher Education, Dublin 9 ( Ireland) 
(First received March 3rd, 1987; revised manuscript received May 28th, 1987)
Tripelennamine, 2-[benzyl(2-dimethylaminoethyl)amino]pyridine (Fig. 1), 
is an antihistamine which acts as a competitive antagonist of histamine at Hj 
receptors [ 1 ]. Tripelennamine is used to control allergic manifestations in humans 
and animals and it has also been used as a stimulant in cows who refuse to stand 
because of various disorders [ 2 ].
The chromatographic methods employed for the determination/detection of 
tripelennamine include thin-layer chromatography [3-5] to detect tripelenna­
mine in urine when screening for drug abuse and gas chromatography (GC) with 
flame ionisation detection for the identification of the drug in urine [3,5], to 
determine tripelennamine residues in bovine milk [2] and in pharmaceutical 
formulations [6]. GC has also been used with nitrogen-specific detection [7,8] 
to determine tripelennamine in the blood of addicts taking a combination of pen­
tazocine and tripelennamine known as T’s and Blues. High-performance liquid 
chromatographic (HPLC) methods have been reported for the determination of 
basic antihistamines including tripelennamine [ 9 ] and in animal feed, human 
urine and waste water [ 10].
All the above methods either lack sufficient sensitivity or a lengthy and tedious 
extraction step is required prior to chromatography. The objective of the present 
study was to develop an HPLC method for the determination of tripelennamine 
in bovine plasma and milk that is sensitive, selective and reproducible, and yet 
convenient in terms of sample handling and speed of analysis. In the following 
sections we describe a technique which fully meets the objectives set out above.
0378-4347/87/$03.50 ©  1987 Elsevier Science Publishers B.V.
T  r ip e le n n a m in e P ro tr ip ty lin e
Fig. 1. Chemical structures of tripelennamine and protriptyline.
EXP ER IM E N TA L
R eagen ts and so lv en ts
Tripelennamine hydrochloride was obtained from Sigma (Poole, U.K.). Pro­
triptyline hydrochloride, internal standard, was obtained as a gift from Jervis 
Street Hospital (Dublin, Ireland). Methanol and acetonitrile (HPLC grade) were 
purchased from Fisons (Loughborough, U.K.) and sodium acetate (Analar grade) 
was purchased from BDH (Poole, U.K.). Pure water was obtained by the Milli- 
Q water purification system. Drug-free bovine plasma and milk were provided by 
the Bimeda Chemicals (Dublin, Ireland), stored frozen at — 4°C and thawed at 
room temperature prior to use. The control plasma and milk showed no interfer­
ence for endogenous components when examined for possible interferences with 
the tripelennamine assay system.
Prepara tion o f  standards
Tripelennamine hydrochloride (11.43 mg) was weighed and dissolved in 100 
ml of methanol to yield a stock solution of 100 ^g/ml. This stock solution was 
then diluted with methanol-water (1:1) to yield working standards in the con­
centration range 0.04-6 fig/ml. Protriptyline hydrochloride (11.39 mg) was 
weighed and dissolved in 100 ml of methanol to yield a stock solution of 100 
fig/ml. This was then diluted with methanol-water (1:1) to obtain a working 
internal standard solution of 4 fig/m\. Spiked plasma samples ranging in concen­
tration from 2 to 50 ng/ml of the drug in plasma were prepared in each assay day 
by spiking 1 ml of plasma with 50^ 1 of working standards (0.04-1 fig/ml) and 50 
//I of internal standard (4 ,«g/ml) solution. Spiked milk samples ranging from 5 
to 300 ng/ml of the drug in milk were prepared by spiking 1 ml of milk with 50 /A 
of working standards (0.1-6 ¿ig/ml) and 50 fil internal standard (4 jig/m\) 
solution.
Samples from cattle undergoing treatment were spiked with 50 fi\ of metha­
nol-water (1:1) to compensate for any changes in the composition of the sample 
plus 50 fil of internal standard (4 fig/m\).
In strum en ta tion  and  ch romatography
The HPLC system consisted of two Waters Assoc. (Milford, MA, U.S.A.) P- 
45 liquid chromatograph solvent delivery systems equipped with a Waters U6K 
manual injector and a Rheodyne (Cotati, CA, U.S.A.) 7000, six-port switching 
valve. A Shimadzu (Tokyo, Japan) SPD-6A variable-wavelength UV detector
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Fig. 2. (Left) Chromatograms of (A) a small pooled bovine drug-free plasma, (B ) drug-free plasma spiked with internal standard and 2 ng/ml 
tripelennamine and (C) plasma of a cattle 30 min after receiving an intravenous injection of a formula containing tripelennamine. (Right) 
Chromatograms of (A) a pooled bovine drug-free milk, (B ) drug-free milk spiked with internal standard and 5 ng/ml tripelennamine and (C) 
milk of a cattle 30 min after receiving an intravenous injection of a formula containing tripelennamine. Peaks: T=tripelennamine; P=protriptyline.
was used and the chromatograms were recorded on a Philips (Eindhoven, The 
Netherlands) PM8251 single-pen recorder.
The instrument arrangement for the chromatography was exactly as described 
in our previous publication [ 11 ]. The chromatographic conditions for the sepa­
ration were as follows: mobile phase pump A, water; concentration column 
(10x1.5 mm), dry packed in house with Corasil (Waters Assoc.) RP 18, 37-50 
//m packing. The mobile phase from pump A was passed through the concentra­
tion column for 3 min (wash time) at a flow-rate of 0.8 ml/min. Mobile phase 
pump B, acetonitrile-0.05 M acetate buffer adjusted to pH 7.2 with acetic acid 
(70:30, v/v); analytical column, Techsphere (HPLC Technology, Macclesfield, 
U.K.) 3CN (10 cmX4.6 mm); flow-rate, 0.9 ml/min; detection wavelength, 246 
nm; injection volume, 250 /ul of plasma or milk sample.
Under the described chromatographic conditions the mean retention times were 
5.2 and 6.8 min for tripelennamine and protriptyline, respectively (Fig. 2).
Column-sw itch ing p ro c edu r e
The column-switching procedure described by Dadgar and Power [11] was 
adopted for use in the present study. The bovine plasma was more viscous than 
human plasma and the wash time was therefore extended to 3.0 min per sample 
to avoid clogging of the pre-column and the resulting high back-pressure. It was 
possible to inject up to thirty samples per concentration column. Chromato­
graphy deteriorated where sample injections exceeded thirty. Because of high 
concentration of fat in milk, it was not possible to directly inject the milk samples. 
Spinning the milk samples in a centrifuge at ca. 1200 g to separate fat from the 
sample proved to be as effective as extraction of fat in hexane. Upon centrifuga­
tion of milk samples, three distinct layers were formed. The top layer was the fat 
and the bottom layer was the precipitated protein. Hence, care should be exer­
cised to inject the middle layer for chromatography. The analysis of separated fat 
and protein showed no detectable amount of tripelennamine (at a spiked level of 
300 ng/ml tripelennamine in milk) in either fat or protein.
Calibration and calculations
Evaluation of the assay was carried out using five-point calibration standards 
in the concentration range 2-50 ng/ml tripelennamine in plasma and six-point 
calibration standards in the concentration range 5-300 ng/ml of the drug in milk. 
The slope and intercept of the calibration curves were obtained by linear regres­
sion of the peak-height ratios of drug/internal standard versus the concentration 
of the drug (internal standard method). These calibration curves were then used 
to interpolate the concentration of tripelennamine in bovine plasma and milk 
from the measured peak-height ratios.
RESULTS AND DISCUSSION
Limit o f  d e t e c t ion
Under the described procedural conditions, the limit of detection using a 250- 
fi\ direct injection of plasma or milk was 2 ng/ml tripelennamine in the biological
TABLE I
PRECISION (R EPEATABILITY AN D  REPRODUCIBILITY) ( n = 4)
Concentration added 
(ng/ml)
Concentration found
(m ean ±S.D .)
(ng/ml)
C.V.
(% )
Difference between added 
and found concentration
(% )
Intra-assay ( repeatability)
2 1.90±0 .19 9.7 5.0
5 4.90 ±0 .33 6.8 2.2
10 10.30 ± 0 .2 5 2.5 3.0
25 25.90 ± 0 .4 9 1.9 3.6
50 49.50 ± 2 .3 3 4.7 1.0
Mean 5.12
In ter-assay (reproducibility)
2 2 .00±0 .18 9.2 0
5 5.30 ±0 .49 9.3 6.0
10 10.40 ± 0 .5 9 5.7 4.0
25 24.30 ± 0 .6 9 2.8 2.8
50 50.20 ± 0 .3 7 0.7 0.4
Mean 5.5
fluid. The detection limit was taken as the amount of compound giving a signal- 
to-noise ratio greater than 3:1.
Prec is ion
The data presented in Table I demonstrate the within-batch (intra-assay) and 
between-batch (inter-assay) variation of the method. Intra-assay variability was 
determined at five concentrations in quadruplicate at levels of 2-50 ng/ml of the 
drug in plasma. Inter-assay variability was determined singly at the same five 
concentrations in four replicate runs. The precision of the method (mean coef­
ficient of variation, C.V. ) for the values of the recovered determinate standards 
when calculated as unknown against the generated linear regression line were 5.1 
and 5.5% for intra- and inter-assay, respectively.
The precision study was not carried out for milk samples as the precision of 
the assay for milk was found to be very similar to that of plasma.
Linearity
Measures of linearity as defined by the correlation coefficients (r) of the 
regression lines generated based on duplicate calibration curves obtained for 
plasma and milk were consistently better than 0.999.
R ecovery
In order to establish the recovery, two calibration curves based on the external 
standard method were set up. One calibration curve was based on spiked plasma 
samples in the concentration range 2-50 ng/ml and the other was based on work­
ing reference standards in the same concentration range. The overall recovery 
was calculated by comparing the slopes of the regression lines generated for the
TABLE II
RECOVERY FROM PLASM A AND FROM M ILK
Concentration Tripelennamine peak heights Recovery
(ng/ml) (mean of duplicates) (cm) (% )
Set A: working Set B: standards extracted
standards from plasma/milk
Plasma
2* 0.9 0.7 78
5 0.9 0.7 78
10 1.9 1.5 79
25 4.5 3.5 79
50 9.1 7.1 77
Mean overall recovery =  78%
Regression line for set A: y =  0 .18133a: -(- 0.0046, /- =  0.9999 
Regression line for set B: >' =  0.14036^ +  0.02612, r =  0.9999
Overall recovery 100 =  77%
0.18133
Mean recovery determined by the two methods: 77.5%
M ilk
5 0.50 0.35 70
10 0.85 0.65 77
25 2.30 1.75 76
75 7.90 5.70 72
150 15.75 11.90 76
300 31.00 22.60 73
Mean overall recovery =  74%
Regression line for set A: ,y =  0.10395* — 0.06310, r =  0.999 
Regression line for set B: y = 0 .0 7 6 1 2 x -0.00869, r =  0.999 
0 07612
Overall recovery =  ' x 100 =  7 3 %
0.10395
Mean recovery determined by the two methods: 73.5%
*More sensitive detector setting.
two sets. The same precedure was applied to the milk samples in the concentra­
tion range 5-300 ng/ml tripelennamine. The overall recovery was also calculated 
by direct comparison of the peak heights. The results obtained are shown in Table
II.
Applications o f  the m ethod
The described method has been successfully applied to the samples from cattle 
receiving an intravenous injection of a formula containing tripelennamine. For
reasons of confidentiality, we were not given permission to reveal the results of
the analysis of plasma and milk samples. However, chromatograms from the actual 
plasma and milk samples are included in Fig. 2. As can be seen, these chromato­
grams resemble the chromatograms obtained from spiked samples and no inter­
ferences were observed from endogenous components of plasma or milk.
CONCLUSION
For routine analysis of tripelennamine in bovine plasma and milk, a new method 
of analysis based on direct injection/column-switching technique was developed. 
Plasma samples could be injected directly while milk samples had to be centri­
fuged first, to separate fat, prior to injection. The method is rapid and eliminates 
the need for lengthy and tedious liquid-liquid extraction procedures with good 
recovery and low running cost. The method achieves a low limit of detection 
comparable with some reported GC methods which require long and elaborate 
extraction procedures. The chromatography was selective, i.e. there were no 
interferences from endogenous plasma components, and sharp peaks were 
obtained for the drug and the internal standard.
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Table 2. Calibration data for ATP - sulphurylase and pyrophosphate
ATP - sulphurylase Pyrophosphate
Activity/ Output/ RSD, Concentration/ Output/ RSD,
U l - 1 V % moll-1 V %
0 0.85 0 0 0.40 0
0.1 0.90 0 1 x 10-7 0.60 0
1.0 1.88 3.2 1 x 10 -6 1.00 0
10.0 2.98 1.5 1 x IO-5 1.73 5.0
20.0 3.56 3.4 1 x 10-^ 1.76 5.0
30.0 3.96 2.7 1 x 10 -3 1.10 0
40.0 4.30 2.6
50.0 4.35 2.3
luciferin (30 |.tl) were simultaneously injected into separate 
carrier streams, each pumped at 0.75 ml min-1 using a 
peristaltic pump. The two zones were synchronously merged 
12.5 cm downstream and passed through a 2.2 cm mixing coil 
before passing into a glass coil (60 X 2.5 mm i.d .) containing 
firefly luciferase (0.1 g o f beads). The detector was as described 
previously.* A  similar manifold was used for the determination 
o f PK. For the determination o f PPi and PEP, ATP - 
sulphurylase and PK, respectively, were immobilised on 
Sepharose beads (0.1 g) and incorporated within the glass coil 
upstream o f  the firefly luciferase. All standards were injected 
in triplicate for each determination.
Results and Discussion
The reagent concentrations and flow-rates were optimised for 
each application to give maximum bioluminescent emission. 
The results obtained for aqueous PK standards (10-60 U  I-1) 
and PEP standards (1.0 x I0-s-1.0 x  10-2 m) are given in 
Table 1 and the relative standard deviations (RSD s) for 
triplicate injections o f  each standard were in the range 0-5.1%. 
The results obtained for A TP - sulphurylase (0.1-50 U  I-1) and 
PPi (1.0 X 10_7-1.0 X 10-3m) are similarly presented inTable 
2, with the RSDs ranging from 0 to 5.0%. Other important 
general characteristics o f  this technique include a wide dynamic 
range and a high sample throughput (> 120  h -1 )-
The results presented for PK and ATP - sulphurylase suggest 
that this is a useful technique for monitoring enzyme activity 
levels in serum for diagnostic purposes, the rapid response time 
(< 1 0  s) and high sensitivity being o f  particular importance.
The results presented for PEP and PPi demonstrate the 
versatility and efficiency o f  the manifold design, whereby two 
enzymes are immobilised in series within the reaction coil, The 
range o f  applications could be extended further by using 
multi-step reaction sequences involving several enzymes, in 
which the enzymes could be immobilised in series or co ­
immobilised on  a single support.
Conclusions
The flow  injection manifold described above is suitable for the 
indirect determination o f  a wide range o f enzymes and 
substrates that can be linked with the firefly luciferase - 
luciferin - A T P  reaction.
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HPLC Determination of Tricyclic Antidepressants in Human Plasma
Anna Power and Darioush Dadgar
School o f Chemical Sciences, National Institute for Higher Education, Dublin 9, Ireland
Since 1975 there has been extensive development o f  H PLC as a 
method for the determination o f  plasma levels o f  the tricyclic 
d r u g s . M o s t  o f  the existing methods are similar. They 
require solvent extraction from basic plasma, followed by 
ion-pair partition, adsorption, bonded phase or reversed phase 
liquid chromatography with a number o f  different types o f 
stationary and mobile phases in each mode. In this paper we 
describe an improved HPLC method based on the extraction o f 
the drugs amitriptyline (A ) and nortriptyline (N ) from plasma 
(method 1), which is comparable with or better in most o f  its 
features than existing methods. A lso, a new HPLC method 
based on a direct injection - column switching technique 
(method 2) will be described and the two methods will be 
compared.
Experimental
Method 1
Plasma (1.5 m l), spiked with the drugs and internal standards 
imipramine (I) and desipramine (D ) for A  and N, respectively, 
was mixed with 0.1 M sodium hydroxide solution (0 .4  ml) and
the drugs were extracted into hexane - isoamyl alcohol (9 9 +  1), 
After centrifugation, the supernatant was transferred into 
clean polypropylene tubes and the solvent evaporated under a 
stream o f  nitrogen. The residue was next reconstituted in 100 nl 
o f methanol and an aliquot o f  70 fil volum e was injected for 
H PLC analysis. The separation o f  drugs was carried out on an 
adsorption colum n, 300 x  3.9 mm, commercially packed with 
uPorasil 10 (un, using methanol containing 0.1%  ammonia as 
the mobile phase at a flow-rate o f  ] .5 ml min - ’ . The drugs were 
detected by ultraviolet absorption at 215 nm. The limit o f  
detection for A  and N in plasma was between 1 and 5 ng ml-1 , 
where the signal to noise ratio was greater than 3:1.  Mean 
percentage coefficients o f  variation for intra-assay and inter- 
assay precision were, respectively, 1.9 and 5.5%  for A  and 2.1 
and 3.8%  for N. Linearity as measured by the correlation 
coefficient o f  the intra-assay linear regression line was 0.999 for 
both drugs. The mean over-all recoveries from plasma for A  
and N were, respectively, 80.8 and 71.0% . All validations were 
carried out in the concentration range 10-200 ng ml * 1 o f  drugs 
in plasma. Fig. 1 shows chromatograms o f a control and a 
spiked plasma sample.
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F ig .  1. Chromatograms of a human drug free plasma (1), and a 
human drug free plasma spiked with the drugs (25 ng m l-1, 2, and 100 
ng m l 1, 3) and internal standards
Method 2
Plasma (250 (d) spiked with the drugs and the internal 
standard, trimipramine (T ), was vortex mixed and directly 
injected through the injector port and washed by the water in 
pump 1 on to the concentration column (10 x  1.5 m m), packed 
with Corasil RP, 37-50 (Am. On switching a simple 6-port 
switching valve, the eluent from pump 2 eluted the drug from 
the concentration column in back flush mode on to the 
analytical column, where they were separated. The mobile 
phase in pump 2 was acetonitrile - 0.03 m acetate buffer (70 + 
30) and the analytical column was Waters ¡.iBondapak CN (300 
x  3.9 mm).
The flow-rate from pump 2 was 2 ml min-1 and drugs were 
detected at 215 nm. The limits o f  detection for both drugs were 
between 8 and I 2 n g ml _1. The mean percentage coefficients o f 
variation for intra-assay and inter-assay precision were, respec­
tively, 3.4 and 4.5%  for A  and 4.1 and 4.4%  for N. Linearity, 
as measured by the correlation coefficient o f the intra-assay 
linear regression line, was 0.999 for both drugs. The mean 
over-all recoveries from plasma for A  and N were, respec­
tively, 85.4 and 89.0% . All validations were carried out in the 
concentration range 15-300 ng ml-1 o f  drugs in plasma. Fig. 2 
shows chromatograms o f  a control and a spiked plasma sample.
Results
The method described based on extraction has been applied to 
the determination o f plasma levels o f A  and N in man after oral 
administration o f A . For quality control, each batch o f  samples 
received from the hospital contained a couple o f split samples 
which were unknown to us. Some representative results o f  
these split samples from the patients are given in Table 1.
Method 2 has also been applied to patient’s plasma. Two 
extra peaks were observed, one as a shoulder after the internal 
standard peak and the other before the amitriptyline peak. 
These extra peaks were not present in any placebo or pre-dose 
samples and therefore could not constitute endogenous com ­
ponents o f plasma. The natures o f  these interfering peaks are 
being studied at present as we have just received other 
metabolites o f amitriptyline. The results o f  plasma samples 
based on method 2 were generally lower than those obtained 
by method 1.
Conclusions
For routine analysis o f  tricyclic drugs in plasma, two methods 
were developed. The advantages o f  direct injection were that it 
was less time consuming, needed a smaller volum e o f  plasma 
and had better isolation pow er than extraction prior to 
chromatography with a comparable precision and detection
F i g .  2 .  Chromatograms of a human drug free plasma ( 1 ) ,  and a 
human drug free plasma spiked with the drugs (37 ng ml-1 , 2, and 300 
ng ml-1 , 3) and the internal standard
limit. The disadvantages were that the concentration column 
had to be changed after every 30 injections and it needed an 
extra pump and a switching valve. W ork is still being carried 
out to extend the capabilities o f  the direct injection - column 
switching technique for the analysis o f  other tricyclic drugs and 
their metabolites.
T a b l e  1 .  Plasma concentration of A  and N in patients with neurotic and 
endogenous depression receiving oral doses of amitriptyline. Samples 
had been split into two parts and their code was revealed after analysis
Concentration found/ng ml-1
Part 1 Part 2
Dosage/
mg A N A N
100 58.2 107.4 66.0 102.9
100 76.4 62.4 85.5 66.9
100 12.8 17.5 12.8 17.5
75 169.9 44.4 150.1 44.4
75 21.9 31.0 21.9 31.0
Placebo N.D.* N.D. N.D. N.D.
150 248.8 187.8 226.6 211.4
Placebo N.D. N.D. N.D. N.D.
* N.D. =  Not detectable (below limit of detection).
The authors are grateful to the research committee o f  NIHE, 
Dublin, for financial support.
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Analytical Applications of Microemulsions
M. Hanif Memon and Paul J. Worsfold
Department o f Chemistry, University o f Hull, Hull HU6 7RX
Surfactant molecules, with their distinct hydrophilic and 
hydrophobic regions, have a tendency to collect at any 
interface where the hydrophobic groups (tail) can be partially 
or completely removed from contact with water and the 
hydrophilic groups (head) can remain wetted. Some o f the 
possible structures that can result from oil - water - surfactant 
mixtures are shown in Fig. 1. The presence o f  such structures 
can modify chemical equilibria, reaction rates and reaction 
pathways1-2 and their analytical applications extend to a variety 
o f electrochemical, spectroscopic and chromatographic tech­
niques.3 The work reported here is concerned specifically with 
analytical applications o f  microemulsions prepared using the 
surfactant bis(2-ethylhexyl) sodium sulphosuccinate (A erosol 
O T; A O T ).
co-surfactant mixture. The size o f  the water pool in w/o 
microemulsions can be altered by changing the water to 
surfactant molar ratio ( R ). This water pool has a low effective 
polarity5 and a high microviscosity6 relative to bulk water, 
which can lead to changes in equilibria, solubility, etc.
The work reported here demonstrates the analytical poten­
tial o f  microemulsions using a flow  injection manifold with 
fluorimetric detection. In particular, the two systems studied 
demonstrate the possibility o f  reaction between water soluble 
reagents and oil soluble samples.
One is the reaction between o-phthalaldehyde - 2-mercap- 
toethanol (aqueous) and Q -C io  primary amines (non- 
aqueous)7 and the other is the enzymatic cleavage o f  4-methyl 
umbelliferyl heptanoate (non-aqueous) by lipase (aqueous).8
Fig. 1. Analytically useful organised surfactant structures. A , Aqueous micelle; B, reversed micelle; C, water in oil microemulsion; D, oil in 
water microemulsion
Microemulsions are thermodynamically stable, optically 
transparent, monodisperse droplets with droplet sizes in the 
range 5-100 nm.4 These droplets can be formed by dispersing 
water in an apolar medium [water in oil (w /o) microemulsionsj 
or by dispersing oil in an aqueous medium [oil in water (o /w ) 
microemulsionsj using a suitable surfactant or surfactant -
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cttob
I
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Experimental
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OPA/2-ME reaction. Primary amine stock solutions (0.01 m )  
were prepared by dissolving hexylamine (133 |il), octylamine 
(166 fil) and decylamine (199 (xl) in heptane (100 cm3) and
- H , 0
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Fig. 2. Mechanism for the OPA/2-ME reaction with primary amines
